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Chapter 1 
THE EMERGING FUNGAL THREAT 
Advances in medical treatment have improved the prognosis for patients with 
cancer. While significant progression has been made in eradicating certain 
malignant diseases, a growing concern for patients who receive cytotoxic 
chemotherapy is the development of fungal infections [14,135,156,183, 186,202J. 
Candidiasis is the most common nosocomial mycosis. There are several 
predisposing factors for hematogenously disseminated candidal infections in patients 
with cancer. These factors include granulocytopenia, the use of extended~spectrum 
antibiotics, and the breakdown of anatomic barriers against infection caused by 
catheterization or the use of cytotoxic chemotherapy. Invasive aspergillosis is now 
the second most common mycosis encountered in patients with cancer, particularly 
in those with hematological malignancies. Patients are at high risk when their 
absolute neutrophil count is < 500/mL and the duration of neutropenia exceeds 1 
week. The diagnosis during life of both invasive candidiasis as well as invasive 
aspergillosis still remains a significant problem [204J. 
Invasive fungal infections are also a serious threat in non-granulocytopenic 
patients. Cryptococcosis, that is caused by Cryptococcus neoformans, is a life 
threatening infection in patients with acquired immunodeficiency syndrome (AIDS). 
Histoplasmosis, blastomycosis, or coccidioidomycosis are serious infections in AIDS 
patients who have resided in, or travelled through endemic regions for Histoplasma 
capsuJatum, Blastomyces dermatitidis, and Coccidioides immitis, respectively. 
Candidiasis. 
Candidiasis is a spectrum of infections that can be classified as cutaneous, 
mucosal, or deeply invasive [204J. Deeply invasive infection may be further 
classified as fungemia, tissue-proven disseminated candidiasis and single organ 
candidiasis. Disseminated candidiasis may be further classified as acute and 
chronic disseminated candidiasis, which constitute two ends of a clinical and 
pathologic spectrum. Among the conditions of mucosal candidiasis commonly 
encountered in granulocytopenic patients are oropharyngeal, esophageal, and 
urinary candidiasis. Candida albicans among the Candida species is the 
predominant cause of candidiasis. The gastrointestinal tract is the principal source 
of infection. 
Aspergillosis. 
Invasive pulmonary aspergillosis in granulocytopenic patients carries a mortality 
as high as 95% [204J. In its most serious form there is widespread growth of the 
fungus (mould) in the lungs and dissemination to other organs often follows. This 
condition occurs in immunocompromised individuals and is fatal if left untreated. 
In granulocytopenic patients this condition is often fatal, even if diagnosed during 
life and treated. Aspergillus fumigatus is widespread in the environment (soil, dust, 
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decomposing organic matter). Most infections follow inhalation by susceptible hosts 
of aspergillus spores that have been released into the air e.g. at sites of construction 
work or building sites [204]. 
TREATMENT OF INVASIVE FUNGAL INFECTIONS WITH AMPHOTERICIN B 
The treatment of choice for most invasive fungal infections still is parenteral 
administration of the fungicidal agent amphotericin B (AMB) [204]. AMB is a 
macrolide polyene antibiotic derived from Streptomyces nodosus. 
CH3 
CH3 O~HH'~ HO '/ '/ '/ '/ '/ '/ '/ 
('yCH3 OH OH OH CH3 
0 
COOH 
0 OH OH OH OH 0 OH 
Figure 1. Chemical structure of amphotericin B. 
AMB binds to ergosterol, the principal sterol in the membrane of susceptible 
fungal cells, causing impairment of membrane barrier function, loss of cell 
constituents, metabolic disruption and cell death. In addition to its membrane 
permeabilizing effects, the drug can cause oxidative damage to fungal cells possibly 
by formation of reactive forms of oxygen (free radicals) after auto-oxidation of AMB 
bound to membrane components [29]. AMB has a broad antifungal spectrum 
including Candida albicans, Aspergillus fumigatus, Cryptococcus neoformans. 
AMB is administered as AMB-desoxycholate (AMB-DOC or Fungizone"). The 
clinical use of AMB-DOC is limited by toxic side effects [62,81,128]. This toxicity 
includes acute side effects during administration (chills, fever, myalgia), 
thrombophlebitis, nephrotoxicity, hypokalaemia, hypomagnesaemia, anaemia and 
more rarely thrombocytopenia. Although AMB-DOC is known to be highly 
fungicidal [62], clinical efficacy is often insufficient because toxicity limits the dose 
(maximum tolerated dose in patients is 0.7-1.5 mg/kg). High failure rates in 
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treatment of invasive fungal infections with AMB-DOC occur, especially in 
persistently granulocytopenic patients. Treatment failure attributable to the 
development of AMB resistance is rare, although resistant strains of Candida spp., 
with alterations in the cell membrane including reduced amounts of ergosterol, 
have been isolated during treatment [212]. 
SEARCH FOR NEW ANTIFUNGAL AGENTS 
Ideally, new antifungal agents should possess the following characteristics: 
A rapid fungicidal action, a lack of clinically relevant toxicity, and a broad spectrum 
of activity including the major species of fungi pathogenic to man. Furthermore, it 
is important that both oral and parenteral formulations are available and that its 
pharmacokinetic profile allows it to reach extra- and intracellular sites of infection. 
To improve antifungal chemotherapy two major lines of development have been 
initiated. On the one hand new antifungal agents [128] have been and are being 
produced, on the other hand lipid formulations of AMB [63,126] have been 
developed. The role of these agents in the treatment of invasive fungal infections 
in the granulocytopenic host is not yet fully defined nor well understood. 
New (investigational) antifungal agents 
Many new agents from different classes, with different mechanisms of action 
have been synthesized and studied. 
Tdazo/es. The triazoles are fungistatic agents that inhibit fungal cytochrome 
P450-dependent biosynthesis of ergosterol, the principal sterol in the membrane of 
fungal cells. The consequent depletion of ergosterol and accumulation of 
methylated sterols leads to disturbances in a number of membrane-associated cell 
functions. 
The triazole fluconazole has a broad antifungal spectrum including Candida 
albicans and Cryptococcus neoformans. It appears to be ineffective against 
Aspergillus fumigatus. Both oral and parenteral formulations of fluconazole are 
available. Fluconazole is well tolerated [71]. Acquired resistance is rare, but 
isogenic resistant strains of Candida albicans have been recovered from AIDS 
patients receiving long-term treatment with fluconazole for oropharyngeal or 
oesophageal candidiasis [28]. 
The antifungal efficacy of the triazole agents fluconazole, itraconazole, 
saperconazole, genaconazole (SCH 39304), ICl195739 or D0870, and BAY-R-3783 
have been studied in experimental models of invasive candidiasis and aspergillosis 
(Table 1 ).In a number of studies immunosuppressed animals were used. From these 
animal studies it was concluded that these triazoles are more active when used for 
preventive and early treament than for treatment of fully established fungal disease. 
12 
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Unfortunately, the carcinogenic potential of genaconazole has precluded its further 
development. 
Figure 2. Chemical structure of fluconazole. 
Echinocandins. pneumocandins. and papu/acandins, These agents are fungicidal 
agents that inhibit 1 ,3-B-glucan synthetase and consequently disturb fungal cell wall 
biosynthesis. Studies with cilofungin (L Y-121019 or L-646,991) and the derivatives 
L-671,329, L-687,901, and L-687,781 in experimental models of invasive 
candidiasis (Table 1) are encouraging. Unfortunately, cilofungin (LY-121019) has 
been withdrawn from clinical trials because of related toxicities. Polyethylene 
glycol, which is used as carrier for cilofungin, has been shown to cause metabolic 
acidosis. 
Nikkomycins. Nikkomycins are another group of fungicidal cell wall active agents; 
they are very specific inhibitors of chitin synthetase and consequently disturb fungal 
cell wall biosynthesis. Preliminary data in a mouse model of candidiasis (Table 1) 
showed only modest efficacy that may be due to their very short elimination half-
lives (minutes) in plasma. 
Lipid formulations of AMB 
Amphiphilic molecules including detergents, such as desoxycholate, and 
phopholipidsbecome arranged in various three-dimensional complexes when added 
to aqueous solutions. 
13 
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Table 1. Animal studies on antifungal efficacy of triazo/es, and other investigational 
agents in models of invasive candidiasis or aspergillosis. 
antifungal agent 
Triazoles: 
itraconazole 
fluconazole 
saperconazole 
genaconazole (SCH 39304) 
IC1195739/D0870 
BAY-R-3783 
Echino- Pneumo- Papulacandins: 
ciloiungin (L Y-121 019) 
cilofungin (L-646,991) 
L-671,329 
L-687,901 
L-687,781 
Nikkomycins 
aimmunosuppressed animals 
bantifungal agent entrapped in liposomes 
fungal 
infection 
candidiasis 
aspergillosis 
candidiasis 
aspergillosis 
aspergillosis 
candidiasis 
aspergillosis 
candidiasis 
aspergi lIosis 
candidiasis 
aspergillosis 
candidiasis 
candidiasis 
references 
112b, 152, 196', 198',203' 
111 b, 1 37',151',196' 
lSJ,19 J,33 J,Si',58,59, 
1 07d, 152, 164, 19Sd, 19SJ, 
199',200',201',213,214 
16' 
16J, 1 SO~, 197J 
33',153,188,201',203' 
16<\51a,149~/188 
217 
217 
78 
78 
19',141,144,180 
21 
21 
21 
21 
22 
Detergents with a hydrophilic polar headgroup and a single hydrophobic 
hydrocarbon tail are arranged into spherical structures, called micelles, in which the 
hydrophobic tails are arranged in the center of the structure. Phospholipids, 
containing a polar headgroup and two hydrophobic hydrocarbon tails, are 
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assembled into lipid-bilayers. The lipid bilayer can either enclose an internal 
aqueous compartment (iiposomes) or can be arranged in a ribbon-like (lipid-ribbon) 
structure. Lipids other than phospholipids, such as cholesteryl sulphate, can be 
arranged in a disk-like structure (lipid-disks). 
micelle bilayer 
0= hydrophilic headgroup 
I = hydrophobic hydrocarbon tail 
Figure 3. Assodation patterns of amphiphilic molecules in aqueous solutions. 
liposomes are vesicles consisting of one or more phospholipid bilayers 
surrounding aqueous compartments. Hydrophobic agents can be embedded in the 
lipid bilayer, whereas hydrophilic agents are entrapped in the internal aqueous 
spaces of the liposomes. 
The charge, rigidity, size, and surface characteristics of liposomes can be 
controlled to a high degree by the choice of lipids and the method of preparation. 
The fate of liposomes in the body is primarily dependent on these parameters. 
Therefore, liposomes are considered to be versatile delivery systems [20,73]. The 
clinical applicability of liposomes, as opposed to other parenteral drug delivery 
systems, is based on the fact that the lipids mostly used for liposome preparation 
are those commonly found in cell membranes; in addition, liposomes are 
biodegradable, relatively nontoxic, and nonantigenic or weakly antigenic [184]. 
After intravenous administration liposomes circulate in blood and can either 
disintegrate in blood or can be taken up in intact form largely by cells of the 
mononuclear phagocyte system (MPS), such as macrophages in the liver (Kupffer 
cells) and spleen. 
15 
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.. Water soluble molecules I lipid soluble molecules 
't{water soluble molecules with hydrophobic 
~ moiety penetrating lipid phase 
Figure 4. Schematic representation of a multi/amellar liposome, according to 
Gregoriadis [74}. 
Recent progress in liposome design has yielded a new generation of liposomes 
characterized by long blood circulation half-lives and reduced hepatosplenic uptake. 
The development of these MPS avoiding liposomes opens new therapeutic ways to 
achieve improved delivery of antimicrobial agents to infected tissues including 
infections outside the MPS [17,18,26J. It was shown already many years ago that 
factors contributing to prolonged liposome circulation times include smaliliposome 
size and increased rigidity of the bilayer. Such liposomes show prolonged 
circulation but only at relatively high lipid doses. Further advances in liposome 
engineering have led to the formulation of sterically stabilized liposomes, with the 
polymer polyethyleneglycol (pEG) conjugated to phosphatidylethanolamine (PE) in 
the bilayer. 
16 
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It was shown in many reports that PEC-PE incorporation into liposomes can 
effectively prolong their blood circulation time without the constraint of high lipid 
dose, small particle size, or rigid nature of the bilayer [8,9,10,11,18,61,104,105, 
146,215,216J. 
Figure 5. Schematic representation of a PEC-PE containing MPS avoiding liposome, 
according to Lasic [T 10}. 
Four lipid-based intravenous formulations of AMB are currently available for 
clinical use (Table 2). One is AMB-DOC prepared in a parenteral fat emulsion 
(intralipid®), while the other three are industrially prepared AMB-lipid formulations. 
It is evident that these four AMB-lipid formulations have quite different structures 
17 
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Table 2. Intravenous formulations of amphotericin B. 
formulation manufacturer 
Fungizone® Bristol Myers-Squibb 
Fungizone® in 20% Intralipid® Kabi Pharmacia 
AmBisome® Vestar, Inc. 
Amphocil® (ABCD) Liposome Technology, Inc. 
AMB Lipid Complex (ABLC) The Liposome Company 
Desoxycholate 
Egg Pho5phatidy1choline 
DOC 
EPC 
HSPC 
DSPG 
Chol 
DMPC 
DMPG 
ABCD 
Hydrogenated Soy Pho5phatidy1choline 
Distearoylpho5phatidylglycerol 
Cholesterol 
Oi myristoyl phophatidylchol i ne 
Dimyristoylphophatidylglycerol 
AMB Colloidal Dispersion 
carrier colloidal type 
sodium-DOC micelle 
triglycerides/EPClglycerol undefined 
HSPClDSPG/Chol unilamellar Iiposome 
cholesteryl sulphate lipid disk 
DMPClDMPG lipid ribbon 
Chapter 1 
and pharmaceutical characteristics. AmBisome'" is a small unilamellar vesical (SUV) 
of about 80 nm in diameter with a lipid composition of hydrogenated soy 
phosphatidylcholine (HSPC) / distearoylphosphatidylglycerol (DSPG) / cholesterol 
(Cho!) (10:5:4) containing 10 mol% AMB [158J. Amphocil'" (Amphotericin B 
Colloidal Dispersion or ABC D) is a stable complex of AMB and cholesteryl sulphate 
in a 1: 1 molar ratio. The particles have a disk-like structure with a diameter of 122 
nm and a thickness of only 4 nm [75J. ABLC (AMB Lipid Complex) was derived 
from a liposomal formulation of AMB, developed by Lopez-Berestein et a/. [118J. 
In the latter formulation AMB was entrapped into multilamellar vesicles (MLVs) 
consisting of dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl 
phosphatidylglycerol (DMPG) in a 7:3 molar ratio, containing 5 mol% AMB. The 
diameter of the MLVs ranged from 1-8 /Jm. ABLC is developed from a fraction of 
these original MLVs. The lipid composition of ABLC is similar to that of the MLVs, 
but this formulation consists of large ribbons (1-11 /Jm), not vesicles, containing 35 
mol% AMB [90,91J. 
Toxicity was studied for a large number of different AMB-lipid formulations, 
including the formulations mentioned above. In vitro cellular toxicity was 
determined for a variety of target cells (Table 3). Various parameters for toxicity 
were used, indicative either for specific cell functions, for membrane permeability, 
or for viability of the cells. It is clear that when AMB is entrapped into liposomes 
or bound to other lipid carriers, its toxicity is greatly reduced. The in vitro 
antifungal activity of the various AMB-lipid formulations (Table 4) was shown to be 
similar to that of AMB-DOC after long term exposure of a great number of fungal 
pathogens. However, when determined after short term exposure the activity of the 
AMB-lipid formulations was less than than that of AMB-DOC. The reduction of 
toxicity and preserved antifungal activity of the AMB-lipid formulations was thought 
to result from differences in affinity of AMB to cholesterol in the human cell 
membrane (lowest affinity) as opposed to the lipids of the liposomal carrier 
(intermediate affinity) and to the ergosterol in the fungus membrane (highest affinity) 
[96,97J. 
The first animal studies were performed with AMB entrapped in MLVs and 
published in 1983 by Lopez-Berestein et a/. [118J. From this moment, an increasing 
number of in vivo studies with a multitude of AMB-lipid formulations have been 
performed (Table 5 and Table 6). Toxicity was monitored in terms of impaired 
kidney and liver functioning or acute or subacute lethality in various animal species 
(Table 5), and was greatly reduced after administration of AMB entrapped in the 
various lipid formulations. With respect to the in vivo antifungal efficacy (Table 6), 
various animal models of fungal infections have been used. Studies have been 
performed in immunocompetent as well as in immunosuppressed animals. From 
these studies it can be concluded that, depending on the model of fungal infection, 
the immune status of the host, and the parameter for efficacy used, the antifungal 
activity of these AMB-lipid formulations is either somewhat less or equal to that of 
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Table 3. Experimental studies on in vitro cellular toxicity of AIvIB-lipid formulations. 
target cell AMB-lipid formulation references 
erythrocyte AmBisome® 159 
ABLC 90,155 
AMB-MLV 96,97,130 
AMB-MLV-lgG 83 
AMB-IL 103 
other 1,30,32,98,99,157',182 
renal cell AmBisome® 3 
AMB-MLV 106,206,207 
AMB-IL 95 
other 93,94 
fibroblast other 30,32,187 
macrophage AmBisome® 3 
AMB-MLV 131 
other 187 
blood neutrophil AmBisome® 147 
ABLC 185 
spleen lymphocyte AmBisome® 173 
AMB-MLV 131 
JAMB administered after incubation of target cells with empty liposomes 
A01Biso01e®: HSPCiDSPGICholesterol 10:5:4, 10 0101% AMB 
Amphocil®, Amphotericin B Colloidal Dispersion (ABCD): AMBICholesteryl sulphate 1: 1 
ABLC, Amphotericin B Lipid Complex: DMPC/DMPG 7:3, 35 0101% AMB 
AMB-MLV: DMPCiDMPG 7:3, 5 mol% AMB 
AMB-MLV-JgG: immunoliposome DMPC/DMPG 7:3, 5 mol% AMB, a-C.albicans IgG 
AMB-IL: AMB-desoxycholate (Fungizone@) in Intralipid® 
other: other AMB-lipid formulations 
AMB-DOC at equivalent dosages. However, using liposomal or lipid-complexed 
AMB much higher dosages are tolerated, and these high doses result in improved 
antifungal efficacy, even in severe infection in immunocompromised animals. 
The promising results of the animal studies along with technical advances in 
liposomal preparation techniques have led to their clinical application. Clinical 
studies with various AMB-lipid lormulations have been in progress for several years 
[52,89J. The lirst studies were published in 1985 and 1889 by Lopez-Berestein et 
al [124, 127J. They treated patients with microbiologically or histologically proven 
invasive fungal infections and a variety 01 underlying diseases. The majority of the 
patients had received prior AMB in the form of AMB-DOC, and either had evidence 
20 
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Table 4. Experimental studies on in vitro antifungal activity of AMB-lipid 
formulations. 
fungal pathogen 
Candida albicans 
non-albicans Candida spp. 
Cryptococcus neoformans 
Aspergillus fumigatus 
non-fumigatus Aspergillus spp. 
Histoplasma capsulatum 
Blastomyces dermatitidis 
Coccidioides immitis 
Paracoccidioides brasiliensis 
Rhizopus spp. 
Sporothrix schenkii 
Fusarium spp. 
Saccharomyces cerevisiae 
AMB-lipid 
formulation 
AmBisome® 
Amphocil® 
ABLC 
AMB-MLV 
AMB-ML V-lgG 
other 
AmBisome® 
Amphocil® 
AMB-MLV 
other 
AmBisome® 
Amphocil® 
AMB-MLV 
other 
AmBisome® 
Amphocil® 
AmBisome® 
AmpllOcil® 
Amphocil® 
AmpllOcil® 
Amphocil® 
Amphocil® 
Amphocil® 
Amphocil® 
AmBisome® 
ABLC 
AMB-MLV 
other 
references 
13,147' 
77 
155 
82,96,97, 
130,160,206 
83 
30,32,80,94, 
98,99,182 
13 
77 
82,160 
187 
13 
77 
82,160 
30,32,98 
13 
77 
13 
77 
77 
77 
77 
77 
77 
77 
13 
155 
160 
187 
Jantifungal activity against intracellular C.albicans in blood neutrophils 
Description of the various AMB-lipid formulations: see Table 3 
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Table 5. Animal studies on in vivo toxicity and/or pharmacokinetics of AMB-lipid 
formulations. 
AMB-lipid formulation animal species references 
AmBisome® mouse 70,158,181 
rat 158 
rabbit 60,113 
Amphocil® rat 55,76 
rabbit 12 
dog 56 
ABLC mouse 90,143 
rat 143 
AMB-MLV mouse 120 
diabetic rat 205 
AMB-IL mouse 95 
rat 103 
other mouse 65,92,117,157',182, 
187,189 
rat 208 
aNv1.B administered shortly after administration of empty liposomes 
Description of the various AMB~ljpid formulations: see Table 3 
of disease progression, or showed intolerance for AMB-DOC. The efficacy of 
liposomal AMB was good in patients with hepatosplenic candidiasis, a very 
protracted and difficult to treat multiorgan infection, and encouraging in patients 
with other fungal infections. The therapeutic efficacy of liposomal AMB in these and 
other 'compassionate treatmenf studies is very impressive, as one should take into 
account the obvious selection bias towards more serious cases, as many patients 
had previously failed on AMB-DOC treatment. These studies were followed by 
many other publications (Table 7). Most published clinical data on efficacy are 
available for AmBisome®, showing encouraging results in a variety of fungal 
infections in immunocompromised patients. 
It is evident that AmBisome®, Amphocil®, and ABLC have quite different 
structures and pharmaceutical characteristics. Their pharmacokinetics depend to a 
large extent on the composition and particle size of the liposomes or the lipid 
complexes (Table 5). Relatively large structures such as ABLC are rapidly taken up 
by the MPS. Due to uptake by the MPS, relatively high concentrations are obtained 
in the liver and the spleen without signs of major toxicity in these organs. The 
serum concentrationsare also highly variable between the formulations. The area 
under the serum concentration-time curve after a standardized dose is highest for 
22 
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Table 6. Animal studies on in vivo antifungal efficacy of AMB-Iipid formulations. 
fungal pathogen 
Candida albicans 
non-albicans Candida spp. 
Cryptococcus neoformans 
Aspergillus fumigatus 
Histoplasma capsula tum 
Blastomyces dermatitidis 
Coccidioides immitis 
Para coccidioides brasiliensis 
aimmunosuppressed animals 
bimmunoliposome 
AMB-lipid 
formulation 
AmBisome0 
ABLC 
AMB-MLV 
AMB-MLV-lgG 
AMB-IL 
other 
AmBisome® 
ABLC 
AmBisome® 
Amphocil'" 
ABLC 
AMB-IL 
other 
AmBisome® 
Amphocil 0 
ABLC 
other 
ABLC 
other 
AmBisome® 
ABLC 
Amphocil'" 
ABLC 
AmBisome® 
animal 
species 
mouse 
mouseJ 
mouse 
mouse.l 
rabbit 
mouse 
mouse.l 
mouse 
mousea 
mouse 
mouse 
mouseJ 
mouse 
mouse 
mouse 
mouse 
rabbit' 
mouse 
mouse 
rabbit' 
mousea 
rabbit' 
mouse.l 
mouse 
mouse 
mouse.l 
mouse.l 
mouse 
mouse 
mouse 
mouse 
mouse 
CAMB administered shortly after administration of empty liposomes 
Description of the various AMB-lipid formulations: see Table 3 
references 
2,70 
145 
40,90 
40 
154 
118,119,123,132 
121,122 
84b 85b 
23b' 24b , 
103 
6,31,116,138,139, 
194 
101 
40 
2 
86 
40 
154 
95 
31 ,53b,64,72, 157' 
60 
7 
12,148 
40 
5,65 
40 
40 
189 
45 
42 
41 
43 
44 
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Table 7. Studies with AMB-lipid formulations in man. 
AMB-lipid 
formulation 
extent of study references 
AmBisome® case report 4,46,47,48,87,88,102,108,109,142, 
163,174,177,178,218 
clinical study 25,38,39,49,54,79,134,136,165, 
166,167,168,169,190,191,192,193 
Amphocil® healthy volunteers 172 
ABLC healthy volunteers 100 
AMB-MLV case report 114,161 
clinical study 124,125,127,162,179,210 
AMB-IL case report 129,209 
clinical study 34,35,36,37,140 
other case report 27,67,69,176 
clinical study 50,68,133,175 
Description of the various AMB-lipid formulations: see Table 3 
AmBisome®, and lowest for ABLe. The clinical pharmacokinetics and safety of 
AmBisome®, ABLC and Amphocil® have been reviewed [89]. It is not clear whether 
the differences in structure and pharmacokinetics may be of importance to tolerance 
and efficacy. Clinical trials comparing such data for the various liposomal and lipid-
complexed AMB preparations are needed to assess the clinical value of these 
preparations and to determine the full spectrum of indications. Studies comparing 
two AMB-lipid formulations are still lacking. 
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AIM OF THE PRESENT STUDY 
The primary aim of the work presented in this thesis was to gain further insight 
into the therapeutic value of existing and newly developed liposomal formulations 
of amphotericin B in the treatment of invasive fungal infections. 
To this end, different animal models of invasive fungal infections were 
developed. Clinically relevant issues including persistent leukopenia and 
dissemination of infection, are addressed. One model was an invasive Candida 
a/bicans infection with dissemination to the kidney, liver, spleen, and lung in mice 
which were rendered persistently leukopenic. In addition, a model of invasive 
candidiasis restricted to the kidney in immunocompetent mice was used. Finally, 
a model of Aspergillus {umigatus one-sided pulmonary infection in persistently 
leukopenic rats was developed, in which the fungus disseminated to the right lung 
and liver during the course of the infection. 
In this thesis the following issues were addressed: 
• fungistatic agent (fluconazole) versus fungicidal agent (AMB-DOC) 
in vitro antifungal activity against extracellular and intracellular Ca/bicans 
(Chapter 2) 
in vivo antifungal efficacy in invasive candidiasis in immunocompetent mice 
versus persistently leukopenic mice (Chapter 3) 
• industrially prepared AMB-liposome formulation (AmBisome®) versus AMB-
DOC 
in vitro antifungal activity, toxicity, in vivo antifungal efficacy in invasive 
candidiasis in immunocompetent mice versus persistently leukopenic mice 
(Chapter 3) 
biodistribution in immunocompetent mice versus persistently leukopenic mice 
infected with Ca/bicans (Chapter 4) 
interactions with extracellular and intracellular Ca/bicans (Chapter 5) 
• in-house prepared pegylated long-circulating AMB-liposome versus industrially 
prepared AmBisome® 
preparation, toxicity and biodistribution of pegylated long-circulating AMB-
liposomes (Chapter 6) 
in vitro antifungal activity, toxicity, in vivo antifungal efficacy in invasive 
candidiasis in persistently leukopenic mice (Chapter 7 and Chapter 8) 
in vivo antifungal efficacy in pulmonary aspergillosis in persistently 
leukopenic rats (Chapter 9) 
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ABSTRACT 
The effects of amphotericin B.desoxycholate (AMB·DOC) and fluconazole (FLU) 
on the extracellular and intracellular growth of Candida atbicans were studied. With 
respect to the extracellular growth of Catbicans, antifungal activity was measured 
in terms of MICs and minimal fungicidal concentrations as well as by determination 
of the concentration that effectively killed (>99.9%) catbicans in the absence or 
presence (AMB·DOC only) of serum. AMB·DOC was highly active in terms of 
killing, even at an increased inoculum size. In the presence of serum, AMB·DOC 
activity was substantially reduced. For FLU, activity was restricted to inhibition of 
fungal growth, even after the inoculum size was reduced. With respect to the 
intracellular growth of Catbicans, antifungal activity was measured by using 
monolayers of murine peritoneal macrophages infected with Catbicans and was 
measured in terms of inhibition of germ tube formation as well as effective killing 
(> 99%) of Catbicans. AMB·DOC was highly active against Catbicans. At an 
increased ratio of infection, AMB·DOC activity was slightly reduced. FLU had no 
antifungal activity. Neither a reduction in the ratio of infection nor exposure of 
Catbicans to FLU prior to macrophage ingestion resulted in activity against 
intracellular catbicans by FLU. Previous exposure of Catbicans to AMB·DOC 
resulted in increased intracellular activity of AMB·DOC. The intracellular antifungal 
activity of the combination of FLU with AMB·DOC was less than that of AMB·DOC 
alone. AMB·DOC showed fungicidal activity against c.atbicans growing both 
extracellularly and intracellularly, whereas FLU inhibited growth only of 
extracellular Catbicans. A slight antagonistic effect between FLU and AMB·DOC 
was found with respect to intracellular as well as extracellular catbicans. 
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INTRODUCTION 
Deep-seated candidal infections are an important cause of morbidity and 
mortality in immunocompromised patients [15,21 ,22J. The current drug of choice 
for most systemic mycoses is still amphotericin B-desoxycholate (AMB-DOC), but 
its use is restricted by a variety of toxic side effects [6,13,15,21 ,22J. Consequently, 
there is a need for effective and less toxic drugs for the treatment of patients with 
these infections. One of these antifungal agents is the triazole fluconazole (FLU) 
[4,10, 14,33,34,41J./n vivo experimental studies suggested that FLU is active against 
disseminated candidiasis [8,9,29,31,32,35,37J. Recently, the antifungal efficacy of 
FLU was demonstrated in persistently granulocytopenic rabbits when it was used 
for prevention or early treatment [39,40J. Little is still known, however, on the role 
of FLU in the treatment of systemic candidiasis in immunocompromised patients. 
Since the host defense mechanisms in these patients are severely impaired, the 
intrinsic antifungal activity of the antifungal agent is of great importance for effective 
treatment. Unfortunately, standardized in vitro methods for assessment of the 
intrinsic activity of antifungal agents are not available. In addition, most of the in 
vitro methods that are used are criticized because of the poor correlation with in 
vivo antifungal activity [5,6,11,12, 18,27,28,36J. 
To gain more insight into the intrinsic antifungal activity of AMB-DOC and FLU, 
the activities of both agents against extracellular Candida a/bicans in relation to 
inoculum size were investigated in this study. Known antagonizing factors for the 
assessment of in vitro antifungal activity were excluded by choosing the 
recommended optimal test conditions for each agent. 
The in vivo efficacy of an antifungal agent is determined not only by its intrinsic 
antifungal activity but also by factors that influence the bioavailability of the agent, 
such as protein binding and intracellular penetrating capacity. Therefore, the effect 
of serum on the antifungal activity against extracellular Ca/bicans was investigated. 
Next, the antifungal activities of AMB-DOC and FLU against intracellular Ca/bieans 
were studied. Activity was determined in relation to the ratio of infection. In 
addition, the effect of exposure of Ca/bicans to one of the antifungal agents prior 
to macrophage ingestion as well as the effect of a combination of both antifungal 
agents on intracellular Calbicans were investigated. 
MATERIALS AND METHODS 
Candida strains. Calbicans ATCC 44858 was used in the experimental studies. 
Ca/bieans ATCC 28516 and Ckefyr (formerly Cpseudotropicalis, Carshalton strain; 
pfizer Code Y0601; kindly provided by Pfizer Central Research, Sandwich, England) 
were used as reference strains in the MIC and minimal fungicidal concentration 
(MFC) determinations with AMB-DOC and FLU, respectively. The yeasts were 
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maintained at -80°C in Todd-Hewitt broth (Difco Laboratories, Detroit, Mich.) 
containing 10% (v/v) glycerol. 
Antifungal agents. AMB-DOC (Fungizone@ for intravenous infusion; Bristol 
Myers-Squibb, Woerden, The Netherlands) was reconstituted with 10 ml of distilled 
water to give a standard solution of 5 giL. Further dilutions were made in distilled 
water. FLU was kindly provided by Pfizer Nederland B.V. as a standard solution of 
2 giL in saline (FLU for intravenous infusion; Pfizer France). Further dilutions were 
made in phosphate-buffered saline (PBS). 
Antifungal activity of AMB-DOC versus that of FLU against extracellular 
Ca/hie.lIS. (I) MIC and MFC. Stationary-growth-phase cultures were obtained after 
incubation of the yeasts in Sabouraud maltose broth (Dileo Laboratories) for 24 h 
at 3rc. Yeasts were washed in PBS, counted in a hemacytometer, and adjusted to 
the desired inoculum in assay medium. For experiments with AMB-DOC, the assay 
medium was Antibiotic Medium no. 3 (Pen assay broth; Dileo Laboratories). whereas 
for FLU the assay medium was high-resolution medium (kindly provided by Pfizer 
Central Research). At twofold increasing inocula ranging from 1.3xlO' to lxlO' 
CFU/L, the MICs and MFCs of AMB-DOC and FLU at twofold increasing 
concentrations ranging from 0.025 to 102 mglL were determined. In order to ensure 
accurate determination of the 99.9% endpoint, the MFC was determined after a 
total volume of 1.0 011 was subcultured onto Sabouraud dextrose agar (Oxoid, 
Basingstoke, England). Before plating, the concentrations of AMB and FLU in these 
specimens were reduced to an inactive level by washing the samples three times 
with PBS. 
(II) Short-term growth. Logarithmic-growth-phase cultures were prepared by 
reincubation of a stationary-phase inoculum in assay medium for 5 h under 
continuous agitation at 3rc. The desired inoculum was obtained after dilution of 
this C.albicans suspension in assay medium at 3rc. The extracellular activity of 
the drug in terms of effective killing (>99.9%) of c.albicans during 6 h of 
incubation was determined. At eightfold increasing inocula, ranging from 1.3xl0' 
to 8.0xlO' CFU/L for AMB-DOC and from 2.0x105 to 1.3xlO' CFU/L for FLU, the 
extracellular activity of AMB-DOC versus that of FLU was assessed at various 
concentrations ranging from 0.05 to 12.8 mglL for AMB-DOC and 0.4 to 102 mglL 
for FLU. The controls contained only the solvent of the antifungal agent in the 
appropriatedilution. During incubation, under continuous rotation at 8 rpm at 3rc 
and protected from light, the numbers of viable organisms were determined at 2-h 
intervals by making plate counts of 1 O-fold serial dilutions of the washed specimen 
on Sabouraud dextrose agar. Additionally, at the concentrations that effected 
> 99.9% killing of C.albicans, the effect of serum on the activity of the antifungal 
agent was measured. At an inoculum of 1.3xlO' CFU/L, C..lbicans was exposed 
during 6 h of incubation to antifungal agent in assay medium supplemented with 
various amounts (5, 50, and 90% lv/v]) of pooled human serum (pHS; from a pool 
of 350 serum samples from healthy volunteer donors). Because the presence of 
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serum induces the formation of germ tubes by C.albicans, the antifungal activity 
was expressed not only in terms of effective killing (> 99.9%) of c.albicans but also 
in terms of inhibition of germ tube formation, which was determined 
microscopically in a hemacytometer. 
Antifungal activity of AMB-DOC versus that of flU against intracellular 
C.alhicans. (I) Activity in relation to ratio of infection. Macrophages were obtained 
from peritoneal cavities of 10- to 13-week-old specified-pathogen-free BALB/c mice 
(lffa Credo, L'Arbresle, France). The macrophages were washed twice in Dulbecco 
modified Eagle medium (Flow Laboratories, Irvine, Scotland) supplemented with 1 % 
glutamine. Monolayers of peritoneal macro phages were cultured at 37"C on 
chamber slides (Lab-Tek, Bayer, The Netherlands) under a humidified atmosphere 
of 7.5% CO, in air in culture medium containing Dulbecco modified Eagle medium 
supplemented with 1 % glutamine and 15% fetal bovine serum (FBS; Hy-Clone, 
Logan, Utah). After the first 2 h of incubation, fresh culture medium was added to 
the monolayer, and the macrophages were incubated for 24 h. After this incubation 
period, various inocula of opsonized c.albicans were added to the monolayefS, 
resulting in increasing C.albicans-to-macrophage ratios ranging from 1 :40 to 5:8. 
c.albicans was opsonized by incubation of a washed stationary-growth-phase 
suspension with 10% normal mouse serum (BALB/c) under continuous rotation at 
8 rpm for 15 min at 37°C, and then the yeasts were washed twice in PBS. After a 
3D-min uptake period, the non ingested yeasts were removed by washing the 
monolayer three times with Dulbecco modified Eagle medium supplemented with 
1 % glutamine and 5% FBS at 37"C (time zero). The macrophages were reincubated 
for 24 h in the presence of twofold increasing concentrations of the antifungal agent 
in culture medium supplemented with 5% FBS; the concentrations ranged from 
0.05 to 1.6 mg/L for AMB-DOC and 0.4 to 102 mg/L for FLU. Control monolayers 
were incubated with the solvent of the antifungal agent in the appropriate dilution. 
Parameters for intracellular antifungal activity were inhibition of germ tube 
formation as well as killing of intracellular c.albicans (> 99% of the number of 
viable intracellular yeasts at time zero). Inhibition of germ tube formation was 
determined microscopically. At 6 and 24 h of incubation, after the monolayer was 
washed three times with PBS, the monolayers were fixed in methanol and stained 
with May-GrOnwald-Giemsa, after removal of the plastic chamber from the slide. 
At the concentrations that inhibited germ tube formation, intracellular killing was 
determined by washing the mono layers three times with ice-cold (DoC) PBS; this 
was followed by disruption of the macrophages by quickly freezing and thawing 
them in the presence of distilled water containing 0.1 % bovine serum albumin 
(Sigma Chemical Co., SI. Louis, Mo.). Suspensions were mixed vigorously. Freezing 
and thawing dit not affect the viability of c.albicans. The number of viable 
intracellular yeasts was determined by making plate counts of lO-fold serial 
dilutions of the specimen. 
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The toxicities of AMB-DOC up to 1.6 mg/L and FLU up to 102 mg/L to the 
macrophages were assessed by determining the effects of the agents on the 
phagocytic capacity and the membrane integrity of the macrophages. The effects of 
the antifungal agents on the phagocytic capacity of the macrophages were 
determined after 24 h of exposure of uninfected macrophage monolayers to the 
antifungal agents. Control monolayers were incubated with the solvent of the 
antifungal agent in the appropriate dilution. After the monolayer was washed three 
times, opsonized Escherichia coli 128K' was added to the monolayers. After a 30-
min uptake period, the uningested bacteria were removed by washing the 
monolayer and the number of viable intracellular bacteria was determined. The 
effects of the antifungal agents on the membrane integrity of the macro phages was 
determined by 51Cr release. Uninfected macrophage monolayers were labeled 
during 1 h with Na, 51CrO, (Amersham International pic., Buckinghamshire, 
England). After labeling, the monolayer was washed to remove non-cell-associated 
51Cr; this was followed by 6 h of exposure to the antifungal agents. Control 
monolayers were incubated with the solvent of the antifungal agent in the 
appropriate dilution. By this method, exposure to antifungal agent for 24 h could 
not be tested because of the high spontaneous 51Cr release, because of passive 
labeling, from the control monolayers after 24 h. After incubation, 51Cr release was 
determined by measuring the radioactivity in the supernatants as well as in the 
disrupted monolayers in a gamma counter (Minaxy 5530; Packard Instrument Co. 
Inc., Downers Grove, 111.). 
(II) Effect of previous exposure of Calbieans to antifungal agent. Monolayers 
of peritoneal macro phages were cultured as described above. After 24 h of 
incubation, opsonized Calbicans was added to the monolayers, resulting in a 
Calbicans-to-macrophage ratio of 1 :8, together with twofold increasing 
concentrations of the antifungal agent in culture medium supplemented with 5% 
FBS; antifungal agent concentrations ranged from 0.05 to 1.6 mg/L for AMB-DOC 
and 0.4 to 102 mg/L for FLU. After a 30-min uptake period, the monolayer was 
washed to remove uningested yeasts and antifungal agent and was reincubated for 
24 h in the presence of antifungal agent. Control monolayers were reincubated with 
the solvent of the antifungal activity in the appropriate dilution. Intracellular 
antifungal activity was determined at 6 and 24 h of incubation, as described above. 
(III) Antifungal activity of a combination of AMB-DOC and FLU against 
intracellular Calbiealls. Monolayers of peritoneal macrophages were cultured as 
described above. After 24 h of incubation, opsonized Calbicans was added to the 
monolayers, resulting in a Calbicans-to-macrophage ratio of 1 :8. After a 30-min 
uptake period, the uningested yeasts were removed by washing the monolayer. The 
macro phages were reincubated for 24 h in the presence of combinations of the 
antifungal agents in culture medium supplemented with 5% FBS; antifungal agent 
concentrations ranged from 0.1 to 1.6 mg/L for AMB-DOC and 0.4 to 102 mg/L for 
FLU. Control monolayers were reincubated with the solvent of the agent in the 
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appropriate dilution. Intracellular antifungal activity was determined at 6 and 24 h 
of incubation, as described above. The effect of combinations of AMB-DOC and 
FLU on the extracellular growth of Calbicans during 24 h of incubation was tested, 
after the addition of fourfold increasing FLU concentrations ranging from 0.4 to 102 
mg/L to AMB-DOC at 0.2 mg/L by the method described above. 
RESULTS 
Antifungal activity of AMB-DOC versus that of FLU against extracellular 
Calbieans in relation to inoculum size. (I) MIC and MFC. At a Calbicans inoculum 
of 1.3xlO' CFU/L, the MIC and MFC of AMB-DOC were 0.1 and 3.2 mg/L, 
respectively, and did not change at an inoculum size increased to 1.0xl 0'. The MIC 
and FLU was 0.8 mg/L and could be assessed only by using the lowest inoculum 
(1.3xl 0' CFU/L). FLU did not show fungicidal activity when it was tested up to 102 
mg/L. 
(II) Short-term growth. The survival of Calbicans at various concentrations of 
AMB or FLU during 6 h of incubation at 3JOC is shown in Figure 1. 
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Figure 1. Antifungal activity of AMB-OOC and FLU at the indicated concentrations 
(mgIL) against extracellular Calbicans during short-term growth at an inoculum size 
of 1.3x1O' CFUIL in the logarithmic phase of growth. The control contained only 
the solvent of the antifungal agent at the appropriate dilution. Each symbol 
represents the mean of three experiments. 
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Because the MIC of FLU could be assessed only at 1.3x1 0' CFU/L, the antifungal 
effect on the short-term growth of Ca/bicans was initially determined at this 
inoculum size. With AMB-OOC, killing of Ca/bicans (> 99.9%) was obtained at 0.2 
mglL. Killing was not affected by an increase in the inoculum by 8- or 64-fold, 
respectively (data not shown). FLU tested up to a concentration of 102 mglL did not 
result in the killing of Ca/bicans but only inhibited fungal growth. A reduction in 
the inoculum size by 8- or 64-fold, respectively, did not result in the killing of 
Ca/bieans (data not shown). 
The effect of serum on the antifungal activity of AMB-OOC against extracellular 
Ca/bicans is presented in Table 1. The minimal AMB-OOC concentration required 
for the inhibition of germ tube formation as well as for effective killing (> 99.9%) 
of Calbicans in the presence of serum are given. FLU was not tested, since it is 
known that protein binding is low for FLU. In the presence of 5% PHS, inhibition 
of germ tube formation as well as effective killing were observed at an AMB-OOC 
concentration of 0.2 mglL. An increase in the amount of serum did result in an 
increase in the concentration of AMB required to obtain the effects. Eventually, 
compared with the effect of 5% PHS, the presence of 90% PHS resulted in a 4-fold 
increase in the concentrations required to inhibit germ tube formation, whereas a 
16-fold increase in concentration was needed to obtain effective killing. 
Table 1. Effect 01 serum on the antilunga/ activity 01 AMB-OOC against extracellu/ar 
Ca/bicans during 6 h 01 incubation,' 
Minimal AMB concn (mglL) required for: 
Medium Inhibition of germ tube formation Effective killing 
Serum-free 
PHS 5% 
50% 
90% 
0.2 
0.4 
0,8 
aC.albicans was used at an inoculum size of 1.3x107 CFU/L 
bpercentages of PHS are by volume 
(>99,9%) 
0.2 
0,2 
1.6 
3,2 
Antifungal activity of AMB-DOC versus that of FLU against intracellular 
C.a/hicans. (I) Activity in relation to ratio of infection. The minimal concentrations 
of AMB-OOC and FLU required for the inhibition of germ tube formation as well 
as for effective killing (>99.9%) of Ca/bieans at 6 and 24 h of incubation at 
various ratios of infection are given in Table 2. In the absence of antifungal agent, 
Ca/bieans grows intracellularly by the formation of germ tubes, and within 24 h 
mycelium is formed, At a Ca/bicans-to-macrophage ratio of 1 :8, inhibition of germ 
46 
Chapter 2 
tube formation and killing were observed within the first 6 h of incubation at AMB 
concentrations of 0.2 and 0.4 mglL, respectively. After prolonged incubation (24 h), 
this activity was not changed. At a fivefold increased ratio of infection, twofold 
increased AMB concentrations were required to obtain both effects. FLU tested up 
to 102 mglL was not effective intracellularly during 6 h of incubation. After 
prolonged incubation (24 h), germ tubes and hyphae were still observed when FLU 
was tested up to 102 mglL. However, the formation of mycelium was inhibited. A 
fivefold reduction in the ratio of infection also did not result in intracellular activity 
of FLU. These data were derived from three separate experiments, in which each 
concentration was tested in triplicate. 
Cellular toxicities of the antifungal agents measured in terms of inhibition of the 
phagocytic capacity of the macrophages or a decrease in membrane integrity were 
not observed with AMB-DOC or FLU when they were tested at concentrations up 
to 1.6 and 102 mglL, respectively (data not shown). 
Table 2. Antifungal activity of AMB-DOC versus that of FLU after 6 and 24 h of 
incubation against intracellular C.albicans in relation to ratio of infection,iI 
Minimal conen (mglL) required for: 
Antifungal agent Inhibition of germ Effective killing and 
C.albicans : macrophage ratio tube formation (>99%) 
6 h 24 h 6 h 24 h 
AMB-DOC 
1 :8 0.2 0.2 0.4 0.4 
5:8 0.4 0.4 0.8 0.8 
FLU 
1 :8 > 102 > 102 ND ND 
1 :40 > 102 >102 ND ND 
JAntifungal agent was present in the incubation medium after Calbicans ingestion 
NO = not done 
(II) Effect of previous exposure of C..lbicans to antifungal agent. The minimal 
concentrations of AMB-DOC and FLU required for the inhibition of germ tube 
formation as well as for effective killing (> 99%) of C.albicans and C.albicans-to-
macrophage ratio of 1:8 after 6 and 24 h of incubation are given in Table 3. 
Exposure of c.albicans for 30 min to one of the antifungal agents at the 
concentrations used during macrophage ingestion did not reduce the number of 
viable intracellular yeasts after 30 min of ingestion. With AMB-DOC, inhibition of 
germ tube formation and killing were observed within 6 h of incubation at 
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concentrations of 0.1 and 0.2 mglL, respectively. FLU tested up to 102 mglL was 
not effective intracellularly. These data were derived from three separate 
experiments, in which each concentration was tested in triplicate. 
Table 3. Antifungal activity of AMB-OOC versus that of FLU after 6 and 24 h of 
incubation against intracellular Calbicans: effect of previous exposure to antifungal 
agent. 
Minimal concn (mgll) required for: 
Antifungal agent 
Inhibition of germ Effective killing and 
Calbieans : macrophage ratio tube formation (>99%) 
6h 24 h 6 h 24 h 
AMB-OOC 
1 :8' 0.2 0.2 0.4 0.4 
1 :8b 0.1 0.1 0.2 0.2 
FLU 
1 :8' > 102 > 102 NO NO 
1 :8b > 102 > 102 NO NO 
aAntifungai agent was present in the incubation medium after C.albicans ingestion 
bAntifungal agent was present in the incubation medium during and after C.albicans 
ingestion 
NO ~ not done 
(II) Antifungal activity of a combination of AMB·DOC and FLU against 
intracellular Ca/bieal1s. The antifungal activity of combinations of AMB-OOC and 
FLU against intracellular Calbicans at a Calbicans-to-macrophage ratio of 1:8 after 
24 h of incubation in terms of inhibition of germ tube formation as well as effective 
killing (>99%) are shown in Tables 4 and 5, respectively. In the absence of FLU, 
inhibition of germ tube formation and effective killing were observed at AMB-OOC 
concentrations of 0.2 and 0.4 mglL, respectively. The addition of FLU up to 102 
mglL to AMB-OOC did not result in a reduction of the AMB-OOC concentrations 
required for inhibition of germ tube formation and effective killing. In contrast, at 
combinations of AMB-OOC at 0.2 mglL plus FLU at 1.6 mglL and of AMB·OOC at 
0.4 mglL plus FLU at 1.6 mglL, inhibition of germ tube formation and effective 
killing, respectively, were no longer observed. In the presence of FLU at 
concentrations from 1.6 mglL, an increase in the AMB-OOC concentration up to 0.8 
mglL was required to obtain both effects. After 6 h of incubation, this antagonistic 
effect of FLU was not observed (data not shown). These data were derived from 
three separate experiments, in which each concentration was tested in triplicate. 
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Regarding the effect of combinations of AMB-DOC with FLU on the extracellular 
growth of C.albicans, we did observe a slight antagonistic effect of FLU during 24 
h of incubation after the addition of fourfold increasing FLU concentrations, ranging 
from 0.4 to 102 mg/L, to AMB-DOC at 0.2 mg/L (data not shown). 
Table 4. Antifungal activity of combinations of AMB-OOC and FLU at various 
concentrations against intracellular C.albicans' after 24 h of incubation: inhibition 
of germ tube formation. 
Antifungal activity with FLU conen (mg/L) of: 
AMB 
can en 102 51.2 25.6 12.8 6.4 3.2 1.6 0.8 0.4 0 (mg/L) 
1.6 + + + + + + + 
0.8 + + + + + + + 
0.4 + + + 
0.2 + + + 
0.1 
0 
JThe C.albicans-to-macrophage ratio was 1:8 
+ I inhibition of germ tube formation; -, no inhibition of germ tube formation 
Table 5. Antifungal activity of combinations of AMB-OOC and FLU at various 
concentrations against intracellular C.albicans' after 24 h of incubation: effective 
killing (> 99%). 
Antifungal activity with FLU conen (mg/L) of: 
AMB 
(oncn 102 51.2 25.6 (mg/L) 
1.6 + + 
0.8 + + 
0.4 
0.2 
0.1 
0 
aThe C.albicans-to-macrophage ratio was 1:8 
+ I effective killing; -, no effective killing 
12.8 6.4 3.2 1.6 0.8 
+ + + 
+ + + 
+ 
0.4 0 
+ + 
+ + 
+ + 
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DISCUSSION 
The observations of the activity of AMB-DOC against extracellular Ca/hieans 
after an incubation period of 24 h showed that, in the absence of serum, AMB-DOC 
is highly active in terms of growth inhibition and killing of Ca/hieans. This 
antifungal activity was maintained when the inoculum was increased. The presence 
of serum greatly influenced the activity of AMB-DOC against extracellular 
Ca/hicans. This is in agreement with observations of others [23J, who found a 
twofold increase in the MIC and MFC of AMB-DOC when Ca/hicans was exposed 
to AMB-DOC in the presence of 25% PHS. This reduction of antifungal activity in 
the presence of serum may be explained by the high protein binding of AMB-DOC, 
resulting in reduced bioavailability. 
FLU was not active in terms of killing of extracellular Ca/hieans. Only an 
inhibitory effect by FLU was observed at a low inoculum. This is in agreement with 
the observations of other investigators [16,28,32,37,38J. Since protein binding is 
reported to be low for FLU [1,14,17], the effect of serum on its antifungal activity 
was not tested. 
The antifungal effect against intracellular Ca/hieans was studied by using 
monolayers of murine peritoneal macrophages infected with Ca/hicans. The 
experimental design varied with respect to different ratios of infection, exposure of 
Ca/hicans to one of the antifungal agents prior to macrophage ingestion, and 
exposure to the antifungal agents alone or in combination. It is known that resident 
peritoneal macrophages are unable to kill Ca/hicans during incubation in vitro and 
are even unable to prevent intracellular germ tube formation [2,3,7,24,38J. As a 
consequence, the antifungal effect on intracellular Ca/hieans could be investigated 
without interference from the direct fungistatic or fungicidal effects of the 
macrophages themselves. The intracellular efficacies of the antifungal agents were 
determined in terms of inhibition of germ tube formation as well as effective killing 
of Ca/hieans intracellularly. With AMB-DOC, inhibition of the development of 
germ tubes was found at concentrations lower than those required for killing of 
intracellular Ca/hieans, which has also been reported by others [25,26,38). After 
an increase in the ratio of infection, slightly increased AMB concentrations were 
required to obtain both effects. The cellular toxicity of AMB-DOC in terms of a 
decrease in membrane integrity ("Cr release) or a reduction in the phagocytic 
capacity of the macrophages (E.co/i phagocytosis) was not observed when 
macro phages were exposed to AMB-DOC for 6 and 24 h, respectively. Other 
investigators [20J reported, however, that AMB-DOC is highly suppressive to 
macrophage differentiation, as measured by transglutaminase induction, and to 
effector functions, as measured by superoxide anion release after 16 h of 
incubation. Immunostimulatory effects of AMB-DOC after in vitro exposure of 
peritoneal macrophages have also been reported. Increased phagocytosis of 
polystyrene beads in macrophages after in vitro exposure to AMB-DOC was 
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observed [19J. In our study, however, an increase in the phagocytosis of E.coli was 
not found. The discrepancies in these observations cannot readily be explained. 
Exposure of c.albicans to AMB-DOC prior to macrophage ingestion slightly 
influenced the antifungal activity of AMB-DOC in terms of a decrease in the AMB 
concentrations required for inhibition of germ tube formation as well as for the 
effective killing of intracellular c.albicans. 
The antifungal activity of AMB-DOC was observed within 6 h. Prolonged 
incubation (24 h) did not change this effect, provided that AMB-DOC was present 
in the incubation medium. It seemed that the continuous presence of AMB-DOC 
extracellularly was necessary to maintain intracellular antifungal activity. 
FLU was not effective intracellularly when macro phages were exposed to FLU 
for 6 h, not even at a reduced C.albicans-to-macrophage ratio, nor after exposure 
of c.albicans to FLU prior to macrophage ingestion. Although the formation of 
mycelium was inhibited after prolonged incubation (24 h), germ tubes and hyphae 
were still observed with FLU, and therefore, FLU was not effective intracellularly. 
The results of the activity of FLU against intracellular c.albicans are in agreement 
with the results of activity against extracellular C.albicans, in which no complete 
growth inhibition was observed. It has been reported by others [42J that FLU, 
despite its observed good intracellular penetrating capacity, did not have a 
significant effect on the killing of intracellular c.albicans or on the formation of 
germ tubes within 4 h of incubation of c.albicans-infected macrophage monolayers 
derived from human blood monocytes, which is in agreement with the results of 
our study. Those investigators [42J also mentioned the prevention of the formation 
of mycelium by FLU after 24 h of incubation and reported a significant growth 
inhibition of c.albicans, as measured by CFU counts of viable intracellular 
c.albicans. CFU counts of intracellular c.albicans can only be determined 
accurately when germ tube formation is completely inhibited. In the presence of 
germ tubes, the CFU count may be an overestimation of viable c.albicans because 
of fragmentation of the germ tubes during disruption of the monolayer, giving rise 
to an increase in CFU. On the other hand, the CFU count can be an 
underestimation of viable C.albicans, since viable c.albicans may be washed away 
after destruction of the macrophages by germ tubes. Other investigators [38] 
described that FLU had only a minimal effect on the number of viable intracellular 
c.albicans in murine macrophage monolayers, but that it significantly inhibited 
germ tube formation within 4 h of incubation. The number of yeasts that produced 
germ tubes as well as the length of the germ tubes appeared to be significantly 
reduced, as measured microscopically. The intracellular activities of antifungal 
agents can only be defined as complete inhibition of germ tube formation, at the 
least. 
To investigate whether the AMB concentrations required for intracellular activity 
could be reduced further, combinations of AMB-DOC and FLU were tested. 
However, the potentiation of intracellular activity was not observed after 
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coincubation of AMB-DOC with FLU. In contrast, antagonism between FLU and 
AMB-DOC was found with respect to intracellular Ca/bicans. This antagonism was 
observed only after 24 h of incubation but was not observed after 6 h of incubation. 
With respect to extracellular Ca/bicans, a slight antagonistic effect between FLU 
and AMB-DOC measured during 24 h of incubation was observed, as was also 
recently described by others [30J. They speculated that competition for binding sites 
on Ca/bicans could be responsible for this antagonism. Intracellular activity could 
also be reduced by competition during intracellular penetration. However, these 
explanations for the observed antagonism are speculative, and further study is 
needed for elucidation. 
In summary, it was observed that although the activity of AMB-DOC against 
extracellular Ca/bicans was high, the antifungal activity was influenced by factors 
relevant to its efficacy in the treatment of infection. The antifungal activity of AMB-
DOC was substantially reduced by the presence of serum; however, it was only 
slightly hindered by the intracellular localization of the yeasts. At an increased ratio 
of infection of intracellular Ca/bicans, the antifungal activity of AMB-DOC was 
slightly reduced. For FLU, antifungal activity against extracellular Ca/bicans was 
restricted to inhibition of fungal growth, despite the use of optimal test conditions, 
such as the recommended assay medium and the use of low Ca/bicans inocula, 
whereas FLU was not effective against intracellular Ca/bicans. Therefore, it is 
questionable whether FLU effectively contributes to the eradication of Ca/bicans 
when host defense mechanisms are severely impaired. A slight antagonistic effect 
between FLU and AMB-DOC was found with respect to intracellular as well as 
extracellular Ca/bicans. 
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ABSTRACT 
The in vitro activities of amphotericin B-desoxycholate (AMB-DOC), liposomal 
amphotericin B (AmBisome®) and fluconazole (FLU) were determined against a 
single strain of Candida albicans. In addition, the efficacies of these agents in the 
treatment of systemic candidiasis in both immunocompetent and leukopenic mice 
were compared. The minimum inhibitory concentrations (MICs) and minimum 
fungicidal concentrations (MFCs) of AMB-DOC and AmBisome® were similar, but 
on the basis of time-kill studies, the fungicidal activity of AmBisome® was 
significantly less than that of AMB-DOC. 
In immunocompetent mice, the dosage of AMB-DOC was limited by toxicity, 
resulting in a maximum tolerated dosage (MTD) of 0.4 mg AMB/kg/day during 
treatment for 5 days; AmBisome® was less toxic, the MTD being 7 mg AMB/kg/day 
following a treatment period of the same duration. Both AMB-DOC and AmBisome® 
led to significant reductions in the numbers of C.albicans in the kidneys of these 
mice and prevented relapse of infection after completion of treatment. FLU in 
dosages of 0.4 and 64 mg FLU/kg/day resulted in initial reductions in the numbers 
of CFU but failed to prevent relapse. 
In leukopenic mice, treatment for 5 days with AMB-DOC in a dosage of 0.3 mg 
AMB/kg/day resulted in survival of the animals and a significant reduction in the 
numbers of CFU in the liver, spleen and lungs. However, there was no reduction 
in the number of CFU in the kidneys and this led to relapse of infection once 
therapy was terminated. FLU in a dosage of 64 mg FLU/kg/day produced effects 
which were similar to those of AMB-DOC; prolonged treatment with FLU for 18 
days did not improve the efficacy of this agent. Only treatment with high-dosage (7 
mg AMB/kg/day) AmBisome® was effective in significantly reducing the numbers of 
CFU of C.albicans in the kidneys and other organs of leukopenic mice, as well as 
preventing relapse, even in severely infected animals. 
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INTRODUCTION 
Deep-seated fungal infection is an important cause of morbidity and mortality in 
immunocompromised patients [22,23]. Currently, the treatment of choice for most 
systemic mycoses is amphotericin B-desoxycholate (AMB-DOC), although the 
amount of this drug which can be administered is limited by a number of side-
effects, some of which may be serious [6,10,23,41]. There is, therefore, a need to 
identify effective and less toxic alternatives for the treatment of patients with life-
threatening fungal infections. One such agent is the triazole, fluconazole (FLU) 
[6,12,41]. Both experimental studies and data in humans have shown that FLU is 
effective therapy for disseminated candidiasis [2,7-9,18,26,30,32,36,38,43]. The 
efficacy of FLU as prophylaxis or early treatment has also been demonstrated in 
persistently granulocytopenic rabbits [39,40], but there is a paucity of evidence to 
support the efficacy of this drug as treatment for immunocompromised hosts with 
systemic candidiasis. 
Another promising approach in the treatment of invasive fungal infections is 
amphotericin B (AMB) which has been incorporated into liposomes or other lipid 
carriers [25,42]. In both experimental [1,5,11,14-16,20,21 ,27,35]and human studies 
[4,17,19,34,24,28,31,33] a reduction in the incidence of side-effects and an 
improvement in the therapeutic index have been reported for various lipid-
associated formulations of AMB. One such preparation is AmBisome® which has 
been shown to be effective in the treatment of immunocompetent mice with 
candidiasis [1,11]. However, its efficacy in leukopenic mice with severe 
disseminated candidiasis has not yet been determined. In the present study, we 
have compared the efficacies of FLU, liposomal amphotericin B (AmBisome®) and 
AMB-DOC as therapy for both immunocompetent and leukopenic mice with 
invasive candidiasis. 
MATERIALS AND METHODS 
Candida strains. Candida albicans ATCC 44858 was used in all of the 
experiments and was stored at -80°C in Todd-Hewitt broth (Difco Laboratories, 
Detroit, MI, USA) containing 10% (v/v) glycerol. 
Antifungal agents. AMB-DOC (Fungizone®; Bristol Myers-Squibb, Woerden, The 
Netherlands) was reconstituted with distilled water to obtain a stock solution of 5 
giL. AmBisome®, AMB encapsulated in small unilamellar vesicles consisting of 
hydrogenated soybean phosphatidylcholine, cholesterol and distearoylphosphatidyl-
glycerol in a molar ratio of 2:1 :0.8, was kindly provided by Vestar Inc. (San Dimas, 
CA, USA) as a lyophilized preparation. The powder was reconstituted according to 
the manufacturer's instructions with distilled water at 65°C to give a liposomal 
suspension containing 4 g AMB/L and 35 g lipid/L. FLU was provided by Pfizer 
Nederland B.V. as a stock solution containing 2g1L. 
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Animals. Specified pathogen-free, 10- to 13-week-old, female BALB/c mice were 
obtained from Iffa Credo (L'Arbresle, france). 
Minimum inhibitory concentrations (MICs) and minimum fungicidal 
concentrations (MfCs). MICs and MfCs were determined by a broth dilution 
method as described previously [37J. Two-fold serial dilutions of the antifungal 
agents in concentrations ranging from 0.025-102 mg/L were prepared in Antibiotic 
Medium No.3 (Difco Laboratories). Stationary growth phase cultures of the Candida 
albieans strain were obtained after incubation in Sabouraud maltose broth (Difco 
Laboratories) for 24 h at 3JOC. The organisms were washed in phosphate-buffered 
saline (PBS), counted in an hemocytometer and adjusted to the desired inoculum 
in Antibiotic Mediuim No.3; the suspension contained 1.3xl0' CfUIL. The MIC 
was defined as the lowest concentration of each antifungal agent which inhibited 
visible growth after 24h of incubation at 37°C. Samples from clear tubes were 
washed in PBS and inoculated on to solid medium. The MfC was defined as the 
lowest concentration which killed> 99.9% of the original inoculum after overnight 
incubation at 37°C. 
In vitro activities of AMB-DOC and AmBisome® during short-term exposure. 
The fungicidal activities of AMB-DOC and AmBisome® were determined by a 
killing curve method as described previously [37J. Briefly, two-fold serial dilutions 
of each agent in concentrations ranging from 0.05-25.6 mg/L were prepared in 
Antibiotic Medium No.3. A logarithmic growth phase culture of C.albicans was 
diluted and added to each tube to give an initial suspension of 1.3xl 0' CfU/L. The 
tubes were incubated for 6 h at 3rc. Samples were withdrawn at 2-h intervals and 
the numbers of viable organisms were determined. 
Determination of maximum tolerated dosage (MTD). The MTDs of AMB-DOC 
and AmBisome® were determined in uninfected mice and expressed in terms of 
death of the animals during the course of treatment or a significant change in renal 
andlor hepatic function in the survivors. Twenty mice (two groups of ten) received 
the targeted dosage of either AMB-DOC (ranging from 0.1 to 1.5 mg AMB/kg/day) 
or AmBisome® (ranging from 1 to 32 mg AMBlkg/day) by the iv route for 5 
consecutive days. Dosages of AMB-DOC of 0.1-1.0 mg AMB/kg/day were reached 
by increments of 0.1 mg AMB/kg/day and a dosage of 1.5 mg AMB/kg/day was 
reached by a single increment of 0.5 mg AMBlkg/day; dosages of AmBisome® were 
reached by increments of ;" 1 mg AMBlkg/day. Time until death was monitored 
from administration of the antifungal agent. Abnormalities of renal function in 
surviving mice were detected by measuring the serum urea and creatinine 
concentrations; abnormalities of hepatic function were detected by measuring the 
serum aspartate aminotransferase and alanine aminotransferase concentrations. All 
biochemical parameters were determined by established methods (Merck 
Diagnostica, Darmstadt, Germany) from samples of blood obtained from the 
surviving mice in one cohort which were killed 24 h after termination of treatment 
and from those in a second cohort killed 14 days after termination of treatment. The 
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MTD was defined as the maximum dosage which did not lead to death during 
treatment or to a statistically significant increase in the concentrations of the 
biochemical parameters used to monitor renal and hepatic functions compared with 
the concentrations of these indices in untreated mice (two groups of ten which were 
killed at the same time intervals as the treated mice). 
Efficacies of AMB-DOC, AmBisome® and FLU in infected immunocompetent 
mice. Mice were infected by the iv inoculation of 5xlO' CFU of C.albicans into the 
tail vein. AMB-DOC and AmBisome® were each administered once daily by the iv 
route to three groups of ten mice. The dosages of the two agents corresponded to 
their MTDs which had been determined previously in immunocompetent mice 
infected with C.albicans according to the method and criterion (i.e. death) described 
above for uninfected mice; (or comparison, AmBisome® was also administered to 
separate cohorts in a dosage which was equivalent to the MTD of AMB-DOC. FLU, 
in a range of dosages up to 64 mg FLUlkglday, was administered twice daily by the 
ip route to three groups of ten mice. Additional cohorts of ten mice received one 
of the following placebos: desoxycholate (DOC; Sigma Chemical Co., St Louis, MO, 
USA) administered iv once daily, liposomes without AMB (placebo liposomes, 
PLACEBO-LIP) administered iv once daily, or PBS administered ip twice daily. 
Treatment with the antifungal agents and placebos was started 48 h after infection 
was initiated, and continued for 5 consecutive days. Just after the start of treatment 
and at 24 hand 14 days after treatment had been completed, surviving animals in 
separate groups of ten mice receiving each of the regimens were killed. The kidneys 
were removed and homogenized in 20 mL of PBS for 30 sec at 10,000 rpm in 
VirTis homogenizer (The VirTis Co. Inc., Gardiner, NY, USA). The antifungal agents 
Were eliminated from the homogenates by washing three times with PBS. Serial ten-
fold dilutions of the homogenates were prepared in PBS and 0.2 mL samples of 
each dilution, as well as 2 mL samples of the undiluted homogenates, were spread 
on to Sabouraud dextrose agar (SDA, Oxoid, Basingstoke, UK); large (20 Col) 
diameter plates were used for the 2 mL samples. The remainder of each 
homogenate, together with an equal volume of double-concentrated SDA, were 
poured into plastic plates. Following incubation at 3rc for 48 h, the numbers of 
C.albicans CFU in the kidneys were calculated and expressed as the geometric 
means. The following criteria were used to assess the efficacy of treatment: a 
statistically significant reduction in the numbers of CFU in the kidneys 24 h after 
termination of treatment compared with those at the start of treatment; a statistically 
significant reduction in the numbers of CFU in the kidneys of antifungal-treated 
mice compared with those in the kidneys of mice receiving the placebos; and 
prevention of a significant increase in the numbers of CFU in the kidneys 14 days 
after termination of treatment compared with the numbers 24 h after termination of 
treatment (equating to relapse of infection). 
In order to determine if treatment prevented hyphal growth, separate cohorts of 
mice (each consisting of ten animals) were killed at 24 h or 14 days after 
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termination of treatment. The kidneys were removed and fixed in 10% buffered 
formalin. Following sectioning and staining by the periodic acid-Schiff method, the 
tissues were examined microscopically. 
Efficacies of AMB-DOC, AmBisome® and FLU in infecled leukopenic mice. 
Leukopenia was induced by the ip administration of cyclophosphamide (Sigma 
Chemical Co.); a dosage of 100 mg/kg was administered 4 days before initiation of 
infection followed by additional doses of 75 mg/kg on the day of inoculation and 
at 3-day intervals thereafter whilst the mice were still alive. This resulted in 
persistent granulocytopenia « 0.1 xl O'/L) from the onset of infection. The mice 
were infected by the iv inoculation of 10' CFU of the Cathicans strain into the tail 
vein. AMB-DOC and AmBisome® were each administered iv once daily to groups 
of ten mice in dosages which corresponded to their MTDs (determined previously 
in infected leukopenic mice according to the method and criterion i.e. death during 
treatment described above for uninfected mice); for comparison, AmBisome® was 
also given to separate cohorts in a dosage which was equivalent to the MTD of 
AMB-DOC. FLU, in a range of dosages up to 64 mg FLU/kg/day, was administered 
twice daily by the ip route. The placebos were the same as those used in the 
experiment with immunocompetent mice. The efficacy of treatment in relation to 
severity of infection was investigated by commencing therapy with AMB-DOC, 
AmBisome®, FLU or,one of the three placebos at 6 h, 16 h or 24 h after inoculation 
and continuing for 5 consecutive days. In a separate experiment, the efficacies of 
prolonged treatment with FLU and as maintenance therapy following initial 
treatment with AmBisome® were evaluated. The treatment regimens were 
commenced 6 h after initiation of infection and consisted of the administration of 
FLU for 18 days, AmBisome® for 5 days or AmBisome® for 5 days followed by FLU 
for a further 13 days. Just after the start of treatment and at 24h and 14 days after 
completing treatment, the surviving animals in separate groups which initially 
comprised ten mice were killed. The kidneys, liver, spleen and lungs were removed 
and processed for the determination of viable counts and histological examination 
as described above for the immunocompetent animals. The efficacies of the various 
treatment regimens were also assessed according to the criteria described above for 
immunocompetent mice and, additionally, in terms of percentage survival. 
AMB concentrations in the blood and tissues of leukopenic mice following 
treatment with AMB-DOC and AmBisome®. In a separate experiment with different 
cohorts of leukopenic mice infected with C.athicans, treatment with AMB-DOC or 
AmBisome® in dosages which corresponded to their MTDs was initiated 6 h after 
inoculation and continued for 5 days as described previously. At 24 hand 14 days 
after completion of treatment, the mice were killed, samples of blood were 
collected in heparinized tubes and the kidneys, liver, spleen and lungs were 
removed, weighed, homogenized in distilled water and prepared for analysis by 
high-performance liquid chromatography (HPLC). The blood and tissue 
homogenates from five mice were pooled. AMB standards were prepared by adding 
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AMB-DOC in concentrations ranging from 0.1-5 mg/L to blood or tissue 
homogenate obtained from untreated mice, followed by incubation at 37°C for 90 
min to allow binding of the antifungal agent to blood and tissue components. Both 
samples and standards were stored at -80°C until just before extraction. The AMB 
was extracted from the blood and homogenized tissues with ethanol in a mixture 
of sample and ethanol in a 4:6 (viv) ratio. The extracts were centrifuged for 5 min 
at 13,000xg and the concentrations of AMB in the supernatants were determined 
by HPLC; a C18 column (Chromspher, 100x3 mm; Perking-Elmer, Norwalk, CT, 
USA) with a Guard precolumn (Chromguard, lOx3 mm; Chrompack, Middelburg, 
The Netherlands) was used for this purpose. The mobile phase, which consisted of 
a 0.1 M sodium acetate solution (pH 7.2) containing 0.2% (v/v) triethylamine and 
60% (viv) acetonitrile, was run at a flow rate of 0.3 mUmin. AMB was detected at 
382 nm (LC 95 detector; Perking-Elmer). The sensitivity of the assay was 0.1 mg/L. 
Statistical analysis. Results were expressed as the geometric means ± S.D. 
Differences between the various treatment groups and times at which the mice were 
killed, in terms of the numbers of CFU, were analyzed by the Mann-Whitney test. 
RESULTS 
III vitro susceptibilities. The MICs of AMB-DOC and AmBisome® were 0.1 and 
0.05 mg/L, respectively; the corresponding MFCs were 3.2 and 6.4 mg/L. The MIC 
of FLU was 0.8 mg/L; fungicidal activity could not be demonstrated with FLU at 
concentrations up to 102 mg/L. 
III vitro activities during time-kill studies. The survival of C.albicans in the 
presence of varying concentrations of AMB-DOC and AmBisome® during 6 h of 
incubation at 37°C is shown in Figure 1. In the presence of 0.2 mg/L, AMB-DOC 
killed> 99.9% of the initial inoculum within 2 h. With AmBisome®, on the other 
hand, a concentration of 25.6 mg/L was required to produce the same fungicidal 
activity and this was only achieved after 6 h of incubation. 
MTDs of AMB-DOC and AmBisome®. The MTDs of AMB-DOC and AmBisome® 
in terms of death or significant abnormalities in the renal andlor hepatic functions 
of survivors 24 h after termination of treatment are presented in Table 1; similar 
result were observed 14 days after termination of treatment (data not shown). For 
AMB-DOC, the MTD which resulted in death was 0.8 mg AMBikg/day. In contrast, 
neither death nor a significant increase in the parameters used to detect 
abnormalities in renal function was observed with dosages of AmBisome® of up to 
32 mg AMB/kg/day. However, the MTD of AmBisome® in terms of significant 
abnormalities in hepatic function was 7 mg AMB/kg/day; from a dosage of 8 mg 
AMBikg/day, the concentrations of both hepatic enzymes were increased by up to 
four-fold. 
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Figure 1. In vitro fungicidal activities of AMB-OOC and AmBisome® in varying 
concentrations (mglL) against c.albicans. Each symbol represents the mean of three 
experiments. 
Table 1. Maximum tolerated dosages (MTOs)' of AMB-OOC and AmBisome® in 
uninfected mice. 
Criterion MTD (mg AMB/kglday) 
AMB-DOC AmBisome® 
Death O.B >32 
Renal function BUNb >0.8 >32 
CREAT' >O.B >32 
Hepatic function ASATd >O.B 7 
ALAT' >0.8 7 
~Expressed in terms of death during treatment or significant 'Increase in the parameters used 
to monitor renal and hepatic functions 24 h after termination of treatment 
bBlood urea nitrogen; 'Serum creatinine 
dAspartate aminotransferase, eAlanine aminotransferase 
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Efficacies of AMB-DOC, AmBisome® and FLU in infected immunocompetent 
mice. In immunocompetent mice infected with Calbicans, infection is confined to 
the kidney (Van Etten et al., unpublished data). The MTD of AMB-DOC for these 
animals in terms of death during treatment was 0.4 mg AMBlkg/day; for 
AmBisome®, dosages of up to 7 mg AMB/kg/day did not lead to death. The effects 
of the various treatments on the growth of Calbicans in the kidneys are shown in 
Table 2. During the study period, both an increase in the numbers of CFU and 
hyphal growth were observed following administration of the placebos. Therapy 
with AMB-DOC in a dosage of 0.4 mg AMB/kg/day (corresponding to the MTD) 
resulted in a significantly lower number of CFU in the kidneys 24 h after 
termination of treatment than did the placebos (P:<;O.OO1) and compared with the 
number of CFU at the start of treatment (P:<;O.OOl); AMB-DOC also prevented the 
number of CFU from increasing significantly at 14 days after termination of 
treatment i.e. relapse of infection. AmBisome®, in the same dosage (0.4 mg AMB/ 
kg/day), was equally effective in respect of these outcome measures. Increasing of 
the dosage of AmBisome® to 7 mg AMB/kg/day (the MTD) resulted in an even 
lower number of CFU 24 h after termination of treatment than AmBisome® at 0.4 
mg AMB/kg/day (p:<;0.01); the number of CFU was reduced still further 14 days 
after termination of treatment (P:<;O.OO1). FLU in a dosage of 0.4 mg FLU/kg/day 
produced a significant reduction in the number of CFU 24 h after completion of 
treatment compared with the number of CFU at the start of treatment (p:<;0.0251, 
but the number was not significantly lower than that observed following 
administration of a placebo. Although there were significantly fewer CFU in the 
kidneys at the 14-day post-treatment assessment with FLU than with the placebos 
(P:<;O.01), relapse of infection, in terms of both an increase in the number of CFU 
compared with the number 24 h after termination of treatment and hyphal growth, 
was not prevented. Nor did increasing the dosage of FLU to 64 mg FLUlkg/day 
improve the efficacy of this agent. 
Efficacies of AMB-DOC, AmBisome® and FLU in infeded leukopenic mice. In 
leukopenic mice infected with Calbicans, infection is disseminated to the kidneys, 
liver, spleen and lungs, and untreated mice die between 24 hand 7 days after 
inoculation (Van Etten et a/., unpublished data). The MTD of AMB-DOC in terms 
of death during treatment was 0.3 mg AMBlkg/day; for AmBisome®, dosages of up 
to 7 mg AMB/kg/day did not cause death. The effects of treatment on the survival 
of leukopenic mice and growth of candida in the kidneys of survivors are shown 
in Tables 3 and 4, respectively. In common with immunocompetent mice, treatment 
with a placebo was associated with both an increase in the number of CFU and 
hyphal growth in the kidneys. Furthermore death of the animals was observed. 
Since almost all placebo-treated mice died, the numbers of CFU in the organs of the 
animals receiving a placebo were not compared with those in the organs of the 
animals receiving one of the antifungal agents. AMB-DOC, in a dosage equivalent 
to the MTD of this agent in leukopenic mice (0.3 mg AMB/kg/day), resulted in 
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Table 2. Effect of treatment on growth of C.albicans in the kidneys of immunocompetent mice. 
treatment' dosage start of treatment 
(mg/lq",day) 
Loglo CFU/kidneyb 
untreated 4.58 ± 0.29 
AMB-DOC 0.4 
AmBisome® 0.4 
AmBisome® 7 
FLU 0.4 
FLU 64 
PLACEBO-DOC -
PLACEBO-UP -
PLACEBO-PBS -
- -_. 
aStarted 48 h after inoculation and continued for 5 days 
bCeometric mean ± S.D. 
24 h after termination 
of treatment 
hypha I Loglo CFU/kidneyb 
growth in surviving m"lce 
- 2.44 ± O.32c 
- 3.06 ± 0.62' 
- 2.20 ± 0.87' 
- 3.57 ± 1.10' 
- 2.97 ± 0.58' 
+ 4.19 ± 0.62 
+ 4.78 ± 0.79 
+ 4.40 + 0.76 
(!P~O.025 compared with number of CFU at start of treatment 
ipS-G.02S compared with number of CFU 24 h after termination of treatment 
- ~ no hyphal growth; + ~ hypha I growth 
14 days after termination of treatment 
hyphal log" CFU/kidneY' no. of mice with 
growth in surviving mice sterile kidneys/no. 
oi surviving mice 
-
2.15 ± 0.88 0/10 
- 2.81 ± 1.18 0/10 
- 0040 ± 0.25 1/10 
+ 4.90 ± 1.32' 0/10 
+ 4.41 ± 1.39' 0/10 
+ 6.08 ± 0.85' 0/10 
+ 6.67 ± 0.80' 0/10 
+ 6.56 + 0.65' 0/10 
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100% survival, as well as significant reductions in the numbers of CFU in the liver, 
spleen and lungs (P';O.OOl) (data not shown). However, at this dosage, growth of 
Candida in the kidneys was only inhibited during treatment i.e. the number of CFU 
24 h after termination of treatment was not significantly different from the number 
at the start of treatment. Consequently, at the 14-day post-treatment assessment 
there was relapse of infection, manifested by hyphal growth and a significant 
increase in the number of CFU compared with the number at the 24 h post-
treatment assessment. AmBisome®, at the equivalent dosage of 0.3 mg AMB/kg/day, 
was completely ineffective and did not even inhibit growth in the kidneys; at 24 h 
following completion of treatment, the number of CFU was greater than that at the 
start of treatment. At a dosage of 7 mg AMB/kg/day (the MTD), however, the 
number of CFU 24 h after treatment was discontinued was significantly reduced 
compared with the number at the start of treatment (P';O.OO1). In addition, relapse 
at the 14-days post-treatment assessment was prevented and the number of CFU 
was further reduced compared with that at 24 h (P';O.OO1). In a dosage of 0.3 mg 
FLU/kg/day, FLU was not effective. But at the higher dosage of 64 mg FLUlkg/day, 
its activity was similar to that of AMB-DOC, except that 24h after termination of 
treatment, the number of CFU in the kidneys was significantly lower than that at the 
start of treatment (P';O.OO1); despite this initial reduction, relapse of infection was 
not prevented. 
Table 3. Effects of treatment on survival of leukopenic mice infected with 
Calblcans. 
treatmenla 
AMB-DOC 
AmBisome® 
AmBisome® 
FLU 
FLU 
PLACEBO-DOC 
PLACEBO-LIP 
PLACEBO-PBS 
dosage 
(mg/kg/day) 
0.3 
0.3 
7 
0.3 
64 
survival (%) 
24 h after 
termination 
of treatment 
100 
90 
100 
60 
100 
80 
80 
40 
14 days after 
termination 
of treatment 
100 
50 
100 
o 
100 
o 
10 
o 
aStarted 6 h after inoculation and continued for 5 days 
The effects of prolonged therapy (18 days) with FLU in a dosage of 64 mg 
FLU/kg/day and maintenance therapy (13 days) at the same dosage following an 
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Table 4. Effects of treatment on growth of C.albicans in the kidneys of leukopenic mice. 
treatment" dosage start of treatment 
(mg/kglday) 
Log" CFU/kidney' 
untreated 2.65 ± 0.22 
AMB-DOC 0.3 
AmBisome® 0.3 
AmBisome® 7 
FLU 0.3 
FLU 64 
PLACEBO-DOC -
PLACEBO-LIP -
PLACEBO-PBS -
JStarted 6 h after inoculation and continued for 5 days 
bCeometric mean ± S.D. 
24 h after termination 
of treatment 
hyphal Log" CFU/kidney' 
growth in surviving mice 
-
2.81 ± 0.49 
ND 4.20 ± 0.67 
- 1.21 ± 0.30' 
ND 5.83 ± 0.61 
- 1.99 ± 0.47' 
ND 5.67 ± 1.10 
ND 5.60 ± 0.93 
ND 6.70 ± 0.48_ 
cP:;;O.025 compared with number of CFU at start of treatment 
dp:=:;O.025 compared with number of CFU 24 h after termination of treatment 
- ~ no hypha I growth; + ~ hyphal growth 
NO = Not done 
14 days after termination of treatment 
hyphal Log" CFU/kidney' no. of mice with 
growth in surviving mice sterile kidneys/no. 
of surviving mice 
+ 5.28 ± 1.14' 0/10 
ND 3.96 ± 1.86 0/5 
- 0.39 ± 0.52 6/10 
ND ND ND 
+ 5.20 ± 1.28' 0/10 
ND ND ND 
ND 5.56 0/1 
ND ND ND 
- - - - -
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initialS days of treatment with AmBisome® (7 mg AMB/kg/day) are shown in Table 
5. Extending the duration of FLU treatment did not result in a significantly lower 
number of CFU in the kidneys 19 days after starting treatment compared with the 
number of CFU after only 5 days of treatment. Similarly, the effects of treatment 
with AmBisome® followed by FLU were not significantly different in terms of the 
number of CFU in the kidneys compared with the effects of treatment with 
AmBisome® alone. 
Table S. Effects of prolonged or maintenance treatment with FLU on growth of 
C.albicans in the kidneys of leukopenic mice. 
treatmentd dosage 
(mg/kg/day) 
FLUd 
AmBisome®e 
AmBisome®/FLU' 
aStarted 6 h after inoculation 
bCeometric mean ± S,D. 
64 
7 
7/64 
Log lO CFU/kidneY' 
in surviving miceC 
2.28 ± 0.36 
0.39 ± 0.52 
0.25 + 0.41 
(Effects of treatment were assessed 19 days after starting 
dAdministered for 18 days 
PAdministered for 5 days 
'AmBisome" for 5 days followed by FLU for 13 days 
no. of mice with 
sterile kidneys/no. of 
surviving micec 
0/10 
6/10 
7/10 
The results of the experiment to assess the effects of treatment in relation to the 
severity of infection are presented in Table 6. Infection of varying degrees of 
severity was produces by increasing the delay between inoculation and the 
initiation of therapy. This was reflected in the number of CFU in the kidneys at the 
start of treatment (2.65±0.22 10gIO when treatment was commenced 6 h after 
inoculation compared with 3.97 ±0.38 log,o when treatment was delayed until 24 
h after inoculation). The greater severity of infection resulting from 16- or 24 h 
delays in starting treatment was also reflected in the lower MTDs of AmB-DOC 
(both 0.1 mg AMB/kg/day) compared with the MTD (0.3 mg AMB/kg/day) when the 
delay was only 6 h. The ultimate effect of withholding treatment until 16 h after 
inoculation was that the efficacy of AMB-DOC was reduced. On the other hand, 
despite a 16 h delay, AmBisome®, in a dosage of 7 mg AMB/kg/day, retained its 
efficacy and still produced 100% survival and a significant reduction in the number 
of CFU in the kidneys. The effects of prolonging the delay to 16 h before 
administering FLU at a dosage of 64 mg FLU/kg/day were similar to those of AMB-
DOC. Even when the initiation of treatment with the higher dosage (7 mg AMB/kg/ 
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Table 6. Effects of treatment in relation to severity of infection, assessed in terms of survival and growth of C.albicans in the kidneys 
of leukopenic mice. 
start of treatment 
(after inoculation) 
6 h 
16 h 
24 h 
JContinued for 5 days 
bCeometric mean ± S.D. 
treatmene 
AMB-OOC 
AmBisome® 
FLU 
AMB-OOC 
AmBisome® 
FLU 
AMB-OOC 
AmBisome® 
FLU 
dosage 
(mg/kg/day) 
0.3 
7 
64 
0.1 
7 
64 
0.1 
7 
64 
'Determined 14 days after termination of treatment 
- - nO hypha! growth; + - hypha! growth 
NO - Not done 
5urvivaiC hypha! 
(%) growth' 
100 + 
100 
100 + 
40 NO 
100 
70 NO 
NO NO 
90 NO 
NO NO 
Log" CFUlkidney' in 
surviving micec 
5.28 ± 1.14 
0.39 ± 0.52 
5.20 ± 1.28 
6.20 ± 0.97 
1.90 ± 0.66 
6.17 ± 0.61 
NO 
1.29 ± 0.82 
NO 
no. of mice with 
sterile kidneys/no. 
of surviving micec 
0/10 
6/10 
0/10 
0/4 
0/10 
0/7 
NO 
0/9 
NO 
'" '" 
Table 7. AMB concentrations in blood and tissues after treatment of infected leukopenic mice with AMB-DOC or AmBisome®. 
treatmenfi dosage AMB concentrationb 
(mglkg/day) 24h after termination of treatment 
blood liver spleen kidney 
mg/L pg/g pg/g pg/g 
AMB-DOC 0.3 0.2 < 3.3 < 
AmBisome® 7 1.7 356 700 14.5 
"Started 6 h after inoculation and continued for 5 days 
bBlood samples and tissue homogenates from five mice were pooled 
< = not detectable 
AMB concentrationb 
14 days after termination of treatment 
lung blood liver spleen kidney lung 
pg/g mg/L pg/g pg/g pg/g pg/g 
0.6 < < 2.3 < < 
5.9 < 170 243 7.8 < 
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day) of AmBisome® was delayed for 24 h, it remained partially effective, with 90% 
of animals surviving. 
Concentrations of AMB in the blood and tissues of leukopenic mice treated 
with AMB·DOC and AmBisome®. The concentrations of AMB in the blood and 
tissues of leukopenic mice following treatment with AMB·DOC and AmBisome® 
in dosages which corresponded to their respective MTDs are shown in Table 7. At 
24 h after completing treatment with AMB·DOC (0.3 mg AMB/kg/day), only low 
concentrations of AMB were detected in the blood, spleen and lungs; 14 days after 
completion of treatment, AMB was detectable only in the spleen. In contrast, the 
administration of AmBisome® at 7 mg AMB/kg/day led to the detection of much 
higher concentrations of AMB in the blood, liver, spleen, kidneys and lungs 24 h 
after completing treatment. AMB was still detectable in the liver, spleen and kidneys 
14 days after completing treatment. 
DISCUSSION 
It has previously been demonstrated ill vitro [37] that AMB·DOC, following 
short·term exposure, is fungicidal against Ca/bicans, whilst FLU only inhibits 
growth. Other investigators have reported that the activity of AmBisome® against 
Ca/bicans, based on the MICs and MFCs was similar to that of free AMB [3]. The 
present study has confirmed that the activities of AMB·DOC and AmBisome®, in 
terms of the MICs and MFCs, are similar, but with short-term exposure (time-kill 
studies), the activity of AmBisome® is significantly less than that of AMB-DOC. 
Moreover, the in vitro activity of another liposomal formulation of AMB, prepared 
from dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol, has also 
been shown with time-kill studies to be less than that of either AMB-DOC or free 
AMB but to have comparable MICs and MFCs [13,29]. In the present study, the 
effective killing of Ca/bicans by AmBisome® within a 6-h period of incubation was 
observed only at high concentrations, suggesting that the cidal activity of this agent 
during long-term exposure might be attributed to the release of AMB from the 
liposomes into the medium. It is not clear whether the antifungal activity of 
AmBisome® is the result of a direct interaction between AmBisome® and C.a/bicans 
or the release of AMB from liposomes during prolonged incubation or both. 
Treatment with AMB in the form of AMB-DOC was limited to toxicity. When 
AMB was incorporated into liposomes (AmBisome®), much higher dosages of this 
agent were tolerated, although, from dosages of 8 mg AMB/kg/day, disturbances of 
hepatic function were detected. However, as the increase in hepatic enzymes in 
plasma was at most fourfold, according to criteria from hospital practice, the 
disturbances of hepatic function were only mild. It is paradoxical that the mice were 
killed by lower dosages of AMB·DOC than were required to produce abnormalities 
of renal and hepatic function. It may be that the death of animals observed with 
AMB-DOC was related to the way in which the drug was administered. As AMB-
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DOC cannot be administered by slow infusion, it is given as a bolus, and this may 
produce acute adverse reactions, including death. If these reactions could be 
suppressed, it is possible that the dosages of AMB-DOC required to produce 
abnormalities of renal or hepatic function would then be lower than those causing 
death. 
In the immunocompetent mice, treatment was started when infection was well 
established in the kidneys. With this model, both AMB-DOC and AmBisome® were 
shown to be effective in reducing the numbers of CFU in the kidneys and in 
preventing relapse after treatment had been stopped. Other investigators have used 
a lethal model of Candida infection to show that high dosages of AmBisome® are 
able to increase the median survival time and to bring about significant reductions 
in the numbers of CFU in the kidneys of infected immunocompetent mice [1,11]. 
In common with others [8,9,38], we have shown that even high dosages of FLU 
only reduce the numbers of CFU in the kidneys during treatment. 
Treatment was inititiated in leukopenic mice at various intervals after inoculation 
in order to investigate the influence of the severity of infection on the efficacy of 
therapy. When treatment with AMB-DOC was commenced shortly after inoculation, 
the animals survived but relapse of infection was not prevented. The administration 
of high dosages of FLU led to reductions in the numbers of CFU in the kidneys 
soon after termination of treatment; this has also been reported by other 
investigators [39,40] who found low numbers of CFU in the kidneys of 
granulocytopenic rabbits when treatment was started shortly after initiation of 
infection. However, FLU failed to prevent eventual relapse. Nor did prolonged 
treatment with FLU improve the efficacy of this agent in terms of reducing further 
the number of CFU in the kidneys. The use of AmBisome® enabled higher dosages 
of AMB to be administered and treatment with this drug led to the isolation of a 
low number of organisms from the kidney, even at two weeks after termination of 
therapy. Moreover, only with AmBisome® was it possible to sterilize the tissues of 
some of the animals. Maintenance therapy with FLU following initial treatment with 
AmBisome® did not enhance the efficacy of the latter drug. In severe infections 
resulting from a prolonged delay in initiating treatment, the dosage of AMB-DOC 
was limited by its toxicity and this led to a reduction in efficacy. Treatment with 
high dosages of FLU was also relatively ineffective under these circumstances. The 
efficacy of AmBisome®, however, was preserved in the presence of severe infection; 
at 14 days after completion of treatment, the number of CFU in the kidney 
remained low. 
Following treatment with AmBisome® in dosages corresponding to its MTD, high 
concentrations of AMB were detected in the tissues, an observation which is in 
agreement with the results of other studies in which multiple doses of AmBisome® 
were administered [1,27]. No toxic effects were observed with these high AMB 
concentrations and 14 days after treatment had been discontinued, the drug was still 
detectable in the liver, spleen and kidneys. Other investigators have also reported 
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the presence of AMB in the kidneys 8 days after a 5-day course of AmBisome® [1]. 
It has not been determined whether these high AMB concentrations represent the 
liposome formulation or the free drug. 
The initial reduction in the number of CFU in the kidneys of immunocompetent 
mice shortly after completing treatment with FLU, which has no fungicidal activity 
in vitro, can be accounted for by the contribution of host defence mechanisms to 
the eradication of the Candida. In leukopenic animals, however, the role of host 
defence factors is markedly diminished. None the less, killing of candida following 
the administration of FLU to immunocompromised animals was noted in the present 
study and has also been reported by others [39,40J there is no obvious explanation 
for this observation. 
The efficacies of AMB-DOC and FLU in immunocompetent and leukopenic mice 
demonstrated here have also been described by others [38J who reported that 
AMB-DOC was superior to FLU in the treatment of immunocompetent mice but that 
both agents were equally effective in leukopenic mice. 
In summary, treatment with AMB~DOC was effective in immunocompetent mice 
but could not prevent relapse of infection in leukopenic mice once therapy had 
been stopped. With AmBisome®, much higher dosages of AMB were tolerated, 
thereby leading to effective treatment in both immunocompetent and severely 
infected leukopenic mice. Treatment with high dosages of FLU failed to prevent 
relapse in both groups of mice. The results of the present study should provide the 
impetus for clinical trials to evaluate the efficacy of AmBisome® in the treatment of 
invasive candidiasis in neutropenic patients. 
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ABSTRACT 
The biodistribution of liposomal amphotericin B (AmBisome®) and amphotericin 
B-desoxycholate (AMB-DOC) were compared after a single injection of drug in 
un infected immunocompetent mice and in leukopenic mice 6 h after inoculation 
with Candida aJbicans. AMB-DOC was administered at the maximum tolerated dose 
(MTD) of 0.3 mg AMB/kg whereas AmBisome® was given at either 0.3 mg AMB/kg 
or the MTD of 7 mg AMB/kg. Amphotericin B (AMB) concentrations in the blood, 
liver, spleen, lungs and kidneys were determined by HPLC analysis at various 
intervals during the 48 h after administration. The biodistribution of both 
preparations of AMB followed similar patterns in both un infected immuno-
competent mice as well as those that were leukopenic and infected with C.aJbicans. 
Administration of AmBisome® resulted in increased concentrations of drug in the 
blood, liver and spleen but decreased concentrations in the kidney and lung. 
Hepatosplenic uptake of AmBisome® was highly dose dependent with 7 mg 
AMB/kg resulting in a relatively prolonged blood circulation. Blood and tissues 
retained high AMB concentrations after administration of AmBisome® at the MTD. 
By using radiolabeled AmBisome®, it was found that the high AMB concentrations 
in blood represented liposome-associated AMB and that during circulation in blood 
slow release of AMB occurred. 
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INTRODUCTION 
Parenteral administration of amphotericin B (AMB) remains the treatment of 
choice for most invasive fungal infections but its clinical utility is limited by the 
toxic side effects resulting from treatment with the desoxycholate preparation 
[11, 17J. Recently, AMB has been incorporated into liposomes or other lipid-carriers 
leading to a reduction in toxicity thereby improving the therapeutic index 
[6,12, 17,21J. One of these formulations, AmBisome"', has been shown to result in 
improved efficacy in the treatment of various experimental fungal infections in both 
immunocompetent and imunocompromised animals [2,4,5,9, 13,23J although little 
is known about the way in which AmBisome® exerts its antifungal activity in vivo. 
There are some data on the biodistribution of AmBisome® in uninfected 
immunocompetent mice [2,13], rats [20], and rabbits [9J but there are no published 
data for infected leukopenic animals. Moreover, the published data do not allow a 
distinction to be made between liposome-encapsulated AMB and non-encapsulated 
AMB because only data on the total concentrations of AMB in serum and tissues are 
available. We therefore undertook a study to compare the biodistribution of 
AmBisome® with that of amphotericin B-desoxycholate (AMB-DOC) in leukopenic 
mice infected with Candida albicans and in uninfected immunocompetent mice by 
radiolabel ing AmBisome® with a radioactive marker that represents intact I iposomes. 
MATERIALS AND METHODS 
Candida strain. Candida albicans ATCC 44858 was used in all of the 
experiments and was stored at -80°C in Todd-Hewitt broth (Difco laboratories, 
Detroit, MI, USA) containing 10% (v/v) glycerol. 
Animals. Specified pathogen-free, 14- to 20-weeks-old female BALB/c mice were 
obtained from Iffa Credo (L' Arbresle, France). 
Amphotericin B preparations. Amphotericin B-desoxycholate (AMB-DOC; 
Fungizone"', Bristol Myers-Squibb, Woerden, The Netherlands) was reconstituted 
with distilled water to obtain a stock solution of 5 g AMB/l. Liposomal AMB, 
AmBisome"', AMB encapsulated in small unilamellar vesicles consisting of 
hydrogenated soybean phosphatidylcholine, cholesterol and distearoylphospha-
tidylglycerol in a molar ratio of 2: 1 :0.8, was kindly provided by Vestar Inc. (San 
Dimas, CA, USA) as a lyophilized preparation. The powder was reconstituted in 
distilled water at 65°C according to the manufacturer's instructions to give a 
liposomal suspension containing 4 g AmB/L and 35 g lipid/l. 
Induction of leukopenia and infection with C.albicans. Leukopenia was induced 
by injecting 100 mglkg cyclophosphamide (Sigma Chemical Co., St.Louis, MO) ip 
4 days before inoculation with Calbicans. A further dose of 75 mglkg was given 
on the day of infection. Infection was induced by inoculating 104 CFU of Calbicans 
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into the tail vein. This treatment resulted in persistent granulocytopenia of 
<0.lx10'/L granulocytes from the time of inoculation up to the end of the study. 
Radiolabelingof AmBisome®. LyophilizedAmBisome® powder was reconstituted 
with distilled water containing 5 mM deferoxamine mesylate (OF; Ciba Geigy, 
Basel, Switzerland). AmBisome® was radiolabeled with "Ga·OF as described by 
Woodle [24J using "Ga-citrate from Nordian (Montreal, Canada) which formed a 
"Ga-OF complex in the aqueous interior of the liposomes. This complex is 
appropriate for tracing of intact liposomes in vivo because there is minimal 
translocation of radioactive label to plasma proteins and renal clearance is rapid 
once the label is released from the liposomes [lOJ. Liposomes were separated from 
free OF and radiolabel by gel filtration on a Sephadex G-50 column (Pharmacia, 
Uppsala, Sweden) eluted with a buffer solution containing 10 mM sodium-succinate 
and 5% (w/v) glucose (pH 5.5) and concentrated using 300 kOa Microsep filters 
(Filtron, Breda, The Netherlands). The concentration of AMB was determined 
spectrofotometrically at 405 nm, after destruction of the liposomes in OMSO-
methanol (1: 1, v/v). 
Determining the biodistribution of AMB following administration of both 
preparations. The biodistribution of AMB was determined in groups of mice after 
iv administration of AMB-OOC or AmBisome® at 0.3 mg AMB/kg, which was the 
maximum tolerated dosage (MTO) of AMB-OOC after five consecutive days of 
treatment of infection due to c.albicans in leukopenic mice [23J. AmBisome® was 
also given at the MTO of 7 mg AMB/kg, which had been determined previously 
[23J. Each preparation of the drug was administered to leukopenic mice 6 h after 
inoculation with C.albicans. 
Determining the concentrations of AMB. AMB concentrations were determined 
in two separate sets of experiments in the blood, liver, spleen, lungs and kidneys 
of five mice at each of the various time points during the first 48 h after 
administration. Blood was collected in heparinized tubes immediately before the 
mice were killed. After removal, the spleen, kidneys, lungs, and liver were weighed 
and homogenized separately in distilled water. The blood samples and tissue 
homogenates from each group of five mice were pooled and stored at -80°C until 
required for assay using high-performance liquid chromatography (HPLC) analysis 
[23J. Illln-labeled syngeneic red blood cells were employed to determine the total 
blood volume and the correction factors for the blood in each organ [14J. 
Blood levels of AMB and "Ga-DF following administration of radiolabeled 
AmBisome®. Radiolabeled AmBisome® was administered to un infected mice as a 
single iv dose of 7 mg AMB/kg in two separate experiments. The concentrations of 
"Ga-OF were determined in heparinized blood of each of the five mice at each of 
various time points during the first 24 h after administration. Counts of "Ga-OF 
were determined in 200 tiL samples of blood as well as in the liposomes contained 
in the original dose using a gamma counter (Minaxy 5530, Packard Instruments, 
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Downers Grove, USA). Blood samples from each of five mice were then pooled and 
stored at -80°C until required for HPLC analysis for AMB concentrations. 
RESULTS 
Biodistribution of AMB following administration of AmB-DOC or AmBisome® 
at an equivalent dosage. In both infected leukopenic mice and uninfected 
immunocompetent mice, liposomal encapsulation of AMB resulted in increased 
concentrations of AMB in the blood, liver, and spleen but lower concentrations in 
the kidney and lungs (Figure 1). Five minutes after injection, 41 % of the dose of 
AmBisome® was recovered from the blood of uninfected mice and 4% of the 
original dose was retrieved 4 h after administration whereas 61 % AMB was 
recovered from liver and 10% from spleen 1 h after administration and there was 
no decrease in drug recovery during the first 12 h after injection. In contrast, 13% 
of AMB-DOC was recovered in blood 5 min after injection and 4% was retrieved 
2 h after administration whereas 26% of the drug was recovered from the liver and 
only 3% was recovered from the spleen after 15 min. At 12 h after administration 
16% was retrieved from the liver. Up to 6% of AMB was detected in the kidneys 
15 min after administration of AMB-DOC and up to 5% in the lungs 4 h after 
injectioll whereas none of the AmBisome® was retrieved in these organs. The 
biodistribution of AMB in both infected and uninfected mice followed a similar 
pattern. 
Biodistribution of AMB following administration of AmBisome® in relation to 
dosage. The biodistribution of AmBisome® in both infected and uninfected mice 
was similar and hepatosplenic uptake of AmBisome® was highly dosage dependent 
(Figure 2). Five minutes after injecting 0.3 mg AMB/kg, 54% of the drug was 
recovered from the liver and spleen of uninfected mice and increased to 81 % 
within 12 h after administration whereas 41 % of the drug was recovered from 
blood 5 min after injection and less than 3% 12 h later. In contrast, the 
hepatosplenic uptake was less than 3% 5 min after injection of 7 mg AMB/kg 
whereas 99% of the dose was retrieved in blood. Twelve hours after administration, 
uptake by the liver and spleen had increased to 64% while the amount recovered 
from blood decreased to 15%. 
Blood and tissue levels of AMB following administration of AMB-DOC or 
AmBisome® both at their MTDs. Within 48 h after administration of AmBisome®, 
blood concentrations of AMB in uninfected mice decreased from 104 mg/L to 0.2 
mg/L (Table 1) Peak concentrations occurred in the liver 12 h after injection, in the 
kidneys and lungs 12 h later and in the spleen 48 h after administering the drug, 
and there was no decrease in drug recovery during the first 24 h after injection. 
Blood concentrations of AMB decreased from 0.6 to 0.2 mg/L within 2 h after 
injecting AMB-DOC. Peak concentrations occurred in the liver, and spleen 5 min 
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Figure 1. AMB levels in blood and tissues after a single dose iv of AMB-OOC or 
AmBisome'" at an equivalent dosage of 0.3 mg AMBlkg in uninfected immuno-
competent mice as well as in leukopenic mice infected with c'albicans. 
181 AMB-OOC in uninfected mice; III AMB-OOC in infected leukopenic mice; I2ll 
AmBisome® in un infected mice; 0 AmBisome® in infected leukopenic mice. Each 
symbol represents the mean of two experiments. Blood and tissue samples from five 
mice were pooled. 
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Figure 2. Blood levels and hepatosplenic uptake of AMB after a single dose iv of 
AmBisome® in relation to dosage in un infected immunocompetent mice as well as 
in leukopenic mice infected with C.albicans. 411 AmBisome® at 0.3 mg AMBlkg in 
uninfected mice; 0 AmBisome® at 0.3 mg AMBlkg in infected leukopenic mice; 
l1li AmBisome® at 7 mg AMBlkg in un infected mice; 0 AmBisome® at 7 mg 
AMBlkg in infected leukopenic mice. Each symbol represents the mean of two 
experiments. Blood and tissue samples from five mice were pooled. 
after injection and 10 min later in the kidney and lung. Concentrations of drug 
gradually decreased in liver, spleen and kidney during the first 12 h after 
administration. The biodistribution of AMB in both infected (Table 2) and 
un infected mice followed a similar pattern. 
Blood levels of AMB and "Ga-DF following adminislralion of radiolabeled 
AmBisome®. Following injection of 7 mg AMBikg radiolabeled AmBisome®, a 
relatively prolonged circulation of intact liposomes indicated by the detection of 
"Ga-OF was observed, while the concentration of AMB declined more rapidly 
(Figure 3). Incubating AmBisome® in 90% (vlv) serum at 3JOC in vitro for 6 h did 
not lead to any detectable loss of drug from the liposomes (data not shown). 
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Table 1. AMB concentrations in blood and tissues after a single dose iv of AMB-OOC or AmBisome® in un infected immuno-
competent mice. 
AMB concn' (mg/l) AMB concn' (jig/g) 
Time 
after BLOOD LIVER SPLEEN KIDNEY 
injection 
A-DOCb L_Ab A-DOCb L_Ab A-DOCb L_Ab A-DOCb 
5 min 0.6 104.4 1.8 5.7 2.0 29.4 0.9 
15 min 0.3 95.4 1.4 19.4 2.0 37.0 1.2 
1 h 0.2 53.8 1.2 38.7 < 51.1 0.9 
2 h 0.2 46.5 1.1 49.1 < 64.2 0.9 
4 h 0.1 30.3 1.1 50.4 < 77.3 0.6 
12 h < 15.1 0.8 76.1 < 69.6 0.6 
24 h < 0.7 < 70.9 < 88.1 < 
48 h < 0.2 < 62.7 < 106.6 < 
<lBlood samples and tissue homogenates from five mice were pooled 
bA dosage of 0.3 mg AMBlkg AmB·DOC (A·DOC) or 7 mg AMBlkg AmBisome® (L-A) was administered iv 
< = not detectable 
L_Ab 
3.0 
3.0 
4.3 
5.2 
7.3 
3.9 
9.1 
6.1 
LUNG 
A-DOCb L_Ab 
0.8 < 
1.3 < 
0.8 < 
0.8 < 
1.3 < 
0.8 8.3 
< 15.6 
< 15.0 
'" en 
Table 2. AMB concentrations in blood and tissues after a single dose iv of AMB-DOC or AmBisome® in infeaed leukopenic mice. 
AMB concn' (mg/L) AMB concn' (jig/g) 
Time 
after BLOOD LIVER SPLEEN KIDNEY LUNG 
injection 
A-DOCb L_Ab A-DOCb L_Ab A-DOCb L-Ab A-DOCb L_Ab A_DOCb L_Ab 
5 min 0.5 102.0 1.9 17.7 < 28.0 1.3 6.3 1.1 < 
15 min 0.4 96.7 2.1 25.9 4.9 38.0 1.0 4.0 1.1 < 
1 h 0.3 76.8 2.2 48.6 3.3 92.0 1.0 1.3 1.1 < 
2 h 0.2 53.9 1.8 57.9 3.3 90.0 0.7 1.3 1.1 < 
4 h 0.2 39.7 1.4 64.6 < 122.0 < 2.7 < < 
12 h < 13.1 1.0 85.2 < 118.0 < 3.0 < 1.4 
24 h < 1.5 0.8 97.8 < 140.0 < 4.0 < 7.1 
48 h < 0.3 < 82.3 < 134.0 < 4.0 < 6.2 
OIB!ood and tissue samples from five mice were pooled 
bA dosage of 0.3 mg AMB/kg AmB·DOC (A·DOq or 7 mg AMB/kg AmBisome® (L·A) was administered ivat 6 h after Calbicans inoculation 
< = not detectable 
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Figure 3. Blood levels of AMB (0) as well as "Ca-DF (l1li) after a single dose iv of 
radiolabe/ed AmBisome® at a dosage 01 7 mg AMB/kg in uninfected immuno-
competent mice. Each symbol represents the mean of two experiments. 
DISCUSSION 
The blood, liver and spleen concentrations 01 AMB were consistently higher after 
administration of AmBisome® than were those of the desoxycholate preparation. 
The biodistribution of both preparations of AMB exhibited a similar pattern in 
uninfected immunocompetent mice as well as in leukopenic mice infected with 
c.albicans which suggests that infection does not influence the disposition of the 
drug. Lopez-Berestein et al. [16] demonstrated the same phenomenon when 
comparing a different liposomal preparation of AMB (dimyristoyl phosphatidyl-
choline and dimyristoyl phosphatidylglycerol in a 7:3 molar ratio) with AMB-DOC 
in immunocompetent mice. The immune status of the mice also had little influence 
on the biodistribution of the drug. The higher AMB concentrations found in the 
tissues of leukopenic mice, especially in the spleen, was probably due to the 
decrease in organ weight as a result either of infection or the aplasia induced by 
cyclophosphamide to inhibit hematopoiesis. 
Hepatosplenic uptake of AmBisome® was highly dose dependent and the higher 
dose of AmBisome® produced a relatively long AMB circulation time as also shown 
by others [9,13,20]. When AmBisome® was given at the MTD, blood and tissue 
retained relatively high drug concentrations without evidence of toxicity as also has 
been noted by others [13,20]. 
When an equivalent dose of the liposomal preparation and AMB-DOC was given 
to immunocompetent uninfected mice, encapsulation of AMB resulted in increased 
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drug concentrations in blood, liver and spleen as has also been reported by Gondal 
et a/. [13] and Francis et a/. [9]. Gondal et al. [13] reported increased AMB levels 
in the liver and spleen and found equal drug concentrations in the kidneys and 
slightly elevated concentrations in the lungs during the first hour after 
administration. In contrast, concentrations in the kidneys and lungs were decreased 
in our study which we believe explains the lower efficacy of AmBisome® to an 
equivalent dosage of the desoxycholate preparation when treating systemic 
candidiasis in neutropenic mice [23]. The discrepancies might be the result of 
residual blood in the organs which will inflate the concentration unless a correction 
factor, such as the one we used, is employed. 
Different patterns of biodistribution in animals were observed for the other 
industrially produced AMB lipid preparations, AmB-Lipid-Complex (ABLC) and 
AmB-Colioidal-Dispersion (ABCD, Amphocil®). Tissue concentrations of AMB in the 
liver and spleen were higher after administering ABLC than were those of AMB-
DOC. Lung concentrations were similar to those after AMB-DOC whereas those in 
the kidney were slightly higher after the desoxycholate preparation [3,18]. Due to 
its large size (1.6-11 jJm) ABLC is rapidly entrapped by the mononuclear phagocyte 
system resulting in blood levels that are considerably lower than those achieved 
with AMB-DOC. Animals receiving ABCD showed reduced peak concentrations of 
AMB in plasma and decreased concentrations in the spleen, kidney and lung but 
increased concentrations in the liver compared to the concentrations after treatment 
with AMB-DOC [7,8]. 
It is still thought that AMB is pharmacologically inactive when bound to 
liposomes. It was recently shown by Adler-Moore [1] and Proffitt et a/. [19] that 
AMB remains tightly associated with the liposomal strucuture of AmBisome® in vitro 
and in vivo and that AmBisome® can interact directly with both phagocytized and 
non phagocytized fungal cells, resulting in death of the fungi. The extent to which 
release of AMB is important to the antifungal activity of AmBisome® is at present 
under investigation. However, a distiction should be made between liposome-
encapsulated AMB and non-encapsulated AMB in blood and tissues in order to gain 
more insight into the antifungal activity of AmBisome® in vivo [6,15]. None of the 
assays originally used to measure AMB concentrations allowed this distinction to 
be made until Sculier et a/. [22] developed a method for estimating the ratio of non-
encapsulated and encapsulated liposomal AMB concentrations in serum by 
determining the total AMB concentrations by HPLC and the concentration of 
liposomes by the amount of inorganic phosphorus. Accurate assay of blood 
concentrations of liposomal AMB is further complicated if liposomal drug sediments 
together with erythrocytes during centrifugation to prepare plasma or serum. To 
obviate this, we measured AMB concentrations in whole blood and also 
investigated whether AMB concentrations in blood represented liposome-associated 
AMB by measuring the residence time of both AMB as well as intact liposomes in 
blood. 
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The data from th is study suggest that the largest proportion of the total AMB 
concentration in blood represented liposome-encapsulated AMB. We tested various 
methods for separating AMB bound to lipoproteins and other plasma components 
from liposome-encapsulated AMB. Gel filtration on Sephacryl S500 or S 1000, 
Sepharose 4B, Biogel A.15 columns were inappropriate for this purpose as was 
filtration/centrifugation through 300kDa Microsep filters. In the present study we 
opted to investigate whether AMB concentrations in blood represented liposome-
associated AMB by labeling AmBisome® with the radioactive marker 67Ga_DF which 
is a representative for intact liposomes. A relatively prolonged residence time of 
intact liposomes was shown after administration of AmBisome® at 7 mg AMBikg. 
AMB levels in blood were equal or lower than the levels of intact liposomes 
suggesting that total AMB levels represent liposome-associated AMB, with slow 
release of AMB from the liposomes during circulation. As no AMB was released 
from AmBisome® in 90 % (v/v) serum at 37°C (unpublished data), the AMB 
released in whole blood was thought to be due, at least partly, to the interaction of 
AmBisome® with blood cells. 
In summary, the biodistribution of neither preparation of AMB in mice was 
influenced by immunocompetence nor by infection with C.albicans. Encapsulation 
of AMB in AmBisome® yielded increased concentrations of drug in the blood, liver 
and spleen whereas levels in kidney and lung were decreased. Hepatosplenic 
uptake of AmBisome® was highly dosage dependent resulting in a relatively 
prolonged blood circulation time at the higher doses of 7 mg AMB/kg. After 
administration of AmBisome® at the MTD, blood and tissues retained high AMB 
concentrations which represented liposome-encapsulated AMB and the drug was 
released slowly during circulation in the blood. The extent to which the release of 
AMB is important for effective antifungal activity is presently under investigation. 
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ABSTRACT 
The in vitro activities of liposomal amphotericin B (AmBisome®) and 
amphotericin B-desoxycholate (AMB-DOC) against extracellular Calbicans during 
6 h of incubation in the presence of human serum were determined. With AMB-
DOC inhibition of germ tube formation and effective killing were observed at AMB-
concentrations of 0.8 mglL and 3.2 mglL, respectively. With AmBisome® for both 
parameters tested, 32-fold increased AMB concentrations were needed. 
Preincubation of AmBisome® in human serum during 6 h did not influence the rate 
of killing of Calbicans. 
Antifungal activity against intracellular Calbicans was assessed at 4 hand 24 h 
after incubation of Calbicans-infected monolayers of peritoneal macrophages with 
antifungal agent. In the absence of antifungal agent Calbicans grows intracellularly 
by formation of germ tubes, and within 24 h mycelium is formed. Antifungal 
activity was evaluated in terms of both stabilization of the state of Calbicans 
infection, as well as eradication of Calbicans from infected macrophages. For 
AmBisome® only stabilization was observed at a concentration of 102 mglL after 24 
h of incubation. For AMB-DOC stabilization and eradication were observed only 
after 24 h of incubation at 0.8 mglL and 1.6 mglL, respectively. After previous 
exposure of macrophages to AmBisome® during 6 h before infection, increased 
antifungal activity of AmBisome® was observed: stabilization was observed at 4 h 
of incubation at 102 mglL; at 24 h of incubation stabilization and eradication were 
observed at 25.6 mglL and 102 mglL, respectively. Prolongation of the exposure 
time before Calbicans infection from 6 h up to 24 h resulted in a further increase 
in antifungal activity of AmBisome®. Localization studies of AmBisome® and 
Calbicans in macrophages were performed using fluorescent-labeled Calbicans and 
fluorescent-labeled AmBisome®. It was observed that the presence of AmBisome® 
within a macrophage does not influence uptake of Calbicans by the same 
macrophage, or the other way around. 
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INTRODUCTION 
Systemic candidiasis is seen with increasing frequency in the immuno-
compromised patient. Although restricted by a variety of toxic side effects, 
parenteral amphotericin B (AMB) is still the drug of choice for most invasive fungal 
infections [6, 12J. AMB is administered as amphotericin B-desoxycholate (AMB-DOC 
or Fungizone®). It has been shown that incorporation of AMB in liposomes or other 
lipid-carriers results in a reduction of toxic effects, and thereby in improvement of 
therapeutic index [5,7]. For one of the industrially prepared AMB-lipid preparations, 
AmBisome®, little is still known about the way in which this formulation exerts its 
antifungal activity in vivo. It is still thought by many investigators that AMB is 
biologically inactive when associated with liposomes. Still, it has been shown in 
two short reports [2,18J that AMB remains tightly associated with the liposomal 
structure of AmBisome® in vitro and in vivo and that AmBisome® can act on both 
phagocytized and non-phagocytized fungal cells, resulting in death of the fungi. In 
a study from our laboratory [24J it was previously shown that during circulation of 
AmBisome® in blood slow release of AMB occurred. As it is still not clear to what 
extent release of AMB is of importance for antifungal activity, in the present study 
the interactions of AmBisome® versus AMB-DOC with Candida albicans in the 
presence of serum were investigated. 
Another issue on which only very limited data are available [16], is the antifungal 
activity of AmBisome® against intracellularly growing Calbicans. Calbicans can be 
considered as a facultative intracellular pathogen, as it is able to survive within 
unactivated macrophages and to grow out of these cells by forming germ tubes 
[22,25]. AMB-DOC is higly active against intracellular Calbicans, as was previously 
shown [13,22,25]. Therefore, it is questionable whether encapsulation of AMB in 
AmBisome® will be an advantage with respect to antifungal activity against 
intracellular Calbicans. Numerous studies have demonstrated that liposomes are 
phagocytized effectively by macrophages both in vitro and in vivo [20]. It is 
expected that high concentrations of AMB can be obtained intracellularly after 
exposure of macrophages to AmBisome®. It was also demonstrated in studies 
investigating liposomal ampicillin [3], that the liposomallipid composition greatly 
influenced the rate of intracellular liposomal degradation and hence the rate at 
which liposome encapsulated agent was released intracellularly and became 
available to exert its antibacterial effect. As AmBisome® is a solid liposome type, 
containing saturated phospholipids with high transition temperatures (above 3rC), 
slow intracellular degradation and thereby delayed intracellular antifungal activity 
might be expected. 
Furthermore, as the mononuclear phagocyte system (MPS) plays an important 
role in the host defence against Calbicans [10, 11J, it is important to know whether 
the uptake and degradation of AmBisome® by uninfected macrophages has effects 
on subsequent Calbicans infection. 
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In the present study several aspects on the interactions of AmBisome® with 
intracellular Ca/bicans were investigated: antifungal activity of AmBisome® against 
intracellular Ca/biean', the effect of previous exposure of uninfected macrophages 
to AmBisome® on Ca/bicans ingestion and intracellular antifungal activity, and the 
localization of both Ca/bicans and AmBisome® in macrophages. 
MATERiAlS AND METHODS 
Materials. Antibiotic Medium no. 3 (Penassay broth) and Todd-Hewitt broth were 
from Difco Laboratories (Detroit, MI). Sabouraud dextrose agar was from Oxoid 
(Basingstoke, England). Amphotericin B-desoxycholate (AMB-DOC or Fungizone® 
for intravenous infusion) was kindly provided by Bristol Myers-Squibb, Woerden, 
The Netherlands. AMB-DOC was reconstituted with distilled water to obtain a stock 
solution of 5 gil. AmBisome®, AMB encapsulated in small unilamellar vesicles 
consisting of hydrogenated soybean phosphatidylcholine, cholesterol and distearoyl-
phosphatidylglycerol in a molar ratio of 2:1 :0.8, was kindly provided by Vestar Inc. 
(San Dimas, CAl as a lyophilized preparation. The powder was reconstituted 
according to the manufacturer's instructions with distilled water at 65°C to give a 
liposomal suspension containing 4 g AMB/L and 35 g lipid/l. Fluorescein isothio-
cyanate (FITC) was obtained from Sigma (St. Louis, MO). Pooled human serum 
(PHS) was obtained from a pool of 350 serum samples from healthy volunteer 
donors. Dulbecco modified Eagle medium (DMEM) and Trypan Blue (0.4% v/v in 
saline) were from Flow Laboratories, Irvine, Scotland. Lab Tek® chamber slides were 
from Nunc Inc.(Naperville, ILl. Fetal bovine serum (FBS) was from Hy-Clone (Logan, 
Utah). Fluorescent marker 1, 1 '-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine 
perchlorate D282 (Dil) was kindly provided by Eric Claassen from the Dept. of 
Immunology and Medical Microbiology, TNO Medical Biological Laboratory, 
Rijswijk, The Netherlands. Glycerol was from Merck (Darmstadt, Germany). 
Glutamine was from Flow (Amstelstad, The Netherlands). 
Candida strain. Candida a/bican, ATCC 44858 was used in all experiments and 
was stored at -80°C in Todd-Hewitt broth containing 10% (v/v) glycerol. Of AMB-
DOC and AmBisome® the MIC values were 0.1 mglL and 0.05 mglL, respectively, 
and MFC values were 3.2 mglL and 6.4 mglL, respectively, as described previously 
[23]. 
Fluorescent labeling of Ca/hiedns. A stationary-growth-phase suspension of 
Ca/biean, was washed three times with a buffer solution containing 0.1 M 
NaHCO/Na,CO] (pH 9.5). Then the pellet of Ca/bican, was resuspended and 
incubated with 1 g FITC/L buffer solution for 72 h at 4°C, after which the 
nonbinding FITC molecules were removed by washing three times with buffer 
solution. 
Opsonization of Ca/hieans. Ca/bieans was opsonized by incubation of a 
washed stationary-growth-phase suspension with 10% normal mouse serum 
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(BALB/c) under continuous rotation at 8 rpm for 15 min at 37°C, after which the 
yeasts were washed twice in PBS. 
Fluorescent labeling of AmBisome®. AmBisome® was labeled with the 
fluorescent marker Dil. As shown by Claassen [4J this label is appropriate for 
determining the localization of liposomes in vitro and in vivo. Furthermore, this 
label can be used for labelling of preformed liposomes [4J, such as AmBisome®. Dil 
was dissolved in 100% ethanol (2.5 mglmll and the stock solution was kept at 4°c' 
Dil was added to AmBisome® at an amount of 4-5 mglg liposomallipid. To obtain 
homogeneously labeled material, the addition of Dil was always performed under 
rigorous vortexing. Non-incorporated Dil was removed by filtration of the labeled 
AmBisome® suspension through 0.2 jim membranes. 
Antifungal activity of AmBisome® versus AMB-DOC in the presence of serum 
against extracellular Calbieans during short-term growth. The in vitro activities of 
AmBisome® and AMB-DOC against Calbieans at an inoculum of 1.3x107 CFU/L 
during 6 h of incubation in the presence of serum were determined as decribed 
previously [22J. Briefly, a logarithmic-growth-phase culture of Calbicans was 
prepared. Calbieans was exposed during 6 h of incubation under continuous 
rotation to twofold increasing concentrations of each agent in Antibiotic Medium 
no. 3 supplemented with 90% (v/v) PHS ranging from 0.05-102 mglL. During 
incubation the numbers of viable Calbicans were determined at 2 h intervals by 
making plate counts of ten-fold serial dilutions of the washed specimen on 
Sabouraud dextrose agar. Because the presence of serum induces the formation of 
germ tubes by Calbicans, the antifungal activity was expressed not only in terms 
of effective killing (> 99.9%) of Calbicans, but also in terms of inhibition of germ 
tube formation, which was determined microscopically in a hemacytometer. 
Effect of previous incubation of AmBisome® or AMB-DOC in serum on 
antifungal activity against extracellular Calbicans during short-term growth. The 
in vitro activities of AmBisome® at 102 mglL and AMB-DOC at 3.2 mglL against 
Calbicans at an inoculum of 1.3x107 CFU/L during 6 h of incubation in the 
presence of 90% (v/v) PHS were also determined after previous incubation of 
AmBisome® and AMB-DOC during 6 h in PHS in the absence of Calbicans. 
Antifungal activity of AmBisome® versus AMB-DOC against intracellular 
Calbicans. Macrophages were obtained from peritoneal cavities of 12- to 14-weeks-
old specified pathogen-free female BALB/c mice (lffa Credo, L'arbresle, France). The 
macro phages were washed twice in DMEM supplemented with 1 % glutamine. 
Monolayers of peritoneal macrophages were cultured at 37°C on chamber slides 
under a humidified atmosphere of 7.5% CO, in air in culture medium containing 
DMEM supplemented with 1 % glutamine and 15% FBS. After the first 2 h of 
incubation, fresh culture medium was added to the monolayer, and the 
macrophages were incubated for 24 h. After this incubation period, an inoculum 
of 2x1 05 CFU of opsonized Calbicans were added to the monolayer, resulting in 
a Calbicans-to-macrophage ratio of 5:8. After a 3D-min uptake period, the 
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noningested yeasts were removed by washing the monolayer three times with 
DMEM supplemented with 1 % glutamine and 5% FBS at 37°C (time zero). The 
macrophages were reincubated for 24 h in the presence of twofold increasing 
concentrations AmBisome® (3.2 up to 102 mglL, equivalent to 28 up to 896 mg 
lipid/L) or AMB-DOC (0.1 up to 1.6 mglL) in culture medium supplemented with 
1 % glutamine and 5% FBS. Control mono layers were incubated with the solvent 
of the antifungal agent in the appropriate dilution. The proportion of viable 
macrophages following incubation for 24 h with the antifungal agents was assessed 
by means of a trypan blue exclusion method (0.2% v/v). At time zero and at 4 h 
and 24 h of incubation, the monolayers were washed three times with PBS, fixed 
in methanol, stained with May-Grunwald-Giemsa, and examined under a 
microscope. Three experiments were performed in which in each individual 
experiment for each incubation condition a total number of 150 macrophages were 
scanned. The treatment status pertaining to individual slides was not known to the 
observer. The results were expressed as percentages of total macrophages in which 
the macrophages were divided into four categories: (1) uninfected macro phages, (2) 
macrophages infected with Ca/bieans blastospores, (3) macrophages infected with 
both Ca/bieans blastospores as well as germ-tubes or hyphae, and (4) macrophages 
infected with Ca/bieans germ-tubes, hyphae or even mycelium. 
Using the method of microscopic examination, no discrimination was made 
between Ca/bieans attached to the macrophages or Ca/bicans interiorized by the 
macrophages. As endocytosis does not occur at 4°C [26], attachment of Ca/bieans 
to the macrophages was studied by incubation of the macrophages and opsonized 
Ca/bicans at a Ca/bieans-to-macrophage ratio of 5:8 during 30 min at 4°C instead 
of 3rC, followed by washing of the monolayer. 
Effect of previous exposure of macrophages to AmBisome® on antifungal 
activity against intracellular C./bie.ns. Monolayers of peritoneal macro phages 
were cultured as described above. After 24 h of incubation, macrophages were 
reincubated for 6 h or 24 h in the presence of twofold increasing concentrations 
AmBisome® (3.2 up to 102 mglL) in culture medium supplemented with 1 % 
glutamine and 5% FBS. Control mono layers were incubated with the solvent of the 
antifungal agent in the appropriate dilution. After this incubation period, the 
monolayer was washed three times with culture medium at 3rc Opsonized 
Ca/bicans was added to the monolayer, and ingested as described above. 
Noningested yeasts were removed by washing the monolayer three times with 
culture medium at 37°C (time zero). The macrophages were reincubated for 24 h 
in the presence of AmBisome® just as before Ca/bicans ingestion. Intracellular 
antifungal activity was determined at time zero and at 4 hand 24 h of incubation, 
as described above. 
Localization of AmBisome® in macrophages infected with Ca/bieans. 
Monolayers of peritoneal macrophages were cultured as described above. After 24 
h of incubation, FITC-Iabeled Ca/bieans was added to the monolayer, and ingested 
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as described above. Noningested yeasts were removed by washing with culture 
medium at 3rc. Macrophages were reincubated for 4 h in the presence of twofold 
increasing concentrations of Oil-labeled AmBisome® (3.2 up to 102 mglL) in culture 
medium, as described above. After this incubation period, the monolayer was 
washed three times with ice-cold PBS and observed directly by fluorescence 
microscopy after mounting with PBS with 10% (v/v) glycerol. 
Localization of Ca/bicans in macrophages previously exposed to AmBisome®. 
Monolayers of peritoneal macrophages were cultured as described above. After 24 
h of incubation, macrophages were reincubated for 4 h in the presence of twofold 
increasing concentrations of Oil-labeled AmBisome® (3.2 up to 102 mglL) in culture 
medium, as described above. After this incubation period, the monolayer was 
washed three times with culture medium at 37°C. FITC-Iabeled C.albicans was 
added to the monolayer, and ingested as described above. Noningested yeasts were 
removed by washing with ice·cold PBS and the monolayer was observed directly 
by fluorescence microscopy after mounting with PBS with 10% (v/v) glycerol. 
RESULTS 
Antifungal activity of AmBisome® versus AMB-OOC in the presence of serum 
against extracellular Calbicans during short-term growth. The in vitro activities of 
AmBisome® and AMB-OOC against C.albicans at an inoculum of 1.3x107 CFU/L 
during 6 h of incubation in the presence of PHS are presented in Table 1. With 
AMB-DOC inhibition of germ tube formation and effective killing were observed 
at AMB-concentrations of 0.8 mglL and 3.2 mglL, respectively. With AmBisome® 
for both parameters tested, 32-fold increased AMB concentrations were needed. 
Table 1. Antifungal activity of AmBisome® versus AMB-OOC in the presence of 
90% (vlv) PHS against c.albicans (inoculum 1.3x 1 07 CFUlL) during 6 h incubation. 
AMB-DOC 
AmBisome® 
Minimal AMB conen (mglL) required for: 
Inhibition of germ tube formation 
0.8 
25.6 
Effective killing 
(>99.9%) 
3.2 
102 
Effect of previous incubation of AmBisome® or AMB-OOC in serum on 
antifungal activity against extracellular Ca/bicans du";ng short-term growth. 
Antifungal activities of AMB-DOC at 3.2 mglL or AmBisome® at 102 mglL against 
C.albicans at an inoculum 1.3x1 0 7 CFU/L during 6 h of incubation in PHS, without 
preincubation or after preincubation during 6 h in PHS is shown in Figure 1. For 
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both AMB-OOC as well as for AmBisome®, preincubation in PHS did not influence 
the rate of killing of Calbicans. 
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Figure 1. Effect of preincubation of AMB-DOC and AmBisome® in PHS on 
antifungal activity against Calbicans. Antifungal activity of AMB-DOC at 3.2 mg/L 
or AmBisome® at 702 mg/L against Calbicans (inoculum 7 .3x7 0' CFUlL) during 6 
h of incubation in 90 % lv/v) PHS, without preincubation (III) or after preincubation 
during 6 h in PHS (D). Each symbol represents the mean of three experiments. 
Antifungal activity of AmBisome® versus AMB-OOC against intracellular 
Ca/hieans. Intracellular growth of Calbicans in monolayers of peritoneal 
macrophages in the absence of antifungal agent is shown in Figure 2. Immediately 
after the 3D-min Ca/bicans ingestion period (time zero) 65% of total macrophages 
were infected with Calbicans blastospores. Attachment of Calbicans to the 
macrophages after 30 min of incubation at 4°C was shown to be very low: 
Ca/bicans association was observed for only 3% of macrophages (data not shown). 
After 4 h of incubation all intracellular Calbicans had formed germ-tubes or 
hyphae. After 24 h of incubation massive hyphal or mycelial growth of Calbicans 
was observed within a heavily disrupted monolayer. Antifungal activities of 
AmBisome® or AMB-OOC after 4 hand 24 h of incubation against intracellular 
Calbicans is shown in Figure 3. Cellular toxicity of AmBisome® or AMB-DOC at 
the concentrations used was not observed as measured by trypan blue exclusion. 
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Furthermore, total numbers of macro phages in the mono layers were not decreased 
following antifungal treatment. 
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Figure 2. State of Calbicans infection in macrophage monolayers. (I) uninfected 
macrophages 0; (2) macrophages with intracellular Calbieans blastospores 0; (3) 
macrophages with intracellular Calbicans blastospores and germtubes or hyphae 
or mycelium 1&1; (4) macrophages with intracellular Calbicans germtubes or hyphae 
or mycelium III. 
Antifungal activity was evaluated in terms of both stabilization of the state of 
Calhicans infection, as well as eradication of Calhicans from infected 
macrophages. As about 65% of total macro phages were infected with Calhieans 
blastospores immediately after the Calhicans ingestion period, stabilization of this 
state of Calhicans infection was considered when percentage of Calhieans-infected 
macrophages did not exceed 65%, with percentage of macrophages infected with 
Calhicans was considered when percentage of Calhicans-infected macrophages 
waS reduced from 65% to less than 10%. For AmBisome® eradication of Calhicans 
was not observed up to a concentration of 102 mglL within 4 h or even 24 h of 
incubation of the monolayer infected with Calbicans. Stabilization was observed 
99 
0 
0 
100 AtvS-OOC t=4 h 
• 90 • 8. 80 8. 
% 70 % 
" 
60 
" ~ 50 ~ 
'0 40 '0 30 
<I' 20 <I' 
10 
0 
0.' 0.2 OA OS '.6 
AJv13 CQI"\Cn {mQ!L} 
100 ArrSiSOl'T"le t=4 h 
• 90 1i. 80 i 70 60 
~ 50 
40 
'0 30 
<I' 20 
10 
0 " " ~ B:.. l1. ~ I 
• 
• 
" •I 
'0 
<I' 
3.2 6.4 t2.8 25.0 512 102.4 
Atv'EI concn (motU 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
AM3-DOC t=24 h 
I-
-n 
0.' 
IT ~ ~di 
0.2 0.4 0.8 
AJv13 concn (mg/U 
- AmSisome t=24 h 
f-
I!i h ~i Pill 
IJ:t 
'.6 
Fit 
3.2 6.4 12.8 25.6 51,2 102.4 
AtvS concn (mg/U 
Figure 3. State of C.albicans infection in macrophage mono/ayers during incubation with AmBisome® versus AMB-OOC. Uninfecred 
macrophages 0; macrophages with intracellular C.afbicans blastospores fZl; macrophages with intracellular C.afbicans blastospores and 
germtubes or hyphae or mycelium Il!l; macrophages with intracellular C.albicans germtubes or hyphae or mycelium III. 
NO ~ not determined 
Exposure time before C.albicans ingestion: 6 h 
100 Am9iSOfl"lG t=4 h 100 Am8i5Orne t=24 h 
00 90 00 90 1\ 80 1\ eo f 70 i 70 60 0 60 
~ 50 • 50 E 
'0 40 '0 40 30 
* 
30 
* 20 20 10 10 
0 0 ~. I3aJ U ~. ~ .. IT ~ 
SA 
"'" 
25.. .,,, 102.4 3.2 6.4 12.8 25.6 51..2 10:2..4 
AIvB concn (mg/L) AIvB concn (rngIL) 
Exposure time before C.albicans ingestion: 24 h 
100 Am9isome t=4 h 100 AtnSisome t=24 h 
00 90 00 90 
• 8 
" 
eo 80 • i 1 70 70 60 0 60 ~ 50 ~ 50 
'0 40 '0 40 30 30 
* 
20 
* 20 10 10 
0 0 3.2 6.4 12.8 25.6 51" 102.4 
fi11 ~-~ fi1 I'iL 
3.2 6.4 12.8 25.6 51..2 102.4 
Atv'6 concn (rng/U AM3 concn (moIU 
Figure 4. State of C.albicans infection in macrophage monolayers previously exposed to AmBisome®~ during incubation with AmBisome®. 
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only after 24 h of incubation at 102 mglL. For AMB-DOC stabilization and 
eradication of Catbicans were observed only after 24 h of incubation at 0.8 mglL 
and 1.6 mglL, respectively. 
Effect of previous exposure of macrophages to AmBisome'" on antifungal 
activity against intracellular Cathieans. The effect of exposure to AmBisome® of 
uninfected macrophages during 6 h or 24 h before Catbicans infection on 
antifungal activity of AmBisome® after 4 hand 24 h of incubation against 
intracellular Catbicans is shown in Figure 4. Previous exposure of the macrophages 
to AmBisome® up to a concentration of 102 mglL during 6 h or 24 h did not have 
any effect on the total numbers of macro phages in the monolayers or on the 
numbers of macrophages infected with catbicans at time zero (data not shown). 
Increased antifungal activity was observed after previous exposure to AmBisome'" 
during 6 h: stabilization was observed after 4 h of incubation at 102 mglL; after 24 
h of incubation stabilization and eradication of Catbicans were observed at 25.6 
mglL and 102 mglL, respectively. Prolongation of the exposure time before 
Catbicans infection from 6 h up to 24 h increased antifungal activity even further. 
After 4 h of incubation stabilization was observed at 12.8 mglL; after 24 h of 
incubation stabilization and eradication of Catbicans were observed at 6.4 mglL 
and 12.8 mglL, respectively. 
Localization of AmBisome'" in macrophages infected with Calhieans. 
Macrophages infected with FITC-Iabeled Catbicans were thereafter incubated for 
4 h in the presence of various concentrations of Oil-labeled AmBisome® ranging 
from 3.2 up to 102 mglL. As significant autofluorescence was observed with air-
dried and fixed slides, it should be stressed that the slides were observed directly 
after incubation and subsequent rinsing, without drying and fixation. Another reason 
for leaving out fixation of the slides with organic solvent was to prevent possible 
dissolution and thereby removal of the liposomal phospholipid bilayers together 
with fluorescent label, subsequent to the fixation procedure. 
It was observed that AmBisome'" was localized in all macrophages infected with 
Catbicans as well as in part of the uninfected macrophages, with increased intensity 
of fluorescence at increased AmBisome® concentrations. 
Localization of Calhieans in macrophages previously exposed to AmBisome®. 
Un infected macrophages were incubated for 4 h in the presence of various 
concentrations of Oil-labeled AmBisome® ranging from 3.2 up to 102 mglL, 
followed by infection with FITC-Iabeled Catbicans. It was observed that all of the 
macro phages in which Catbicans was localized already contained AmBisome®, 
with increased intensity of fluorescence at increased AmBisome® concentrations. 
DISCUSSION 
For two different liposomal formulations of AMB, AmBisome® and AMB in di-
myristoylphosphatidylcholine / dimyristoylphosphatidylglycerol (DMPC / DMPG 
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7:3, 5 0101% AM B), the in vitro antifungal activities against c.albicans in the 
absence of serum have been investigated previously [1,8,15, 19,23J. It was shown 
for both liposomal formulations that the in vitro activity of liposomal AMB was less 
than that of AMB-DOC after short term exposure of c.albicans [19,23J, whereas 
after long-term exposure (MIC, MFC) liposomal AMB was either less active than 
AMB-DOC [15, 19J or equally active as AMB-DOC [1,8, 19,23J. It is still thought by 
many investigators that AMB is biologically inactive when associated to liposomes. 
AMB should be released from the liposomes to exert antifungal activity. The 
antifungal activity of liposomal AMB during short term incubation is low as a 
consequence of marginal release of AMB in medium without serum. After long term 
incubation release of AMB may be substantial, resulting in antifungal activity similar 
to that of AMB-DOC. However, for AmBisome® it was reported [18J that AMB 
remains tightly associated with the liposomal structure for up to 24 h in vitro, either 
in the absence or in the presence of 50% (v/v) human plasma, as well as in vivo 
during circulation after intravenous administration of AmBisome® in mice. The 
investigators also reported a direct interaction between AmBisome® and fungal cells. 
For a lipid formulation of AMB at 50 mol% in DMPC/DMPG (7:3), it was reported 
that AMB can be released from the lipid-complex by fungallipases [17J. Whether 
fungal lipases playa role in the release of AMB from AmBisome® in the close 
vicinity of the fungus, and whether this is necessary for antifungal activity has to be 
investigated. We have previously shown for AmBisome® [24J that slow release of 
AMB occurred during circulation in blood. Until now it remained unclear to what 
extent release of AMB is of importance for antifungal activity. In the present study 
the interactions of AmBisome® with c.albicans in the presence of serum were 
examined. During short-term incubation in the presence of 90 % (v/v) human serum 
still 32-fold increased AMB concentrations are required for effective killing of 
c.albicans as compared to AMB-DOC. This indicates that even in 90% (v/v) serum 
AMB remains tightly associated to the liposome in AmBisome®, as effective killing 
is expected at only 3% release of AMB (rom AmBisome®. Furthermore, it was 
investigated for AmBisome® whether killing of c.albicans was due to serum-induced 
AMB release. As killing of c.albicans with AMB-DOC was much faster than with 
AmBisome®, release of AMB from AmBisome® during preincubation in serum 
would result in an increased killing rate of c.albicans. We found that the rate of 
killing of c.albicans by AmBisome'" was not influenced by preincubation of 
AmBisome® in serum, indicating that serum~induced AMB release is not necessary 
for antifungal activity against extracellular c.albicans. 
With respect to the interactions of AmBisome® versus AMB-DOC with 
intracellular C.albicans, in the present study the parameters for intracellular 
antifungal activity used, were different from those used in a previous study from our 
laboratory [22J. In that previous study [22J the parameters for intracellular antifungal 
activity were inhibition of germ tube formation and effective killing (>99%) of 
intracellular c.albicans. Effective killing was measured by CFU counts of viable 
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intracellular Calbicans. As discussed previously [22J, CFU counts of intracellular 
Calbicans can only be determined accurately in case only Calbicans blastospores 
are present and germ tube formation is completely inhibited. In the present study, 
it became clear for two reasons that use of these parameters could lead to 
misinterpretation of the results. First, under conditions in which the total number 
of Calbicans-infected macrophages was reduced substantially, intracellular 
Calbicans germ tubes or hyphae were still observed. Secondly, intracellular 
Calbicans germ tubes or hyphae were sometimes eradicated from infected 
macrophages between 4 hand 24 h of incubation, indicating that Calbicans germ 
tubes or hyphae are still susceptible for the antifungal activity of AMB. It is also 
reported by other investigators [14J that Calbicans germ tubes or hyphae are 
susceptible for AMB, even more susceptible than Calbicans blastospores. We 
decided that for determining antifungal activity against intracellular Calbicans it is 
more relevant to investigate what is actually changing in the state of infection of 
macrophages, instead of just focussing on aspects of the intracellular Calbicans 
(germ tube formation and viability) alone. Therefore, microscopic observation of the 
infected monolayers was used in the present study. 
The data clearly show that, in parallel with the antifungal activities against 
extracellular Calbicans, the intracellular antifungal activity of AMB-DOC is much 
higher than that of AmBisome®. Of course, it should also be noted that blood and 
tissue levels of AMB that can be achieved in vivo with AmBisome® are much higher 
than with AMB-DOC. We have previously reported [24J that after administration of 
a single dose of AMB-DOC at the MTD of 0.3 mg AMB/kg, a maximum 
concentration of 0.6 mg/L in blood, and tissue concentrations up to 2.2 flg/g in liver 
and 4.9 flg/g in spleen were achieved. With AmBisome®, at the MTD of 7 mg 
AMB/kg, concentrations up to 104 mg/L in blood, 98 flg/g in liver and 140 flg/g in 
spleen were obtained. In human patients [9J peak levels of 1.5-2 mg/L in serum 
were observed with AMB-DOC at 1 mg AMB/kg, whereas with AmBisome® at 2.5 
mg AMB/kg plasma concentrations were measured up to 20.3 mg/L. It is clear that 
although for intracellular antifungal activity much higher dosages of AmBisome® 
than AMB-DOC are required, much higher extracellular concentrations can be 
achieved with AmBisome® than with AMB-DOC. Still, extrapolation of the data 
derived from the in vitro experiments in the present study to the clinically relevant 
situation in vivo remains speculative. 
Although numerous studies have demonstrated that liposomes are phagocytosed 
effectively by macrophages both in vitro and in vivo [20J, an explanation for the 
low intracellular activity of AmBisome® might be low uptake of AmBisome® by 
macrophages infected with Calbicans. However, from our localization experiments 
with flourescent-Iabeled AmBisome® it is clear that AmBisome® is avidly taken up 
by macro phages, both by un infected macrophages as well as by macrophages 
infected with Calbicans. Another more reasonable explanation for the low 
intracellular activity is slow intracellular degradation of AmBisome®. AmBisome® 
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is a solid liposome type, composed of saturated phospholipids with high transition 
temperatures and cholesterol, which is expected to be slowly degraded 
intracellularly. For ampicillin encapsulated in two types of liposomes, differing in 
the rigidity of the lipid bilayer, it was clearly demonstrated [3J, that the liposomal 
lipid composition greatly influenced the rate of intracellular liposomal degradation. 
Relatively slow intracellular degradation was demonstrated for the solid liposome 
type. This relatively slow degradation resulted in a delayed intracellular release of 
the encapsulated ampicillin, as reflected in absent or delayed intracellular killing 
of intracellular Listeria monocytogenes. 
As macrophages seem to be occupied with the intracellular degradation of 
AmBisome'" for a substantial period of time, an important question is whether 
uptake and degradation of AmBisome'" in uninfected macrophages has unfavourable 
effects on subsequent c.albicans infection. Other investigators [16J reported that 
after previous exposure of human polymorphonuclear neutrophils (PMNs) to 
AmBisome'" at a concentration of 20 mglL subsequent uptake of c.albicans was not 
influenced, whereas intracellular killing of c.albicans during subsequent incubation 
for 60 min with AmBisome'" was increased. The rapid effect of AmBisome'" reported 
in this study may result from a rapid degradation of AmBisome'" in human PMNs. 
Another explanation is related to the fact that the PMNs used in this study had 
already candidacidal activity of their own. This candidacidal activity is possibly 
easily enhanced after only minimal damage of intracellular c.albicans by 
AmBisome"'. In the present study it was shown that exposure to AmBisome'" of 
uninfected macrophages does not influence the state of c.albicans infection in 
macrophage monolayers. From our localization experiments it is clear that the 
presence of AmBisome'" within a macrophage does not influence uptake of 
c.albicans in the same macrophage. It is clearly shown that previous exposure of 
uninfected macrophages to AmBisome'" is advantageous for antifungal activity of 
AmBisome'" against intracellular c.albicans. These results indicate once more that 
for intracellular degradation of AmBisome'" time is needed. 
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ABSTRACT 
In this study it was investigated whether long-circulating amphotericin B (AMB) 
containing liposomes could be prepared by incorporation of polyethyleneglycol 
(1900) derivatized distearoylphosphatidylethanolamine (pEG-DSPE), and whether 
the incorporation of PEG-DSPE affected toxicity and biodistribution of the 
preparation in mice. Toxicity of two formulations of liposomes containing both PEG-
DSPE and AMB (pEG-AMB-LlP, types 1 and 2) was compared with that of AMB-
liposomes without PEG-DSPE (AMB-LlP) as well as that of AMB-desoxycholate 
(AMB-DOC). The maximum tolerated dosage (MTD) of AMB-DOC, expressed in 
terms of death during treatment for 5 consecutive days or significant increases in 
the parameters used to monitor renal and hepatic functions, was 0.8 mg AMB/kg/ 
day. AMB-LlP were the least toxic, the MTD being 11 mg AMB/kg/day. The 
formulation with AMB complexed to DSPG (PEG-AMB-LlP type 1) was as toxic as 
AMB-DOC. This PEG-AMB-LlP formulation was omitted from further studies on 
biodistribution. With AMB complexed to PEG-DSPE (PEG-AMB-LlP type 2) toxicity 
was substantially reduced, resulting in a MTD of 9 mg AMB/kg/day. Biodistribution 
of radiolabeled PEG-AMB-LlP type 2 was compared with that of AMB-LlP. Blood 
residence time of PEG-AMB-LlP type 2 was prolonged as compared to AMB-LlP; For 
PEG-AMB-LlP type 2 at 24 h after administration 30% of the injected dosage of 
AMB in intact liposomes was circulating versus 6% for AMB-LlP. 
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INTRODUCTION 
The therapy of choice for most invasive fungal infections remains amphotericin 
B (AMB), administered as amphotericin-desoxycholate (AMB-DOC or Fungizone®). 
However, its clinical use is limited by toxic side effects [17]. A promising approach 
in the treatment of deep systemic fungal infections is AMB incorporated in 
liposomes or other lipid-carriers [11,17,19]. With respect to the industrially 
produced preparations AmBisome®, ABLC (AMB Lipid Complex) and Amphocil® it 
is evident that these have quite different structural and pharmacokinetic 
characteristics [13]. The relatively large structures of ABLC as well as the small 
discoidal particles of Amphocil® are rapidly taken up by the mononuclear 
phagocyte system (MPS), whereas small liposomes as in AmBisome® remain in the 
circulation for relatively prolonged periods. Until now it is not known whether 
blood residence time is an important variable influencing the therapeutic index of 
AMB-liposomes. 
The ability to achieve a significantly longer blood residence time of liposomes 
creates new opportunities for improving the delivery of antimicrobial agents to 
infected tissues [6,7]. Recently, many reports have shown that hydrophilic 
phosphatidylethanolamine derivatives of monomethoxy polyethyleneglycols (PEG-
PEl attached to the liposomes enhance blood circulation time without the 
limitations of lipid dose or rigid composition [1-4,7-9,14-16,18,20,22,23]. Such 
long-circulating liposomes have been named sterically stabilized liposomes. 
As the effects of inclusion of PEG-DSPE on the therapeutic index of AMB-
liposomes are not yet reported, we have investigated whether long-circulating AMB 
containing liposomes can be prepared by incorporation of PEG-DSPE, and whether 
the incorporation of PEG-DSPE affects the toxicity and biodistribution of the 
preparation. 
Successfulliposomal encapsulation of AMB requires that AmB is complexed e.g. 
to DSPG, as in the current AmBisome® formulation. We have demonstrated that 
complexation of AMB to PEG-DSPE can also be achieved (manuscript in 
preparation). In this study the preparation of two different formulations of Iiposomes 
containing both PEG-DSPE and AMB is described. PEG-AMB-LlP type 1, in which 
PEG-DSPE was added to AMB-liposomes with AMB complexed to DSPG, as well 
as PEG-AMB-LlP type 2, in which AMB was complexed to PEG-DSPE and DSPG 
was omitted from the preparation, were prepared. These pegylated formulations 
were compared with non-pegylated AMB-liposomes (referred to as AMB-LlP) 
regarding toxicity and biodistribution. 
MATERIALS AND METHODS 
Materials. AMB and AMB-DOC (Fungizone'" for intravenous infusion) were 
kindly provided by Bristol Myers-Squibb, The Netherlands. AMB-DOC was 
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reconstituted according to the manufacturer's instructions with distilled water to 
give a standard solution of 5 g AMB/L. Lipid powder consisting of Hspc:chol: 
DSPG:AMB in a molar ratio of 2: 1 :0.8:0.4 in which AMB is complexed to DSPG 
was kindly provided by Vestar Inc. (San Dimas, CAl. Hydrogenated soybean 
phosphatidylcholine (HSPC), cholesterol (Chol), monomethoxy polyethyleneglycol 
(1900) succinimidyl succinate (activated PEG), distearoylphosphatidylethanolamine 
(DSPE), were all kindly provided by Vestar Inc. Dimethylsulphoxid (DMSO) was 
from Janssen Chimica (Tilburg, The Netherlands). Deferoxamine mesylate (DF) was 
from Ciba-Geigy (Basel, Switzerland). "Ga-citrate was from Nordian (Montreal, 
Canada), JIlin-chloride from Frosst (Quebec, Canada). Hydroxyquinoline sulfate 
(oxine) was from Sigma (51. Louis, MO). PEG(1900) derivative of DSPE (PEG-DSPE) 
was synthesized as described by Blume and Cevc [8J. 
Liposome preparation. Liposome preparations consisted of HSPC:Chol:DSPG: 
AMB in a molar ratio of 2: 1 :0.8:0.4 (AMB-LlP), HSpc:chol:DSPG in a molar ratio 
of 2:1 :0.8 (PLACEBO-LIP), PEG-DSPE:HSPC:Chol:DSPG:AMB in a molar ratio of 
0.29:2: 1 :0.8:0.4 (PEG-AMB-LlP type 1), PEG-DSPE:HSPC:Chol:AMB in a molar ratio 
of 0.21: 1.79: 1 :0.32 (PEG-AMB-LlP type 2), and PEG-DSPE:HSPC:Chol in a molar 
ratio of 0.21 :1.79:1 (PEG-PLACEBO-LiP type 2). AMB is very poorly soluble in 
chloroform-methanol (1: 1, v/v), and therefore as a first step in the preparation of 
AMB containing liposomes AMB was complexed to either DSPG (AMB-LlP and 
PEG-AMB-LlP type 1) or to PEG-DSPE (PEG-AMB-LlP type 2). For AMB-LlP, 
PLACEBO-LIP, PEG-AMB-LlP type 1, and PEG-PLACEBO-LiP type 2 a chloroform-
methanol (1 :1, v/v) solution of lipid powder or lipid mixture was evaporated to 
dryness in a round-bottom flask at 65°C. For PEG-AMB-LlP type 2, AMB was 
complexed to PEG-DSPE by adding small volumes (20-50 JlI) of 1 N HCI to a 
suspension of AMB and PEG-DSPE in 2 mL chloroform-methanol (1: 1, v/v), 
followed by heating at 65°C and Vortex mixing until the solution cleared. Small 
volumes (10-15 JlI) of 1 N NaOH were added, followed by addition of HSPC and 
Chol. When precipitation of AMB was observed, again small volumes of 1 N HCI 
were added until the solution cleared. This lipid mixture was evaporated to dryness 
in a round-bottom flask at 65°C. The lipid film was hydrated by Vortex mixing in 
a buffer solution containing 10 mM sodium-succinate and 10% (w/v) sucrose (pH 
5.5) at 65°C. For biodistribution experiments 5 mM DF was added to this buffer. 
Liposomes were sonicated resuiting in an average particle size of 100 nm (range 95-
105 nm), as measured by dynamic light scattering (Malvern 4700 system, Malvern, 
U.K.). Biodistribution of intact liposomes was performed using liposomes radio-
labeled with 67Ga_DF as described by Woodle [24J. The labeling resuited in 
formation of a 67Ga_DF complex in the aqueous interior of liposomes. As shown by 
Gabizon et al. [10J, this complex is appropriate for in vivo tracing of intact 
liposomes because of the advantages of minimal translocation of radioactive label 
to plasma proteins and the rapid renal clearance rate when the label is released 
from the liposomes extracellularly. Liposomes were separated from non-entrapped 
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AMB, DF, or radiolabel by gel filtration on a Sephadex G-50 column (Pharmacia, 
Uppsala, Sweden), and concentrated by using 300 kDa Microsep filters (Filtron, 
Breda, The Netherlands). Phospholipid concentration was determined by a 
phosphate assay [5]. AMB concentration was determined spectrophotometrically at 
405 nm, after destruction of the liposomes in DMSO-methanol (1: 1, v/v). 
Determination of Maximum Tolerated Dosage (MTD). Toxicity of AMB-DOC, 
AMB-LlP, PEG-AMB-LlP type 1, and PEG-AMB-LlP type 2 was measured in 
uninfected specified pathogen free female BAlBIc mice (14 to 20-week-old, 22-27 
g Iffa Credo, l'arbresle, France). Mice (6 per group) were treated iv for five 
consecutive days with each of the preparations once daily (q24h) with AMB dosages 
ranging from 0.1-25 mg AMB/kg/day. Acute mortality was assessed directly 
following injection of the preparation. Blood urea nitrogen (BUN) and serum 
creatinine (CREAT), as parameters for renal toxicity, and aspartate aminotransferase 
(ASAT) and alanine aminotransferase (ALAT), as parameters for liver toxicity, were 
determined by established methods in serum samples of mice sacrificed at 24h after 
termination of treatment. The MTD was defined as the maximum dosage that did 
not result in death during treatment or more than threefold increase in the indices 
for renal and liver function, as compared to untreated mice. 
Biodistribution studies. Biodistribution of AMB-LlP, PLACEBO-LIP, PEG-AMB-LlP 
type 2 and PEG-PLACEBO-LIP type 2 was investigated. Radiolabeled liposomes 
were administered iv at 85 pmol lipid/kg (equivalent to 9 mg AMB/kg) as a single 
dose in uninfected mice. In two separate experiments of three mice for each 
different time interval after injection, 200 pi blood was collected from the mice in 
heparinized tubes. Mice were sacrificed, and whole organs (liver, spleen, lungs, and 
kidneys) were excised. Blood and organs, as well as the injected dosage of 
liposomes were counted for "Ga-DF in a gamma counter (Minaxy 5530, Packard 
Instruments, Downers Grove, U.S.A.). For the AMB containing preparations blood 
or organs from three mice were pooled and organs were homogenized in distilled 
water. Blood and tissue samples were stored at -80°C until just before HPlC 
analysis, as decribed before [21]. In a separate experiment using lllin-labeled red 
blood cells [12] blood volume was determined to be 7.5% of body weight and 
blood correction factors were determined for each organ. 
RESULTS AND DISCUSSION 
The MTDs in uninfected mice of AMB-DOC, AMB-LlP, PEG-AMB-LlP type 1, and 
PEG-AMB-LlP type 2 are presented in Table 1. The MTD of AMB-DOC in terms of 
death during treatment was 0.8 mg AMB/kg/day. At this dosage renal or liver 
toxicity was not seen. With AMB-LlP (a formulation with a lipid composition as in 
AmBisome®) the MTD with no death during treatment was 19 mg AMB/kg/day. At 
this dosage renal toxicity was not yet observed, whereas the MTD with respect to 
liver toxicity was 11 mg AMBlkg/day. Incorporation of PEG-DSPE resulting in PEG-
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AMB-lIP type 1 led to a preparation that was as toxic as AMB-DOC. For PEG-AMB-
LIP type 2 death during treatment was shown at dosages higher than 13 mg AMBI 
kg/day. At this dosage renal toxicity was not seen. For liver toxicity the MTD was 
9 mg AMBIkg/day. 
Table 1. Maximum Tolerated Dosage (MTD) of AMB-DOC, AMB-LlP, PEG-AMB-LlP 
type 1, and PEG-AMB-LlP type 2 in uninfected mice'. 
MTD' (mg AMB/kg/day) 
parameter of toxicity AMB·DOC AMB-LlP PEG-AMB·LlP PEG-AMB-LlP 
type 1 type 2 
death during treatment 0.8 19 0.8 13 
impaired renal function >0.8 >19 >0.8 >13 
impaired liver function >0.8 11 >0.8 9 
aM ice were treated iv for five consecutive days once daily (q24h) with AMB·DOC or with 
sonicated liposomes with an average diameter of 100 nm: AMB-LlP (HSPClChoI/DSPGI 
AMB), PEG·AMB-LlP type 1 (PEG-DSPElHSPClChoI/DSPG/AMB), or PEG·AMB-LlP type 2 
(PEG-DSPE/HSPClChoI/AMB). AMB dosages ranged from 0.1-1.0 mg AMBI kg/day in steps 
of 0.1 mg AMB/kg/day, and above 1.0 mg AMB/kg/day in steps of 2.0 mg AMB/kg/day. 
Two experiments of three mice each (n = 6) for each dosage were performed. 
bToxicity was determined in terms of death during treatment, or more than threefold 
increase in the indices for renal function (BUN and CREAn and liver {unction (ASAT, 
AlAT) as compared to placebo-treated mice, determined at 24h after termination of 
treatment 
The high toxicity of the PEG-AMB-lIP type 1 preparation is probably due to a very 
toxic subpopulation of small particles containing AMB. A heterogeneity in particle 
size was observed after ultracentrifugation of the PEG-AMB-lIP type 1 preparation 
at 260,000xg. It was shown by dynamic light scattering measurements that particles 
of approximately 100 nm containing AMB were sedimented at this speed, whereas 
small particles of approximately 40 nm containing AMB remained in the 
supernatant. There was a marked difference with respect to toxicity in terms of 
acute death in mice between the particles of 40 nm and 100 nm. Acute death was 
observed after iv administration of the 40 nm AMB·particies at a dosage of 0.6 mg 
AMB/kg, whereas no toxicity was observed with the 100 nm AMB-particles at a 
dosage of 6 mg AMB/kg. As a first step in the preparation of PEG-AMB-lIP type 1, 
AMB is complexed to DSPG. This lipophilic AMB-DSPG complex is inserted in the 
phospholipid bilayer during spray-drying and thus helps to retain AMB in the 
liposome. PEG-DSPE is added to this formulation in which AMB is already 
complexed to DSPG. It is conceivable that competition between PEG-DSPE and 
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DSPG for complexation of AMB occurred, resulting in the formation of highly toxic 
AMB-containing lipid particles of 40 nm beside less toxic 100 nm AMB-liposomes. 
In PEG-AMB-LlP type 2 in which DSPG was omitted from the preparation, AMB 
was complexed to PEG-DSPE. PEG-AMB-LlP type 2 did not show the heterogeneity 
in particle size, and this was also not observed for AMB-LlP. As the PEG-AMB-LlP 
type 1 preparation was very toxic, these liposomes were omitted from further 
studies on biodistribution that were performed with AMB-LlP and PEG-AMB-LlP 
type 2. 
Biodistribution studies were performed with "Ga-DF labeled liposomes. "Ga-DF 
was used as marker for intact liposomes. In studies with AMB-containing liposomes 
both "Ga-DF levels as well as AMB concentrations were determined. For both 
AMB-LlP as well as PEG-AMB-LlP type 2, AMB levels as percentage of injected 
dosage in blood and liver+spleen were equivalent to levels of intact liposomes 
(Figures 1 and 2), suggesting that AMB levels primarily represent liposome-
associated AMB. For both AMB-LlP and PEG-AMB-LlP type 2 levels in kidney and 
lung never exceeded 3% and 1 % of injected liposome dose, respectively (data not 
shown). Comparison of the blood residence of AMB-LlP versus PLACEBO-LIP shows 
that the presence of AMB in the liposome preparation induced a dramatic drop in 
blood level of intact liposomes within five minutes after administration (Figure 1). 
As this initial drop is seen in both the "Ga-DF marker as well as in AMB 
concentration (Figure 1) it is unlikely that this initial decrease is due to leakage of 
"Ga-DF or AMB. Although the initial hepatosplenic uptake of AMB-LlP within five 
minutes after administration is high (29% of injected dosage), this can still not 
account for the low blood level (47% of injected dosage) at this time point. As the 
exact localization of the distributed liposomes in other organs, such as bone 
marrow, brain, muscle, and skin at 5 min after administration was not determined, 
the rapid elimination of AMB-LlP is unexplained. After this initial drop in blood 
level of liposomal AMB a relatively prolonged blood residence time was observed 
with 6% of injected dosage circulating at 24h after administration. In line with 
expectations, it was shown that inclusion of PEG-DSPE into PEG-AMB-LlP type 2 
resulted in a prolonged blood residence time of liposomal AMB as compared to 
AMB-LlP. Unfortunately, due to problems with repect to aggregation of liposomes 
during preparation, it was not possible to compare PEG-AMB-LlP type 2 with its 
appropriate control, i.e. non-pegylated AMB-liposomes with omission of not only 
PEG-DSPE but also DSPG. Successfulliposomal encapsulation of AMB requires that 
AMB is complexed to either DSPG, as in AMB-LlP, or to PEG-DSPE, as in PEG-
AMB-LlP type 2. An effect of AMB on blood residence time of the pegylated 
liposomes was not observed with PEG-AMB-LlP type 2 (Figure 2). Both PEG-
PLACEBO-LIP type 2 as well as PEG-AMB-LlP type 2 showed a long blood 
residence time with 20-30% of the injected dosage of liposomes still circulating at 
24h after administration. These results are in good agreement with those reported 
elsewhere for PEG-liposomes with similar particle size [1,2,7,22]. However, in the 
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Figure 1. Biodistribution of 67Ca-OF labeled liposomes at various intervals after iv 
in;ection. Sonicated liposomes with an average diameter of 100 nm were in;ected 
intravenously in mice at a dosage of 85 jJmol lipid/kg. 
(0) PLACEBO-LIP: HSPC/Chol/oSPC; (et) AMB-LlP: HSPc/ChoIIDSPC/AMB. Data 
are expressed as percentage of in;ected dosage cpm 67Ca-OF (solid line) as mean 
± S.D. for two separate experiments of three mice each (n ~ 6), or as percentage 
of in;ected dosage AMB (broken line) as mean ± range for two separate 
experiments with in each experiment blood or tissue from three mice pooled. 
Where no error-bars are seen the range is smaller than the data points. 
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Figure 2. Biodistribution of 67Ga_DF labeled liposomes at various intervals after iv 
injection. Sonicated liposomes with an average diameter of 100 nm were injected 
intravenously in mice at a dosage of 85 pmol lipid/kg. 
(0) PEG-PLACEBO-LiP type 2: PEG-DSPE/HSPC/Chol; (l1li) PEG-AMB-LlP type 2: 
PEG-DSPE/HSPC/Chol/AMB. Data are expressed as percentage of injected dosage 
cpm 67Ga-DF (solid line) as mean ± S.D. for two separate experiments of three 
mice each (n ~ 6), or as percentage of injected dosage AMB (broken line) as mean 
± range for two separate experiments with in each experiment blood or tissue from 
three mice pooled. Where no error-bars are seen the range is smaller than the data 
points. 
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present study a relatively high hepatosplenic uptake of the liposomes of 34-43% 
was observed at 24h after aministration, as compared to the other studies [1,2,7,22] 
in which the hepatosplenic uptake ranged from 7-28% at 24h after iv 
administration. This might be related to differences in size distribution of the 
liposome dispersion, as different methods for liposome sizing were used (sonication 
in the present study versus extrusion in the other studies). It is possible that 
sonication, as compared to the extrusion method, yields a preparation with 
relatively increased numbers of liposomes smaller than 100 nm. Extravascular 
localization of these small liposomes after passage through the fenestrated vascular 
endothelial lining of the liver sinusoids may occurr. 
In conclusion, incorporation of PEG-DSPE in AMB-LlP with AMB complexed to 
DSPG (PEG-AMB-LlP type 1) results in an extremely toxic preparation. When AMB 
is complexed to PEG-DSPE and DSPG is omitted from the preparation (pEG-AMB-
LIP type 2) toxicity is substantially reduced. In comparison with AMB-LlP this PEG-
AMB-LlP type 2 preparation shows a slightly increased toxicity. Blood residence 
time of liposomal AMB is prolonged with PEG-AMB-LlP type 2 as compared to 
AMB-LlP. To what extent the increased toxicity as well as prolonged blood 
residence time of liposomal AMB with PEG-AMB-LlP type 2 are determining factors 
with respect to improved efficacy as compared to AMB-LlP in the treatment of 
fungal infections is now under investigation. 
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ABSTRACT 
Pegylated AMB-liposomes (PEG-AMB-lIP) were compared with laboratory 
prepared non-pegylated AMB-liposomes (AMB-lIP), a formulation with a lipid 
composition as in AmBisome®, as well as with industrially prepared AmBisome®, 
regarding in vitro antifungal activity, toxicity, blood residence time, and therapeutic 
efficacy. Killing of C.atbicans (> 99.9%) during short-term (6 h) incubation was 
observed at 0.2 mglL for amphotericin B desoxycholate (AMB-DOC), 0.4 mglL for 
PEG-AMB-lIP, 0.8 mglL for AMB-lIP and 12.8 mglL for AmBisome®. The maximum 
tolerated dosages (MTDs) of PEG-AMB-lIP, AMB-lIP, and AmBisome® were 15 mg 
AMB/kg, 19 mg AMB/kg and > 31 mg AMB/kg, respectively. In contrast to AMB-
LIP, blood residence time of PEG-AMB-lIP was prolonged and dosage independent. 
In a model of systemic candidiasis in leukopenic mice at a dosage of 5 mg AMBlkg, 
PEG-AMB-lIP was completely effective, AMB-LlP was partially effective, whereas 
AmBisome® was not effective. AMB-lIP at 11 mg AMBlkg was partially effective. 
AmBisome® at 29 mg AMBlkg was completely effective. In conclusion, therapeutic 
efficacy of AMB-liposomes can be improved by preparing AMB-liposomes in which 
a substantial reduction of toxicity is achieved, while antifungal activity is retained. 
In addition, therapeutic efficacy is favored by a prolonged residence time of AMB-
liposomes in blood. 
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INTRODUCTION 
There has been a steady increase in the incidence of invasive fungal infections 
in immunocompromised patients. Presently, these infections are among the most 
important causes of morbidity and mortality among patients with cancer and among 
other severely immunocompromised hosts. As the overall prognosis for patients 
with invasive fungal infections remains poor, there is a critical need to improve 
methods for treating these infections. 
Parenteral administration of amphotericin B (AMB) remains the therapy of choice 
for most invasive fungal infections. AMB is administered as amphotericin B-
desoxycholate (AMB-DOC, Fungizone®l. but its clinical use is limited by toxic side 
effects [15,23]. A promising approach in the treatment of deep systemic fungal 
infections is AMB incorporated in liposomes or other lipid-carriers [12,16,27]. With 
respect to the industrially produced preparations AmBisome®, ABLC (AMB Lipid 
Complex) and Amphocil® it is evident that these have quite different structural and 
pharmacokinetic characteristics [20,27]. The relatively large structures of ABLC as 
well as the small discoidal particles of Amphocil® are rapidly taken up by the 
mononuclear phagocyte system (MPS), whereas small liposomes as in AmBisome® 
remain in the circulation for relatively prolonged periods. Until now it is not known 
whether long blood residence time is of importance for improved efficacy of AMB-
liposomes. 
The ability to achieve a significantly longer blood residence time of liposomes 
opens new ways to achieving improved delivery of antimicrobial agents to infected 
tissues including infections in non-MPS tissues [8]. Recently, many reports have 
shown that hydrophilic phosphatidylethanolamine derivatives of monomethoxy 
polyethyleneglycols (pEG-PE) attached to the I iposomes can effectively prolong their 
blood circulation time without the limitations of lipid dose, small particle size, or 
rigid lipid composition [2-5,8,9,21,22,25,31,32]. Such liposomes have been named 
sterically stabilized liposomes. The distinctive properties of sterically stabilized 
liposomes makes them excellent candidates for many therapeutic applications. 
In our laboratory it was recently shown [30] that long-circulating AMB containing 
liposomes can be prepared by incorporation of PEG-DSPE. In the present study the 
effects of incorporation of PEG-DSPE in AMB-liposomes on in vitro antifungal 
activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice is reported. 
The pegylated AMB-liposome formulation was compared with laboratory prepared 
non-pegylated AMB-liposomes, a formulation with a lipid composition as in 
AmBisome®, as well as with industrially prepared AmBisome®. 
MATERIALS AND METHODS 
Materials. Antibiotic Medium No.3 was from Difco Laboratories (Detroit, MI). 
Sabouraud dextrose agar was from Oxoid (Basingstoke, England). Amphotericin B 
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and amphotericin B-desoxycholate (AMB-DOC, Fungizone® for iv infusion) were 
kindly provided by Bristol Myers-Squibb, The Netherlands. AMB-DOC was 
reconstituted with distilled water to give a standard solution of 5 giL. AmBisome®, 
consisting of HSPC:Chol:DSPG:AMB in a molar ratio of 2: 1 :0.8:0.4, and lipid 
powder, consisting of HSPC:Chol:DSPG:AMB in a molar ratio of 2:1 :0.8:0.4 in 
which AMB is complexed to DSPG were both kindly provided by Vestar, Inc. (San 
Dimas, CAl. Hydrogenated soybean phosphatidy!choline(HSPC), cholesterol (Chol), 
monomethoxy polyethyleneglycol (1900) succinimidyl succinate (activated PEG), 
distearoylphosphatidylethanolamine(DSPE), were all kindly provided by Vestar Inc. 
Dimethylsulphoxid (DMSO) was from Janssen Chimica (Til burg, The Netherlands). 
Deferoxamine mesylate (DF) was from Ciba-Geigy (Basel, Switzerland). 6'Ga-citrate 
was from Nordian (Montreal, Canada), '''In-chloride from Frosst (Quebec, Canada). 
Hydroxyquinoline sulfate (oxine), and cyclophosphamide were from Sigma (St. 
Louis, MO). PEG(1900) derivative of DSPE (PEG-DSPE) was synthesized as 
described by Blume and Cevc [9]. 
Candida strain. Candida albicans ATCC 44858 was used in all of the 
experiments and was stored at -80°C in Todd-Hewitt broth (Difco laboratories, 
Detroit, MI, USA) containing 10% (v/v) glycerol. 
Animals. Specified pathogen-free, 12- to 20-weeks-old female BALB/c mice were 
obtained from Iffa Credo (L' Arbresle, France). 
Liposome preparation. Liposome preparations consisted of PEG-DSPE:HSPC: 
Chol:AMB in a molar ratio of 0.21 :1.79: 1 :0.32 (PEG-AMB-LlP), PEG-DSPE:HSPC: 
Chol in a molar ratio of 0.21:1.79:1 (PEG-PLACEBO-LlP), HSPC:Chol:DSPG:AMB 
in a molar ratio of 2:1 :0.8:0.4 (AMB-LlP), and HSPC:Chol:DSPG in a molar ratio of 
2:1:0.8 (pLACEBO-LIP). AMB is very poorly soluble in chloroform-methanol (1:1, 
v/v), and therefore as a first slep in the preparation of AMB containing liposomes 
AMB was complexed to either PEG-DSPE (PEG-AMB-LlP) or to DSPG (AMB-LlP). For 
PEG-AMB-LlP, AMB was complexed to PEG-DSPE by adding small volumes (20-50 
JlI) of 1 N HCI to a suspension of AMB and PEG-DSPE in 2 mL chloroform-methanol 
(1:1, v/v), followed by heating at 65°C and Vortex mixing untill the solution 
cleared. Small volumes (10-15 JlI) of 1 N NaOH were added, followed by addition 
of HSPC and Chol. When precipitation of AMB was observed, again small volumes 
of 1 N HCI were added untill the solution cleared. This lipid mixture was 
evaporated to dryness in a round-bottom flask at 65°C. For PEG-PLACEBO-LlP, 
AMB-LlP, and PLACEBO-LIP a chloroform-methanol (1:1, v/v) solution of lipid 
mixture or lipid powder was evaporated to dryness in a round-bottom flask at 65°C. 
The lipid film was hydrated by Vortex mixing in a buffer solution containing 10 mM 
sodium-succinate and 10% (w/v) sucrose (pH 5.5) at 65°C. For biodistribution 
experiments 5 mM DF was added to this buffer. Liposomes were sonicated resulting 
in an average particle size of 100 nm (range 95-105 nm), as measured by dynamic 
light scattering (Malvern 4700 system, Malvern, U.K.). Biodistribution of intact 
liposomes was performed using liposomes radiolabeled with 6'Ga_DF as described 
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by Woodle [33]. The labeling resulted in formation of a 67Ga-DF complex in the 
aqueous interior of liposomes. As shown by Gabizon et al. [14], this complex is 
appropriate for in vivo tracing of intact liposomes because of the advantages of 
minimal translocation of radioactive label to plasma proteins and the rapid renal 
clearance rate when the label is released from the liposomes. Liposomes were 
separated from non-entrapped AMB, DF, or radiolabel by gel filtration on a 
Sephadex G-50 column (Pharmacia, Uppsala, Sweden), and concentrated by using 
300 kDa Microsep filters (Filtron, Breda, The Netherlands). Phospholipid 
concentration was determined by a phosphate assay [6]. AMB concentration was 
determined spectrofotometrically at 405 nm, after destruction of the liposomes in 
DMSO-methanol (1:1, v/v). 
AmBisome®, consisting of HSPC:Chol:DSPG:AMB in a molar ratio of 2: 1 :0.8:0.4 
was provided as a lyophilized preparation. The powder was reconstituted according 
to the manufacturer's instructions with distilled water at 65°C to give a liposomal 
suspension containing 4 g AMB/L and 35 g lipid/L, with an average liposome 
particie size of 90 nm (range 88-92 nm). 
III vitro antifungal activities of AMO·DOC, PEG·AMB·LlP, AMB·LlP, and 
AmBisome®. The in vitro activities of AMB-DOC, PEG-AMB-LlP, AMB·LlP, and 
AmBisome® in terms of effective killing (> 99.9%) of Calbicans at an inoculum of 
1.3x107 CFU/L during 6 h of incubation were determined as described previously 
[28]. Briefly, a logarithmic-growth·phase culture of Calbicans was prepared. 
Calbicans was exposed during 6 h of incubation to twofold increasing 
concentrations of each agent in Antibiotic Medium No.3, ranging from 0.05-25.6 
mglL. During incubation the numbers of viable Calbicans were determined at 2 h 
intervals by making plate counts of ten-fold serial dilutions of the washed specimen 
on Sabouraud dextrose agar. 
Determination of Maximum Tolerated Dosage (MTD). Toxicity of PEG·AMB-LlP, 
AMB·LlP and AmBisome® was measured in uninfected mice. Mice (6 per group) 
were treated iv with a single dose. AMB dosages ranged from 1 to 31 mg AMB/kg 
in steps of 2 mg AMB/kg. Acute mortality was assessed directly following injection 
of the preparation. Blood urea nitrogen (BUN) and serum creatinine (CREAT), as 
parameters for renal toxicity, and aspartate aminotransferase (ASAT) and alanine 
aminotransferase (ALAT), as parameters for liver toxicity, were determined by 
established methods in serum samples of mice sacrificed at 48h after termination 
of treatment. The MTD was defined as the maximum dosage that did not result in 
death or more than threefold increase in the indices for renal and liver function, as 
compared to untreated mice. 
Blood residence time of PEG·AMB·LlP versus AMB·LlP in uninfected mice at 
various dosages. 67Ga-DF labeled liposomes were administered iv at 0.5 mg AMBI 
kg or 5 mg AMB/kg (equivalent to 4.7 /lmolliposomallipid/kg or 47 /lmollipsomal 
lipid/kg, respectively) as a single dose in uninfected mice. In two separate 
experiments levels of 67Ga-DF as well as AMB in blood were determined at various 
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time points during 24 h after administration, using three mice for each time point 
in each experiment. Blood was collected in heparinized tubes. Blood samples (200 
til), as well as the dosage of injected liposomes were counted for "Ga-DF in a 
gamma counter (Minaxy 5530, Packard instruments, Downers Grove, USA). 
Additionally, at 5 mg AMBlkg, AMB concentrations were determined in these blood 
samples. For determination of AMB in blood, samples from three mice were pooled 
and stored at -80°C until just before high-performance-liquid-chromatography 
(HPlC) analysis, as described before [28J. in a separate experiment using '"In_ 
labeled syngeneic red blood cells [18J total blood volume in the mice was 
determined. 
Efficacies of PEG-AMB-UP, AMB-UP, and AmBisome® in leukopenic mice 
infected with Ca/hiealls. leukopenia was induced by ip administration of cyclo-
phosphamide at 100 mg/kg 4 days before Ca/hieans inoculation followed by an 
additional dose of 75 mg/kg on the day of inoculation, and at 3-day intervals 
thereafter. This treatment resulted in persistent granulocytopenia « 0.1 x lO'/l) 
from the time of Ca/hieans inoculation up to termination of the study. leukopenic 
mice were infected by inoculation of 3x104 CFU Ca/hieans into the tail vein. PEG-
AMB-UP, AMB-UP, AmBisome® and placebo's were each administered iv as a 
single dose at 20 h after Ca/hicans inoculation at dosages corresponding to their 
MTDs. AMB-UP and AmBisome® were also administered at a dosage which was 
equivalent to the MTD of PEG-AMB-UP. Just before treatment and at 48 h as well 
as 6 days after treatment, the surviving mice were sacrificed. The kidneys, liver, 
spleen and lungs were removed and processed for the determination of viable 
counts, as described previously [28]. The following criteria were used to assess the 
efficacy of treatment: survival of mice up to 6 days after treatment; a statistically 
significant reduction in the numbers of CFU Ca/hieans in the kidneys at 48 h after 
treatment as compared to the numbers at the time of treatment, as well as 
prevention of a significant increase in the numbers of CFU Ca/hieans in the kidneys 
at 6 days after treatment as compared to the numbers at 48 h after treatment 
(equating to relapse of infection). 
Statistical analysis. Results were expressed as the geometric means ± S.D. 
Differences in Ca/hieans CFU between the various treatment groups were analyzed 
by the Mann-Whitney test. 
RESULTS 
/n vitro antifungal activities of AMB-DOC, PEG-AMB-UP, AMB-UP, and 
AmBisome®. For AMB-DOC, PEG-AMB-UP, AMB-UP, and AmBisome® the minimal 
AMB concentrations required for killing> 99.9% of the initial Ca/hicans inoculum 
within 6 h of incubation were determined. With AMB-DOC, PEG-AMB-UP and 
AMB-UP effective killing was obtained at 0.2 mg/l, 0.4 mg/l and 0.8 mg/l, 
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respectively. With AmBisome"', on the other hand, a concentration of 12.8 mglL 
was required to produce the same fungicidal activity. 
MTDs of PEG·AMB·LlP, AMB·LlP and AmBisome'" in uninfecled mice. The 
MTDs of PEG·AMB-LlP, AMB-LlP, an AmBisome'" are presented in Table 1. With 
PEG-AMB-LlP the MTD with no death after treatment was 15 mg AMBikg. At this 
dosage renal or liver toxicity were not yet observed. For AMB-LlP (a formulation 
with a lipid composition as in AmBisome®) death during treatment was shown at 
dosages higher than 19 mg AMB/kg. At this dosage no renal or liver toxicity was 
seen. With AmBisome'" no toxicity was observed in terms of death, or impairments 
in renal or liver function up to a dosage of 31 mg AMB/kg. 
Table 1. Maximum Tolerated Dosage (MTD) of PEC·AMB-LlP, AMB-LlP and 
AmBisome® in un infected m;ceJ • 
parameter of toxicity 
death after treatment 
impaired renal function 
impaired liver function 
MTDb (mg AMB/kg) 
PEG-AMB-LlP AMB·LlP AmBisome® 
15 
> 15 
>15 
19 
>19 
>19 
>31 
>31 
>31 
aMice were treated iv with a single dose. AMB dosages ranged from 1 to 31 mg AMB/kg 
in steps of 2 mg AMB/kg 
bToxidty was determined in terms of death after treatment, or more than threefold increase 
in the indices for renal function (blood urea nitrogen and serum creatinine) and liver 
function (aspartate amino transferase and alanine amino transferase) as compared to 
placebo-treated mice, determined at 48h after termination of treatment 
Blood residence lime of PEG·AMB·LlP versus AMB·LlP in uninfecled mice al 
various dosages. Blood levels of "Ga-DF following administration of radiolabeled 
PEG-AMB-LlP and AMB-LlP at dosages of 0.5 mg AMB/kg (4.7 pmol lipid/kg) and 
5 mg AMBikg (47 pmol lipid/kg) are shown in Figure 1. "Ga·DF was used as 
marker for intact liposomes. With PEG-AMB-LlP independent of dosage a prolonged 
blood residence time of intact liposomes was observed, with 20% of the injected 
dosage of liposomes still circulating at 24h after administration. For AMB·LlP it was 
shown that levels of intact liposomes dropped within five minutes after 
administration to 26% and 35% of the injected dosage of liposomes at the dosages 
of 0.5 mg AMB/kg and 5 mg AMBikg, respectively. After this initial drop only at the 
highest dosage of 5 mg AMBikg a prolonged blood residence time was observed, 
with 6% of injected dosage circulating at 12 h after administration. At the lower 
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dosage of 0.5 mg AMB/kg blood levels of liposomes declined to 6% of injected 
dosage within 4 h after administration. 
Blood levels of both "Ga·DF and AMB following administration of radiolabeled 
PEG·AMB·LlP and AMB·LlP at 5 mg AMB/kg were determined. For both types of 
liposomes AMB levels declined more rapidly than levels of intact liposomes during 
circulation (data not shown). 
100 
PEG-A1v1B-LIP 
80 
60 
u.. 40 
0 , 
'" (9 20 ~ 
(J) 
0> 
'" 5 min 4 h '" 
12 h 24 h 
a 
"0 
"0 100 (J) 
1:) Atv13-lIP 
(J) 
:S 
~ 
80 
a 
~ 
60 
40 
20 
5 min 4 h 12 h 24 h 
Time after injection 
Figure 1. Blood levels of "Ca· OF after administration of radiolabeled PEC·AMB·L1P 
and AMB·L1P in uninfected mice at various dosages. A single dose was 
administered iv at 0 0.5 mg AMB/kg 14.7 pmol Iiposomal lipid/kg), or l1li 5 mg 
AMB/kg 147 pmolliposomallipid/kg). Data are expressed as percentage of injected 
dosage "Ca·DF as mean ± S.D. for two separate experiments of three mice each 
In ~ 6). Where no error·bars are seen the range is smaller than the data points. 
128 
Chapter 7 
Efficacies of PEG-AMB-LlP, AMB-LlP, and AmBisome® in leukopenic mice 
infected with c.albicans. In leukopenic mice infected with C.albicans the infection 
is disseminated to the kidney, liver, spleen and lung, and untreated mice die 
between 24 h and eight days after C.alhicans inoculation. The MTDs in these 
infected mice of PEG-AMB-LlP, AMB-LlP, and AmBisome® in terms of acute death 
were 5 mg AMB/kg, 11 mg AMB/kg, and 29 mg AMB/kg, respectively. The effect 
of treatment on survival of the animals and growth of C.albicans in the kidney is 
presented in Table 2. Increase of c.albicans CFU and death of the animals was 
observed after placebo treatment. As the placebo-treated animals died, numbers of 
C.albicans in the kidney of these mice could not be compared to those of AMB-
treated mice. Treatment with PEG-AMB-LlP at the MTD (5 mg AMB/kg) was 
completely effective: 100% survival of mice was observed, as well as a significant 
reduction of C.albicans in liver (P:O;O.01), spleen (p:O;O.OO1), and lung (P:O;O.025) 
(data not shown). In the kidney numbers of C.albicans were significantly reduced 
at 48 h after treatment (P:O; 0.001), relapse of infection was prevented; numbers of 
C.albicans were even further significantly reduced at 6 days after treatment (P:O; 
0.01). Treatment with AMB-LlP at an equivalent dosage (5 mg AMB/kg) was 
partially effective: survival of all animals was observed, as well as a significant 
reduction of c.albicans in liver (P:O;O.025), spleen (P:O;O.OO1), and lung (P:O;O.OO1) 
(data not shown); however, in the kidney growth of C.albicans was only inhibited, 
and numbers of c.albicans were not significantly reduced. Although increase of the 
dosage of AMB-LlP up to the MTD (11 mg AMB/kg) resulted in a slight 
improvement of efficacy compared to 5 mg AMB/kg, it did not result in complete 
efficacy of treatment as seen with PEG-AMB-LlP at 5 mg AMB/kg; at 11 mg AMB/kg 
numbers of C.albicans in the kidney were significantly reduced as compared to the 
time of treatment only at 6 days after treatment. AmBisome® at a dosage of 5 mg 
AMB/kg was not effective, as animals died after treatment. AmBisome® at the MTD 
(29 mg AMB/kg) was as effective as PEG-AMB-LlP at 5 mg AMB/kg. 
DISCUSSION 
With respect to the in vitro antifungal activity of the AMB-liposome formulations 
against C.albicans, it is derived from the present study that after encapsulation of 
AMB in PEG-AMB-LlP or in AMB-LlP the high antifungal activity as is seen with 
AMB-DOC is almost fully retained, whereas entrapment of AMB in AmBisome® is 
accompanied with substantial loss of antifungal activity. Although it was previously 
shown that AMB-DOC and AmBisome® were equally active after long-term 
exposure (MIC, MFC) [7, 28) the activity of AmBisome® during short term exposure 
was significantly less than that of AMB-DOC [28). Recently, it is reported [24) that 
even after long-term exposure (24 h) AmBisome® was four to eight times less active 
than AMB-DOC against C.albicans. 
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Table 2. Effect of treatment on survival of mice and growth of Calbicans in the kidney in leukopenic mice' 
treatmentb dosage start of treatment' 48 h after treatment' 6 days after treatmentC 
(mg/kg) 
LoglO CFUlkidnel survival Loglo CFU/kidnel survival Log,o CFUlkidneyd 
% in surviving mice % in surviving mice 
untreated 4.16 ± 0.23 
PEG·AMB-lIP 5 100 3.05 ± 0.76' 100 1.99 ± 0.42' 
AMB-lIP 5 100 4.48 ± 0.83 100 4.04 ± 0.91 
AMB-lIP 11 100 4.27 ± 0.20 100 2.54 ± 0.50' 
AmBisome® 5 70 5.26 ± 0.57 40 3.92 ± 0.51 
AmBisome® 29 100 2.60 ± 0.32' 100 1.01 ± 1.72' 
PEG-PLACEBO-liP 
-
40 6.38 ± 0.22 30 6.12 ± 0.39 
PLACEBO-LIP - 50 6.56 ± 0.21 10 7.39 
J.Leukopenic mice were inoculated iv at zero time with 3x104 CFU of C.albicans 
bpEG-AMB-L1P, AMB-LJP, AmBisome®, PEG-PLACEBO-LIP, and PLACEBO-UP were administered iv 20 h after inoculation 
CEffect of treatment was determined at 48 h (n = 1 0) as well as 6 days (n = 1 0) after treatment 
dEach value represents the geometric mean ± SO 
"'P:=:;:;O.Ol compared with the number of CFU at 20 h after inoculation (time of treatment) 
(P:::;O.01 compared with the number of CFU at 48 h after treatment 
no. mice with 
sterile kidney/no. 
surviving mice 
0/10 
0/10 
0/10 
0/4 
2/10 
0/3 
0/1 
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Comparison of the MTD of the industrially prepared AmBisome® in normal mice 
(> 31 mg AMBlkg) and the MTD of a laboratory prepared AMB-liposome 
formulation (AMB-LlP) having the same lipid composition (19 mg AMB/kg) revealed 
that the method of preparation greatly influences the toxicity of the AMB-liposome 
formulation. As the MTD of AMB-DOC in terms of acute death after a single dose 
treament is 0.8 mg AMBlkg (unpublished data), encapsulation of AMB in AMB-LlP 
still substantially reduced the toxicity of AMB. To the same extent this also applied 
to PEG-AMB-LlP (MTD of 15 mg AMBlkg). 
The prolonged residence time of PEG-AMB-LlP as compared to AMB-LlP was 
previously demonstrated at a dosage of 9 mg AMB/kg (corresponding to 85 polO I 
lipidlkg) [30J. A valuable asset of the PEG-PE-containing liposomes is that they show 
dosage-independent pharmacokinetics [2,3,25,31J. Taking together the data from 
our present and our previous [30J study, it is concluded that for PEG-AMB-LlP 
prolonged blood residence time is not depending on lipid dosage for a dosage 
range of 4.7-85 pmol lipid/kg. These results are in good agreement with those 
reported elsewhere for PEG-PE-liposomes with similar particle size [2,3,25,31], 
demonstrating dosage independent blood circulation times for dosage ranges of 0.5-
500 pmol/kg in mice [3,25,31], and 3-100 pmol/kg [2,31J in rats. On the contrary, 
as reported previously by Allen et al. [3], blood residence times of small liposomes 
of approximately 100 nm in diameter, with a rigid liposomal bilayer and without 
surface modifications are dependent on the lipid dose given. In the present study 
it is shown that AMB-LlP blood residence time is depending on lipid dosage, which 
is in accordance with these previous observations [3J. For AmBisome® dosage 
dependent blood circulation of AMB was already reported previously [13, 17,26,29J. 
The extent to which a prolonged residence time of liposomal AMB is of 
importance for improved therapeutic efficacy was studied in a model of systemic 
candidiasis in leukopenic mice after a single dose treatment. Efficacy of PEG-AMB-
LIP, AMB-LlP, and AmBisome® were compared at an equivalent dosage of 5 mg 
AMB/kg (being the MTD of PEG-AMB-LlP in leukopenic infected mice). At this 
dosage treatment with PEG-AMB-LlP was completely effective, treatment with AMB-
LIP was only partially effective. We conclude that therapeutic efficacy in this model 
of deep systemic candidiasis is favored by a prolonged residence time of AMB-
liposomes in the blood compartment. Whether this is due to sustained release of 
AMB during blood circulation or increased localization of AMB liposomes at the 
sites of infection, as was described by others for localized site of infection [8J or 
solid tumor [25, 19J, is not yet clear. AmBisome® at 5 mg AMBlkg was not effective 
at all. Additionally, AMB-LlP and AmBisome® were both studied at their own MTD. 
Complete efficacy of treatment could not be achieved with AMB-LlP, not even after 
increase of the dosage up to 11 mg AMB/kg (MTD). AmBisome® at 29 mg AMB/kg 
(MTD) was as effective as treatment with PEG-AMB-LlP at the almost six-fold lower 
dosage of 5 mg AMBlkg. Until now, efficacy of AmBisome® is compared with that 
of AMB-DOC in several models of fungal infections [1,10,11,13, 17,28J. From these 
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studies it can be concluded that, depending on the model of fungal infection, 
immune status of the host, and parameter for efficacy used, the antifungal activity 
of AmBisome® is either somewhat less or equal to that of AMB-DOC at equivalent 
dosages. However, treatment with AMB-DOC is restricted by acute toxicity. Using 
AmBisome®, much higher dosages are tolerated resulting in improved antifugal 
efficacy, even in severe infection in immunocompromised animals. Only recently 
[24J, the interpretation of the data from these experimental studies on AmBisome® 
has been critically discussed. The authors rightly note that a difference in toxicity, 
and thereby in therapeutic index, between AmBisome® and AMB-DOC has always 
been claimed on the basis of acute toxicity of rapidly injected AMB-DOC in small 
laboratory animals. As in patients AMB-DOC is not administered as an iv bolus, but 
by slow infusion, the authors studied therapeutic efficacy of both AMB-DOC and 
AmBisome® in localized and systemic murine candidiasis, with AMB-DOC 
administered at high dosages in multiple fractions. The observation that AmBisome® 
was less active than high dosages of AMB-DOC indicate that by entrapment of AMB 
in liposomes therapeutic efficacy might be reduced. From the present study it is also 
clear that in AmBisome® reduction of toxicity is concomitant with reduction in 
antifungal activity, and thereby in antifungal efficacy in vivo. At an equivalent 
dosage, AMB-LlP, a formulation in which somewhat less reduction in toxicity goes 
together with retainment of antifungal activity, shows better antifungal efficacy in 
vivo. 
By combining the data on toxicity, antifungal activity, blood residence time and 
efficacy of treatment, two important conclusions can be drawn: first, (rom a 
comparison between laboratory prepared AMB-LlP with industrially prepared 
AmBisome®, it is clear that the method of preparation of an AMB-liposome 
formulation greatly influences the toxicity, antifungal activity, and thereby the 
antifungal efficacy in vivo. It should be stressed that maximal reduction of AMB 
toxicity results in concomitant loss of antifungal activity and efficacy. Therefore for 
optimization of the preparation of AMB-liposomes it is important to focus on both 
reduction in AMB toxicity, while retaining antifugal activity. In both AMB-LlP and 
PEG-AMB-LlP this is achieved. The second conclusion derived by comparing PEG-
AMB-LlP and AMB-LlP, is that therapeutic efficacy is favored by a prolonged 
residence time of AMB-liposomes in the blood compartment. 
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Efficacy of pegylated long-circulating amphotericin B-
liposomes versus AmBisome® in the treatment of systemic 
candidiasis in leukopenic mice in relation to the severity 
of infection 
Els WM van Etten, Susan V Snijders, Henri A Verbrugh, 
and Irma AJM Bakker-Woudenberg 
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ABSTRACT 
The therapeutic efficacy of pegylated long-circulating amphotericin B·liposomes 
(PEG-AMB-LlP) was compared with that of commercially prepared AmBisome® in 
a model of systemic candidiasis in leukopenic mice in relation to the severity of 
infection. AmBisome® administered as a single dose (5 mg AMB/kg) 6 h after 
Candida a/bicans inoculation was only partially effective: all mice survived up to 
7 days after Ca/bicans inoculation. However, the number of Ca/bicans CFU in the 
kidney had neither increased nor decreased as compared to the start of treatment. 
PEG-AMB-LlP at the same dosage was much more effective: all mice survived, and 
the number of Ca/bicans CFU in the kidney was significantly reduced 3 to 7 days 
after inoculation. If treatment was delayed to 20 h after inoculation, AmBisome® 
was not effective anymore (60% mortality). In contrast, PEG-AMB-LlP retained its 
efficacy. When multidose AmBisome® treatment was started 6 h after inoculation, 
5 daily doses were needed to significantly reduce Ca/bicans CFU. When treatment 
was delayed to 16 h after inoculation, even 5 daily doses of AmBisome® were not 
effective anymore, and some of animals died. Further delay in treatment to 20 h 
after inoculation resulted in increase in mortality to 70%. In sharp contrast, a single 
dose of PEG-AMB·LlP was efficacious (zero mortality) even if treatment was delayed 
to 20 h after inoculation. Since the efficacy of PEG-AMB-LlP could not be matched 
by AmBisome®, even when sustained blood levels of AmBisome® were assessed by 
a multidose regimen, it is concluded that prolonged blood residence time of AMB-
liposomes is not the only factor contributing to superior antifungal efficacy of PEG-
AMB-LlP observed in vivo. The high intrinsic antifungal activity of PEG-AMB-LlP 
may be of great clinical significance in the treatment of severe invasive fungal 
infection. 
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INTRODUCTION 
The ability to achieve a significantly longer blood residence time of liposomes 
opens new ways for improved delivery of antimicrobial agents to infected tissue 
sites outside those that are included in the mononuclear phagocyte system (MPS) 
[5]. Many reports have shown that hydrophilic phosphatidylethanolamine 
derivatives of monomethoxy polyethyleneglycols (PEG-PE) attached to the I iposomes 
can effectively prolong their blood circulation time without the limitations of a high 
lipid dose, small particle size, or rigid lipid bilayer [1,3,7,12,13]. Such pegylated 
liposomes have been named sterically stabilized liposomes. The distinctive 
properties of sterically stabilized liposomes makes them excellent candidates for 
many therapeutic applications [4,5,8J. 
We recently showed [10] that long-circulating amphotericin B (AMB) containing 
liposomes can be prepared by incorporation of PEG-DSPE. With the pegylated 
AMB-liposome formulation developed at our laboratory (PEG-AMB-LlP) [10], 
prolonged blood residence time, as well as substantial reduction of AMB toxicity 
without loss of antifungal activity were achieved. Furthermore, from a study on the 
effects of incorporation of PEG-DSPE in AMB-liposomes on in vitro antifungal 
activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice [11 J two 
important conclusions were drawn: First, from a comparison between laboratory 
prepared AMB-liposomes with commercially prepared AmBisome®, it became clear 
that the method of preparation of an AMB-liposome formulation greatly influences 
the toxicity, as well as antifungal activity, and thereby the antifungal efficacy in 
vivo. For AmBisome® it was found that reduction of toxicity of AMB is associated 
with a reduction of its antifungal activity. Therefore, for optimization of the 
formulation of AMB-liposomes it is important to focus on reduction of AMB toxicity, 
without reducing its antifungal activity. The second conclusion, derived by 
comparing PEG-AMB-LlP and laboratory prepared AMB-liposomes, was that 
therapeutic efficacy is favoured by a prolonged residence time of AMB-liposomes 
in the blood compartment. In the present study, the significance of the 
characteristics of prolonged blood residence time and high intrinsic activity of PEG-
AMB-LlP in the treatment of systemic candidiasis were studied by comparing the 
antifungal efficacy of single dose PEG-AMB-LlP treatment to single- or multidose 
AmBisome® treatment in relation to the severity of infection. 
MATERIALS AND METHODS 
Materials. Sabouraud dextrose agar was from Oxoid (Basingstoke, England). 
Amphotericin B was kindly provided by Bristol Myers-Squibb, The Netherlands. 
AmBisome®, consisting of HSPC:Chol:DSPG:AMB in a molar ratio of 2:1 :0.8:0.4, 
was kindly provided by Vestar, Inc. (San Dimas, CAl. Hydrogenated soybean 
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phosphatidylcholine (HSPC), cholesterol (Choi), monomethoxy polyethyleneglycol 
(1900) succinimidyl succinate (activated PEG), distearoylphosphatidylethanolamine 
(DSPE), were all kindly provided by Vestar, Inc. Dimethylsulphoxid (DMSO) was 
from Janssen Chimica (Tilburg, The Netherlands). Cyclophosphamide was from 
Sigma (St. Louis, MO). PEG(1900) derivative of DSPE (PEG-DSPE) was synthesized 
as described by Blume and Cevc [6]. 
Candida strain. Candida albicans A TCC 44858 was used in all of the 
experiments and was stored at -80°C in Todd-Hewitt broth (Difco laboratories, 
Detroit, MI, USA) containing 10% (v/v) glycerol. 
Animals. Specified pathogen-free, 12- to 20-weeks-old female BALB/c mice were 
obtained from Iffa Credo (L'Arbresle, France). 
Liposome preparation. PEG-DSPE:HSPC:Chol:AMB in a molar ratio of 0.21: 1.79: 
1 :0.32 (PEG-AMB-LlP) was prepared as described previously [1 OJ. Briefly, AMB was 
complexed to PEG-DSPE in chloroform-methanol (1:1, v/v) at 65°C, followed by 
addition of HSPC and Chol. This lipid mixture was evaporated to dryness, and 
subsequently hydrated by Vortex mixing in a buffer solution containing 10 mM 
sodiumsuccinate and 10% (w/v) sucrose (pH 5.5) at 65°(, Phospholipid 
concentration was determined by a phosphate assay [2J. AMB concentration was 
determined spectrophotometrically at 405 nm, after destruction of the liposomes in 
DMSO-methanol (1: 1, v/v). 
AmBisome®, consisting of HSPC:Chol:DSPG:AMB in a molar ratio of 2:1 :0.8:0.4 
was provided as a lyophilized preparation. The powder was reconstituted according 
to the manufacturer's instructions with distilled water at 65°C to give a liposomal 
suspension containing 4 g AMB/L and 35 g lipid/L, with an average liposome 
particle size of 90 nm (range 88-92 nm). 
Efficacies of PEG-AMB-LlP and AmBisome® in leukopenic mice infecled with 
Calbieans. Leukopenia was induced by ip administration of cyclo-phosphamide at 
100 mg/kg 4 days before Calbicans inoculation followed by an additional dose of 
75 mg/kg on the day of inoculation, and at 3-day intervals thereafter. This treatment 
resulted in persistent granulocytopenia « 0.1 xl0'/L) from the time of Calbieans 
inoculation up to termination of the study. Leukopenic mice were infected by 
inoculation of 3x104 Calbicans CFU into the tail vein. Various treatment regimens 
were studied: 
Single dose PEG-AMB-LlP versus single dose AmBisome"', in relation to severity 
of infection. PEG-AMB-LlP and AmBisome® were each administered iv as a single 
dose of 5 mg AMBlkg at 6 h, or 20 h after Calbicans inoculation. This dosage is 
the maximum tolerated dosage (MTD) of PEG-AMB-LlP in leukopenic mice 
administered as a single dose at 20 h after inoculation with Calbicans, as 
determined previously [llJ. 
Sing/e- versus multidose AmBisome®. AmBisome® was administered iv at 5 mg 
AMB/kg as a single dose, or daily for three, or five consecutive days at 5 mg AMB/ 
kg/day. Treatment was started 6 h after Calbicans inoculation. 
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Single dose PEG-AMB-L1P versus multidose AmBisome®, in relation to severity 
of infection. PEG-AMB-LlP was administered iv as a single dose, whereas 
AmBisome® was administered iv daily for five consecutive days. Treatment was 
started 6 h, 16 h, or 20 h after Calbicans inoculation. 
Just prior to the start treatment and at three days as well as seven days after 
Calbicans inoculation, surviving mice were sacrificed. The kidneys were removed 
and processed for the determination of viable Calbieans, as described previously 
[9J. The following criteria were used to assess the efficacy of treatment: survival of 
mice up to seven days after Calbicans inoculation; a statistically significant 
reduction of the numbers of Calbicans CFU in the kidneys at three days as well as 
seven days after Calbicans inoculation as compared to the CFU at the start of 
antifungal treatment. 
Statistical analysis. Results were expressed as the geometric means ± S.D. 
Differences in Calbicans CFU between the various treatment groups were analyzed 
by the Mann-Whitney test. 
RESULTS AND DISCUSSION 
In leukopenic mice infected with Calbicans the infection is disseminated to the 
kidney, liver, spleen and lung, and untreated as well as placebo-treated mice die 
between 24 h and eight days after Calbicans inoculation [11 J. As it was previously 
shown [9, 11J that both PEG-AMB-LlP as well as AmBisome® treatment resulted in 
significantly reduced numbers of Calbicans CFU in liver, spleen and lung, in the 
present study only the numbers of Calbicans CFU in the kidney were determined. 
By increasing the delay between Calbicans inoculation and the start of 
treatment, the efficacy of treatment in relation to the severity of infection could be 
investigated. This was reflected in the number of Calbicans CFU in the kidney at 
the start of treatment (Tables 1 and 3). The effect of single dose PEG-AMB-LlP versus 
AmBisome®, in relation to severity of infection, is presented in Table 1. AmBisome® 
administered 6 h after Calbieans inoculation was only partially effective: all mice 
survived up to 7 days; however, the number of Calbicans CFU in the kidney had 
neither increased nor decreased as compared to the start of treatment. PEG-AMB-LlP 
at the same dosage was much more effective as all mice survived, and the number 
of Calbieans CFU decreased significantly up to seven days after inoculation. If 
treatment was delayed to 20 h after inoculation, AmBisome® was not effective 
anymore, as 60% of animals died; in contrast PEG-AMB-LlP retained its efficacy 
(zero mortality). 
To investigate whether prolongation of the blood residence of AmBisome®, 
obtained by repeated administration, would result in improved efficacy, the effect 
of single- versus multidose treatment of AmBisome® was investigated (Table 2). 
AmBisome® treatment started 6 h after Calbicans inoculation, and administered 
daily for three or for five consecutive days, did not result in a significant reduction 
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Table 1. Effect of single dose PEG·AMB-LlP versus single dose AmBisome® on survival of mice and growth of C.albicans in the 
kidney in leukopenic mice;), in reJaaon to severity of infection. 
start of treatment> number start of treatment day 3 after inoculation C day 7 after inoculation' 
treatment of 
Log lO CFUlkidneyd Log lO CFUJkidneyd doses survival survival LoglO CFUlkidnel no. m ice with 
% in surviving mice % in surviving mice sterile 
kidney/no. 
surviving mice 
6 h untreated 3.20 ± 0.16 
PEG·AMB-lIP 1 100 1.04 ± 0.39' 100 1.16 ± 0.70' 0/10 
AmBisome® 1 100 3.28 ± 0.20 100 3.47 ± 0.41 0/10 
20 h untreated 4.16 ± 0.23 
PEG·AMB·lIP 1 100 3.05 ± 0.76' 100 1.99 ± O.42~ 0/10 
AmBisome® 1 70 5.26 ± 0.57 40 3.92 ± 0.51 0/4 
JLeukopenic mice were inoculated iv at zero time with 3x104 C.aJbicans CFU; untreated as well as placebo-treated mice died betvveen 24 h and eight 
days after C.afbicans inoculation 
bpEG-AMB-lIP or AmBisome® was administered iv as a single dose at 5 mg AMBlkg 
CEffect of treatment was determined at day 3 (n = 1 0) as well as day 7 (n = 1 0) after inoculation. 
dEach value represents the geometric mean ± SO 
'-'PSO.01 compared with number of CFU at the start of treatment 
... 
Table 2. Effect of sing/e- versus multidose AmBisome® on survival and growth of C.albicans in the kidney in leukopenic mice'. 
start of treatmentb number start of treatment day 3 after inoculation<:: day 7 after inoculation C 
treatment of doses 
Log" CFUlkidney' survival lOglO CFUlkidneyd survival Log10 CFUlkidneyd no. mice with 
% in surviving mice % in surviving mice sterile kidney / 
no. surviving 
mice 
6h untreated 3.20 ± 0.16 
AmBisome® 1 100 3.28 ± 0.20 100 3047 ± 0041 0/10 
AmBisome® 3 100 3.08 ± 0.26 100 3046 ± 0.57 0/10 
AmBisome® 5 100 2.90 + 0.44 100 2.63 + 0046' 0/10 
JLeukopenic mice were inoculated iv at zero time with 3x1 04 C.albicans CFU; untreated as well as placebo-treated mice died between 24 h and eight 
days after C.albicans inoculation 
bAmBisome® was administered iv as a single dose, or daily for three, or five consecutive days at 5 mg AMB/kg/day. Treatment was started at 6 h after 
inoculation 
cEffect of treatment was determined at day 3 (n = 1 0) as well as day 7 (n = 1 0) after inoculation 
dEach value represents the geometric mean ± SO 
<.'P::;O_Ol compared with number of CFU at the start of treatment 
... 
'" 
Table 3. Effect of single dose PEC-AMB-UP versus multidose AmBisome® on survival of mice and growth of C.albicans in the kidney 
in leukopenic miceJ., in relation to severity of infection. 
start of treatment' number start of treatment day 3 after inoculationC day 7 after inoculation C 
I 
treatment of 
Loglo CFU/kidneyd Laglo CFU/kidnei Loglo CFU/kidneyd doses survival survival no. mice 
% in surviving mice % in surviving mice with sterile 
kidney / no. 
surviving 
mice 
6 h untreated 3.20 ± 0.16 
PEG-AMB-lIP 1 100 1.04 ± 0.39' 100 1.16 ± 0.70' 0/10 
AmBisome® 5 100 2.90 ± 0.44 100 2.63 ± OA6' 0/10 
16 h untreated 4.01 ± 0.22 
PEG·AMB-lIP 1 100 2.29 ± 0,42' 100 1.35 ± 0.51' 0/10 
AmBisome® 5 90 4.79 ± OAO 90 3A3 ± 0.38 0/9 
20 h untreated 4.16 ± 0.23 
PEG-AMB-lIP 1 100 3.05 ± 0.76' 100 1.99 ± OA2' 0/10 
'---
AmBisome® 5 60 5.39 ± 0,45 30 4.57 + 1.11 0/3 
JLeukopenic mice were inoculated iv at zero time with 3xl04 C.afbicans CFU; untreated as well as placebo-treated mice died between 24 h and eight 
days after C.afbicans inoculation 
bpEG-AMB-lIP was administered IV as a Single dose at 5 mg AMBlkg. AmBisome® was administered iv daily for five consecutive days at 5 mg AMB/kgl 
day 
CEffect of treatment was determined at day 3 (n = 10) as well as day 7 (n = 1 0) after inoculation 
dEach value represents the geometric mean ± SD 
ep:::;;0.01 compared with number of CFU at the start of treatment 
Chapter 8 
of Calbicans CFU at three days after inoculation. Only after five-day treatment the 
number of Calbicans CFU was significantly lowered shortly after treatment (as 
determined seven days after inoculation). Although antifungal efficacy was improved 
after the five-day treatment with AmBisome"', the response to this therapy was, thus, 
relatively slow. 
In this model of systemic candidiasis, in which untreated animals start to die 24h 
after Calbicans inoculation, it was questioned what would be the efficacy of five-
day treatment with AmBisome'" if the start of treatment was delayed. The effect of 
single dose PEG-AMB-LlP versus multidose AmBisome'" for five consecutive days, 
in such delayed treatment protocol, is presented in Table 3. As was already shown 
in the previous experiments both PEG-AMB-LlP as well as AmBisome'" administered 
6 h after Calbicans inoculation were both effective. When treatment was delayed 
to 16 h after inoculation, AmBisome'" was not effective anymore, as a small 
percentage of animals died. Further delay of treatment to 20 h after inoculation 
resulted in a further increase in mortality. In contrast, a single dose of PEG-AMB-LlP 
retained its efficacy even if it was only given 20 h after inoculation. 
It is, thus, clear that single dose treatment with PEG-AMB-LlP is superior to five-
day treatment with AmBisome'" in this model of systemic candidiasis in the 
leukopenic host. We have previously shown [11], by comparing PEG-AMB-LlP and 
laboratory prepared AMB-liposomes, that therapeutic efficacy is favoured by a 
prolonged residence time of AMB-liposomes in the blood compartment. The present 
study shows that the high efficacy as observed for PEG-AMB-LlP could not be 
matched by AmBisome'" even if, by a multidose regimen, its presence in blood was 
prolonged. It is concluded that prolonged blood residence time of AMB-liposomes 
is not the only factor contributing to the antifungal efficacy of such formulations in 
vivo. Our previous studies [11J showed that in AmBisome'" reduction of toxicity of 
AMB is associated with a reduction of its antifungal activity, in vitro as well as in 
vivo. In PEG-AMB-LlP a substantial reduction of AMB toxicity was achieved, 
without such a loss in antifungal activity. The present study clearly demonstrates the 
high intrinsic activity of PEG-AMB-LlP: Only treatment with PEG-AMB-LlP and not 
with AmBisome'" resulted in decreasing numbers of Cafbicans CFU in the kidney 
within short period of time after Cafbicans inoculation. The high intrinsic antifungal 
activity of PEG-AMB-LlP may be of great clinical significance in the treatment of 
severe invasive fungal infection, especially in the immunocompromised host. 
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First evidence of efficacy of pegylated long-circulating 
amphotericin B-liposomes in the treatment of pulmonary 
aspergillosis in leukopenic rats 
Eis WM van Etten, Lorna ET Stearne-Cullen, 
Henri A Verbrugh, and Irma AJM Bakker-Woudenberg 
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ABSTRACT 
In the present study, first evidence of the antifungal efficacy of pegylated long-
circulating amphotericin B-liposomes (PEG-AMB-UP) in a model of pulmonary 
aspergillosis in persistently leukopenic rats is presented. Treatment started 30 h after 
Aspergillus {umigatus inoculation with a single dose of 10 mg AMB/kg PEG-AMB-
UP was evaluated in terms of survival of rats as well as in numbers of viable 
Aspergillus {umigatus in post-mortem cultures of left and right lung, and liver. At 
the start of treatment the Aspergillus {umigatus conidia had germinated to hyphae. 
Survival was significantly prolonged by PEG-AMB-UP treatment. Post-mortem 
cultures in treated rats were not different from those in untreated rats. These data 
are encouraging and warrant further exploration of the therapeutic efficacy of PEG-
AMB-UP in invasive pulmonary aspergillosis. 
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INTRODUCTION 
As in granulocytopenic patients the mortality from pulmonary aspergillosis 
remains high despite aggressive antifungal therapy, there is an urgent need for 
therapeutic advances [1 OJ. Although experimental studies on the efficacy of various 
antifungal agents and amphotericin B (AMBHipid formulations have been performed 
[1,2,3,5,9,10,11,12,13,14], in only two models of pulmonary aspergillosis, one in 
rabbits [3, llJ and another in rats [13J, the respiratory route of infection as well as 
profound and persistent granulocytopenia were part of the experimental design. In 
these two models of invasive pulmonary aspergillosis, improved survival of animals 
after multidose treatment with Amphocil® [3J or AmBisome® [11, 13J has been 
reported. It is evident that Amphocil® and AmBisome® have quite different structural 
and pharmacokinetic characteristics [3,11]. The small discoidal particles of 
Amphocil® are rapidly taken up by the mononuclear phagocyte system, whereas 
small liposomes as in AmBisome® remain in the circulation for relatively prolonged 
periods. Until now it is not known whether prolonged residence of AMB-liposomes 
in the blood compartment is relevant for the efficacy of such formulations in 
invasive pulmonary aspergillosis. A pegylated long-circulating amphotericin B 
(AMB)-liposome formulation (pEG-AMB-LlP) was developed in our laboratory [16J. 
PEG-AMB-LlP has recently been shown to greatly improve the antifungal efficacy 
of AMB in severe invasive candidiasis after only single dose treatment [17J. With 
respect to the treatment of pulmonary infection, it has been shown in our laboratory 
that pegylated liposomes selectively localize at the site of Klebsiella pneumoniae-
infected lung tissue [7], resulting in improved efficacy of gentamicin or ceftazidime 
entrapped in such long-circulating liposomes [8J. In the present study it was 
investigated whether a single-dose of long-circulating PEG-AMB-LlP was effective 
in the treatment of invasive pulmonary aspergillosis in persistently leukopenic rats. 
MATERIALS AND METHODS 
Materials. Sabouraud dextrose agar (SDA) was from Oxoid (Basingstoke, 
England). Amphotericin B was kindly provided by Bristol Myers-Squibb, The 
Netherlands. Hydrogenated soybean phosphatidylcholine(HSPC), cholesterol (Chol), 
and polyethylene glycol (1900) derivatized distearoylphosphatidylethanolamine 
(pEG-DSPE), were all kindly provided by LTI, Inc. (Menlo Park, CAl. 
Dimethylsulphoxid (DMSO) was from Janssen Chimica (Tilburg, The Netherlands). 
Cyclophosphamide was from Sigma (St. Louis, MO). 
Aspergillus strain. A clinical isolate of Aspergillus fumigatus from an immuno-
compromised patient with invasive pulmonary aspergillosis was used. This strain 
was stored under oil on SDA. For inoculation a suspension of conidia of 
A.fumigatus in sterile saline was prepared. 
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Animals. Specified pathogen-free, 18- to 25-weeks-old (weight 185-225 g) female 
R strain albino rats were obtained from Harlan CPB, Rijswijk, The Netherlands. 
Immunosuppression and supportive care. Leukopenia was induced by ip 
administration of cyclophosphamide at 90 mg/kg 5 days before Afumigatus 
inoculation followed by an additional dose of 60 mg/kg on the day before 
inoculation, and at 4-day intervals thereafter. This treatment resulted in persistent 
granulocytopenia « 0.5xlO'/L) from the time of Afumigatus inoculation up to 
termination of the study. To prevent bacterial superinfection strict hygienic care was 
applied, and rats received ciprofloxacin (660 mg/L) and polymyxin E (100 mg/L) in 
their drinking water during the whole experiment. From the day before inoculation 
daily amoxicillin (40 mg/kg/dose), administered intramusculary, was added to this 
regime for the remainder of the experiment. Shortly before and after inoculation 
gentamicin (40 mg/kg/dose) was administered intramusculary. 
Liposome preparation. PEG-DSPE:HSPC:Chol:AMB in a molar ratio of 0.21: 1.79: 
1 :0.32 (PEG-AMB-LlP) was prepared as described previously [16]. Briefly, AMB was 
complexed to PEG-DSPE in chloroform-methanol (1:1, v/v) at 65°C, followed by 
addition of HSPC and Chol. This lipid mixture was evaporated to dryness, and 
subsequently hydrated by Vortex mixing in a buffer solution containing 10 mM 
sodium-succinate and 10% (w/v) sucrose (pH 5.5) at 65°C. Phospholipid 
concentration was determined by a phosphate assay [4]. AMB concentration was 
determined spectrophotometrically at 405 nm, after destruction of the liposomes in 
DMSO-methanol (1: 1, v/v). 
Experimental lung infection. Experimental pulmonary aspergillosis was obtained 
according to the method used in the experimental pneumonia model (left lung) with 
Klebsiella pneumoniae as described by Bakker-Woudenberg [6]. Briefly, rats were 
anaesthetized after which the left main bronchus was intubated and the left lung 
was inoculated with 0.02 ml of conidial suspension. 
Efficacy of PEG-AMB-LlP in leukopenic rats infected with A.fumigatus. 
Leukopenic rats were inoculated with 10' conidia Afumigatus. PEG-AMB-LlP (10 
mg AMBikg) was administered iv as a single dose at 30 h after Afumigatus 
inoculation. Survival (days after inoculation) was recorded for each rat. Post-mortem 
the left and right lung, and the liver were removed and processed for the 
determination of viable Afumigatus, as described previously for C.albicans [15]. 
The following criteria were used to assess the efficacy of treatment: survival of rats 
up to twelve days after Afumigatus inoculation and reduction in the numbers of 
Afumigatus CFU in the various organs at time of death as compared to the numbers 
found in rats left untreated. 
Statistical analysis. Statistical evaluation of differences in the survival curves 
between PEG-AMB-LlP-treated and untreated groups of rats was performed by the 
log rank test. This test examines the decrease in survival with time as well as the 
final percentage of survival. Results of post-mortem cultures were expressed as the 
148 
Chapter 9 
geometric means ± S.D. Differences in Afumigatus CFU between the two groups 
were analyzed by the Mann-Whitney test. 
RESULTS AND DISCUSSION 
In this model of pulmonary aspergillosis untreated rats died between 5 to 8 days 
after inoculation. Post-mortem cultures in these untreated rats (Table 1) revealed that 
at the time of death the infection had disseminated to the right lung in all rats and 
to the liver in the majority of the rats (11 out of 15). Whether mortality is directly 
related to the dissemination of the infection remained unclear. The effect of 
treatment started 30 h after inoculation with a single dose of PEG-AMB-LlP (10 mg 
AMB/kg) on survival of the rats is presented in Figure 1. At the start of treatment the 
conidia had already germinated to hyphae. Treatment resulted in significantly (PO;; 
0.001) prolonged survival. However, post-mortem cultures in the treated rats (Table 
1) were not different from those in untreated rats. 
100 1 I 
90 l- I 
"--I 
80 l- I 
I 
e 70 
l __ 1 
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0 5 10 15 
Time (days after Inoculation) 
Figure 1. Effect of single dose administration of PEG-AMB-LlP on survival of 
leukopenic rats with pulmonary aspergillosis (Kaplan-Meier plot). Leukopenic rats 
were inoculated in the left lobe of the lung with 105 conidia Afumigatus at zero 
time. Rats were treated with PEG-AMB-LlP ( - - - - ) adminstered at 30 h after 
inoculation, or left untreated( --). *PO;; 0.00 1 versus untreated rats. 
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Table 1. Effect of single dose PEG-AMB-L1P on lung infection with A.fumigatus and dissemination to other organs in leukopenic 
rats'. 
start of 
treatment 
30 h 
treatmentb 
untreated 
PEG-AMB-LlP 
dosage 
(mg/kg) 
10 
Log1O CFUlorgan' in deceased ratsd 
left lung right lung liver 
3.4 ± 0.4 1.8 ± 0.9 1.4 ± 1.0 
3.1 ± 0.8 1.4 ± 0.9 0.7 ± 1.0 
"Leukopenic rats were inoculated in the left lung at zero time with 10s conidia A.fum;gatus 
bpEG-Atv1B-lIP was administered iv as a single dose 
cEach value represents the geometric mean ± SD 
dEffect of treatment was determined by post-mortem cultures 
no. culture positive organsd / 
total no. rats 
left lung right lung liver 
16/16 15/15 11/15 
15/15 14/16 6/16 
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With respect to other AMB-lipid formulations only limited data on efficacy in 
animal models of invasive aspergillosis are available [1,3,9,11,12,13,14]. The 
clinical relevance of some of the animal models is questionable, as Afumigatus was 
mostly inoculated iv instead of via the respiratory route [1,9,12,14]. In addition, 
some of the studies were in animals that were not persistently granulocytopenic 
[1,9,12]. In immunocompetent animals or in animals treated with corticosteroids for 
suppresion of macrophage antifungal actvity, high doses of various AMB-lipid 
formulations proved to be efficacious in terms of survival of animals andlor 
clearance of Afumigatus from infected organs. A recent study reported on the effect 
of prophylaxis of pulmonary aspergillosis with aerosolized AmBisome'" [2], which 
was found to be highly protective against the development of pulmonary 
aspergillosis after intranasal challenge with Afumigatus conidia. 
In the two clinically relevant models of pulmonary aspergillosis in 
granulocytopenic animals, one in rabbits [3,11] and another in rats [13] improved 
survival of animals after multidose treatment with Amphocil® [3] or AmBisome'" 
[11,13] has been reported. The data from the present study indicate increased 
survival of rats after only a single dose of long-circulating PEG-AMB-LlP, and are 
encouraging for further exploring the therapeutic efficacy of PEG-AMB-LlP in 
invasive pulmonary aspergillosis. 
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There has been a steady increase in the incidence of invasive fungal infections. 
Presently, these infections are among the most important causes of morbidity and 
mortality among patients with cancer and among other severely 
immunocompromised hosts [5,39,42J. As the overall prognosis for patients with 
invasive fungal infections remains poor, there is a critical need to improve the 
treatment of these infections. Parenteral administration of amphotericin B (AMB) 
remains the therapy of choice for most invasive fungal infections. AMB is 
administered as AMB·desoxycholate (AMB·DOC or Fungizone®), but its use is 
significantly limited by its toxic side effects [17J. New antifungal agents, such as the 
triazole fluconazole (FLU) and liposomal AMB have been developed for the 
management of invasive fungal infections [9,13,18,20,21 ,29,42J. The role of these 
new agents in the treatment of invasive fungal infections in the leukopenic host is 
not clearly defined nor well understood. 
The primary aim of the work presented in this thesis was to gain further insight 
into the therapeutic value of existing and newly developed liposomal formulations 
of AMB in the treatment of invasive fungal infections. 
To this end, different animal models of invasive fungal infections were 
developed. Clinically relevant issues including persistent leukopenia and 
dissemination of infection, are addressed. One model was an invasive Candida 
albicans infection with dissemination to the kidney, liver, spleen, and lung in mice 
which were rendered persistently leukopenic. In addition, a model of invasive 
candidiasis restricted to the kidney in immunocompetent mice was used. Finally, 
a model of Aspergillus fumigatus one·sided pulmonary infection in persistently 
leukopenic rats was developed, in which the fungus disseminated to the right lung 
and to the liver during the course of the infection [28J. 
The question of the impact of a fungistatic agent, FLU, versus that of the 
fungicidal agent, AMB·DOC, on treatment of invasive candidiasis was covered in 
the first two studies (chapters 2 and 3). Although the in vitro activity of AMB·DOC 
against Calbicans was high, the antifungal activity was influenced by factors 
relevant to its efficacy in the treatment of infection: activity of AMB·DOC was 
substantially reduced by the presence of serum. AMB·DOC activity was only slightly 
hindered by an intracellular localization of the yeast (in peritoneal macrophages). 
For FLU, even at high concentrations, antifungal activity against extracellular 
Calbica/lS was restricted to inhibition of fungal growth. Furthermore, FLU was not 
effective against intracellular Catbicans. Therefore, it was questioned whether FLU 
could effectively eradicate Calbicans in vivo, in particular when host defense 
mechanisms are severely impaired. In immunocompetent mice FLU was effective 
as long as treatment was given, whereas in leukopenic mice efficacy was only 
obtained if treatment was started in the early phase of the disease. In well 
established Calbicans infection in leukopenic mice FLU was definitely not 
efficacious when treatment was delayed. Other investigators [40,41] came to a 
similar conclusion regarding FLU efficacy in their models of invasive candidiasis in 
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persistently granulocytopenic rabbits. It is now generally accepted that treatment 
with FLU in established invasive candidiasis in granulocytopenic patients is not 
recommended, although limited studies in such patients have shown some 
encouraging results [9,20,29J. Another issue that became clear once more in the 
present study, was that in contrast with the potent antifungal activity of AMB-DOC 
in vitro, the in vivo therapeutic efficacy of AMB-DOC is very limited, especially in 
leukopenic animals, due to the low maximum tolerated dosage (MTD). 
The rationale for the use of AmBisome®, one of the industrially prepared AMB-
lipid formulations, was to make use of the potent fungicidal effect of AMB while, 
at the same time, reducing its toxicity by liposomal encapsulation. The antifungal 
efficacy of AMB was far improved with AmBisome®, being highly effective in 
multidose treatment regimens. High dosages reduced C.albicans in the kidney and 
other organs as well as prevented relapse of infection, even in severe infection 
(chapter 3). It should be noted, however, that at equivalent dosages, AmBisome® 
was less effective than AMB-DOC. On the other hand, much higher dosages were 
tolerated for AmBisome® in these mice, resulting in improved therapeutic efficacy. 
Studies of AmBisome® in other models of fungal infection showed either equivalent 
or reduced antifungal efficacy at equal dosages when compared to AMB-DOC [1, 
11,12,14,19,31]. 
With respect to the biodistribution of AMB after administration of AMB-DOC or 
AmBisome® (chapter 4), it was shown for both formulations that the condition of 
the animals (immunocompetent uninfected mice versus leukopenic mice infected 
with C.albicans ) did not influence on the biodistribution patterns. Comparing the 
biodistribution of AMB-DOC and AmBisome® at equivalent dosages revealed that 
encapsulation of AMB resulted in increased AMB levels in blood. In addition 
increased AMB concentrations were present in the mononuclear phagocyte system 
(MPS), particularly the liver and spleen, whereas concentrations in kidney and lung 
were lower. The low AMB levels in the kidney after AmBisome® treatment may 
explain the decreased antifungal efficacy in invasive candidiasis when compared 
with AMB-DOC at equivalent dosages. Uptake of AmBisome® by MPS-tissues was 
highly dosage dependent and saturable. As a result, at high lipid dosages a 
prolonged circulation of AmBisome® in blood could be obtained. After 
administration of AmBisome® at the MTD, blood and tissues retained high AMB 
concentrations. It should be emphasized that these high concentrations of AMB did 
not lead to toxicity. Recently, similar results were published with respect to the 
biodistribution of AmBisome® in rabbits [27J. 
In studies from other investigators on biodistribution of AmBisome® and other 
AMB-lipid formulations only data on total AMB concentrations in serum and tissues 
have been reported [14, 19,23,27,34J. No distinction could be made between lipid-
associated AMB and non-lipid-associated AMB. Radiolabeling of AmBisome® using 
a radioactive marker which is a representative of intact liposomes [15], allowed us 
to determine whether AMB concentrations measured in blood represented liposome 
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associated AMB or not. The high AMB concentrations in blood represented 
liposome entrapped AMB. During circulation slow release of AMB occurred 
(chapter 4). 
It is suggested by many investigators that AMB is biologically inactive when 
associated with liposomes. Even today it remains unclear whether release of AMB 
is of importance for antifungal activity. In vitro AMB remains tightly associated to 
the liposomes in AmBisome® in the presence of serum, and AMB has not 
necessarily to be released from AmBisome® in order to express antifungal activity 
against Ca/bieans (chapter 5). Similar results have recently been reported by others. 
These authors even showed that AmBisome® can act on both phagocytized and 
non·phagocytized fungal cells, resulting in death of the fungi [2,35J. For a lipid 
formulation of AMB in DMPC/DMPG (7:3), it was reported that AMB can be 
released from the lipid·complex by fungallipases [33J. Whether fungallipases play 
a role in the release of AMB from AmBisome® in the close vicinity of the fungus, 
and whether this is necessary for antifungal activity is not yet clear. 
An important issue on which only very limited data were available, is the 
antifungal activity of AmBisome® against intracellularly growing Ca/bicans. 
Ca/bicans can be considered as a facultative intracellular pathogen, as it is able to 
survive inside unactivated macrophages and to grow out of these cells by forming 
germ tubes (chapter 2). AMB·DOC is higly active against intracellular Ca/bicans 
(chapter 2). Therefore, it was questioned whether encapsulation of AMB in 
AmBisome® would be an advantage with respect to antifungal activity against 
intracellular Ca/bicans in peritoneal macrophages (chapter 5). In parallel with the 
antifungal activities against extracellular Ca/bieans (chapter 3), the intracellular 
antifungal activity of AMB·DOC was much higher than that of AmBisome®. 
Although numerous studies have demonstrated that liposomes are phagocytized 
effectively by macrophages both in vItro and in vivo [37J, an explanation for the 
low intracellular activity of AmBisome® might be low uptake of AmBisome® by 
macrophages infected with Ca/bicans. However, in the present study localization 
experiments with fluorescens·labeled AmBisome® clearly showed that AmBisome® 
is taken up by macrophages, both by un infected macrophages and macrophages 
infected with Ca/bicans. A more likely explanation for the relatively low 
intracellular activity is slow intracellular degradation of AmBisome®. AmBisome® 
is a solid type liposome, composed of saturated phospholipids with high transition 
temperatures and cholesterol, which is expected to be slowly degraded 
intracellularly. In another study using ampicillin entrapped in a solid liposome type, 
relatively slow intracellular degradation in macrophages was demonstrated [6J, 
resulting in a delayed intracellular release of the entrapped ampicillin, and hence 
absent or delayed killing of intracellular Listeria monocytogenes. 
As macrophages seemed to be occupied with the intracellular degradation of 
AmBisome® for a substantial period of time, an important question was whether 
uptake and degradation of AmBisome® in un infected macrophages had effects on 
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subsequent Calbicans ingestion and on intracellular growth of Calbicans (chapter 
5). The presence of AmBisome® inside uninfected macrophages did not influence 
uptake of Calbicans by the same macrophages. Furthermore, previous exposure of 
uninfected macrophages to AmBisome® was advantageous for antifungal activity of 
AmBisome® against intracellular Calbicans. It was recently reported that phagocytic 
cells may even playa role in transport and accumulation of liposomal AMB into 
inflammatory sites in vivo [30J. Whether leukocytes play an important role in 
transport or degradation of AmBisome® at inflammatory sites should be investigated. 
We hypothesize that AmBisome® exerts its antifungal activity in the leukopenic 
host at sites of infection outside the MPS via two different routes, as illustrated in 
Figure 1. 
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Figure 1. Schematic representation of the routes via which AmBisome® exerts its 
antifungal activity. 
After intravenous administration of AmBisome®, intact liposomes circulate in 
blood with only negligible release of AMB from the liposomes during circulation. 
One route is that following uptake and processing of AmBisome® by macrophages 
of the MPS, AMB is released inside the macro phages. In this way the cells of the 
MPS serve as a 'depot' from which AMB is slowly released without reaching toxic 
levels in blood. The second route is that intact AmBisome® reaches the site of 
infection; at the site of infection direct interaction between AmBisome® and the 
fungal cell may occur or AMB may be released from AmBisome® in the close 
vicinity of the fungus. 
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In case direct interaction between AmBisome® and the fungal cells is crucial for 
the in vivo antifungal efficacy, it is important that intact AMB-liposomes localize at 
the site of infection. Prolonged blood residence probably allows the localization of 
more intact liposomes at sites of infection outside MPS-tissues. For liposome types 
such as AmBisome®, that have a small particle size and a rigid bilayer without 
surface modifications, blood residence time is primarily dependent on the lipid dose 
administered. Only at high lipid dosages blood circulation times are prolonged due 
to decrease in hepatosplenic uptake of liposomes, indicative of saturation of the 
MPS (chapter 4). Advances in liposome technology, especially the incorporation of 
hydrophilic phosphatidylethanolamine derivatives of monomethoxy polyethylene-
glycols (PEG-PE) into liposomes, have resulted in the ability to achieve longer blood 
residence time of liposomes without the constraints of high lipid dose, small particle 
size, or rigid nature of the bilayer [4,25,32,43,44J. Such pegylated long-circulating 
liposomes have been named sterically stabilized liposomes or MPS avoiding 
liposomes. 
Can pegylated 10ng-circulatingAMB-liposomes be prepared?Successfulliposomal 
encapsulation of AMB requires that AMB is complexed, e.g. to the negatively 
charged phospholipid distearoylphosphatidylglycerol (DSPG), as in AmBisome®. We 
reasoned that the net negative charge of PEG-DSPE could also be used for 
complexation of AMB. Two different formulations of PEG-DSPE containing 
liposomes with AMB were prepared (chapter 6). PEG-AMB-L1P type 1, in which 
AMB was complexed to DSPG, as well as PEG-AMB-L1P type 2, in which AMB was 
complexed to PEG-DSPE and DSPG was omitted from the preparation. PEG-AMB-
LIP type 1 was as toxic as AMB-DOC, and was omitted from further studies on 
biodistribution. With PEG-AMB-L1P type 2 a relatively non-toxic preparation with 
a prolonged blood residence time was obtained. Now that a pegylated long-
circulating AMB-liposome formulation was available, an urgent question was that 
of the efficacy of this PEG-AMB-L1P type 2 (further referred to as PEG-AMB-L1P) in 
the treatment of fungal infections in the leukopenic host. 
In our model of invasive candidiasis in leukopenic mice PEG-AMB-L1P was 
compared with industrially prepared AmBisome® and with AMB-liposomes (AMB-
LIP), that had the lipid composition as in AmBisome®, but were prepared at our 
laboratory (chapter 7). PEG-AMB-L1P and AMB-L1P were almost equal in in vivo 
toxicity and in vitro antifungal activity, however they differed in blood residence 
time. Blood residence time of PEG-AMB-L1P was more prolonged, even at a low 
lipid dosage. Industrially prepared AmBisome® and laboratory prepared AMB-L1P 
differed in in vivo toxicity and in vitro antifungal activity. AmBisome® was less toxic 
than AMB-L1P, however antifungal activity in vitro was substantially reduced as 
compared to AMB-L1P. In our model of invasive candidiasis in leukopenic mice 
PEG-AMB-L1P was completely effective after a single dose of its MTD, whereas at 
this AMB dosage AMB-L1P was partially effective and AmBisome® was not effective. 
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At its own MTD, which was almost six-fold higher than the MTD of PEG-AMB-LlP, 
AmBisome® was also completely effective. 
Evaluating the data from these three different AMB-liposome formulations on in 
vivo toxicity, in vitro antifungal activity, blood residence time and efficacy of 
treatment in vivo allow two important conclusions to be drawn: First, from a 
comparison between laboratory prepared AMB-LlP and industrially prepared 
AmBisome®, it became clear that the method of preparation of an AMB-liposome 
formulation greatly influences the toxicity, in vitro antifungal activity, and thereby 
the antifungal efficacy in vivo. A substantial reduction of AMB toxicity is clearly 
associated with considerable loss of antifungal activity in vitro and efficacy in vivo. 
Ideally, for optimization of an AMB-liposome formulation it is important to focus 
on reduction in AMB toxicity, without reducing its potent antifungal activity. The 
second conclusion, derived by comparing PEG-AMB-LlP and AMB-LlP, was that 
therapeutic efficacy is favored by a prolonged residence time of AMB-liposomes in 
the blood compartment. Whether this was due to sustained release of AMB during 
blood circulation or to an increased localization of AMB liposomes at the sites of 
infection, as was described by others for localized infection [7,8J or solid tumor 
[16,22J, has to be further investigated. Apart from the prolonged blood circulation 
time of PEG-AMB-LlP its high intrinsic antifungal activity may be of great clinical 
significance in the treatment of severe invasive fungal infection. Only treatment with 
PEG-AMB-LlP, and not with AmBisome®, even if administered repeatedly, resulted 
in decreasing numbers of C.a/bicans in the kidney within short period of time after 
C.a/bicans inoculation (chapter 8). It has been reported recently that, even at high 
doses, AmBisome® treatment was not effective in an experimental model of 
hematogenous infection with two non-a/bicans Candida strains, showing moderate 
susceptibility for AMB [24J. For the treatment of such infections the high intrinsic 
antifungal activity of PEG-AMB-LlP and the reduced frequency of administration of 
these pegylated long-circulating AMB-liposomes open new therapeutic options. 
The final challenge was to investigate whether the improved antifungal efficacy 
of PEG-AMB-LlP, as observed in our candidiasis model, could be extrapolated to 
another very difficult to treat fungal infection: pulmonary invasive aspergillosis in 
the leukopenic host (chapter 9). In granulocytopenic patients the mortality from 
pulmonary aspergillosis remains high despite aggressive antifungal therapy; thus, 
there is an urgent need for therapeutic advances. Our first data from a model of 
invasive pulmonary aspergillosis in persistently leukopenic rats showed that survival 
was significantly prolonged after only a single dose of PEG-AMB-LlP. These data are 
very encouraging and warrant further exploration of the therapeutic advantages of 
PEG-AMB-LlP in this model of pulmonary aspergillosis in rats. Whereas the present 
study focused on systemic intravenous administration of AMB-liposomes in the 
treatment of pulmonary aspergillosis, local administration of aerosolized 
AmBisome® in the prophylaxis of pulmonary aspergillosis has been recently 
described as an alternative modality for achieving high concentrations of antifungal 
159 
Chapter 10 
agent at the site of infection [3,38]. Whether the approaches of systemic 
administration of pegylated 10ng-circulatingAMB-liposomes, or local administration 
of AMB-liposomes, or combinations thereof will be successful in the prophylaxis 
andlor treatment of an established pulmonary fungal infection in man should be 
further evaluated. 
In addition to antifungal chemotherapy, it is important to remember the critical 
role played by host defense mechanisms. A functional nonspecific and specific 
immune system is the best defense against opportunistic fungi. Thus, biological 
response modifiers, such as interferons, interleukins and colony-stimulating factors 
may in the future prove to be important adjuncts to antifungal chemotherapy 
[10,26,36J. 
Coming back to the aim of the present study, stated on the first page of this 
chapter, a number of clear answers were obtained. For treatment of established 
invasive fungal infections in the leukopenic host, it is absolutely necessary to use 
a fungicidal agent, such as AMB-DOC, even though it is highly toxic. With 
AmBisome® it is possible to virtually eliminate the toxicity of AMB. However, the 
reduction of intrinsic antifungal activity associated with the reduction of AMB's 
toxicity is not well recognized. It should be emphasized that high dosages of 
AmBisome® are needed for treatment to be effective. However, the present study 
shows that it is now possible to abolish the toxicity of AMB by liposomal 
encapsulation without reducing its intrinsic antifungal activity. Pegylated long-
circulating AMB-liposomes (PEG-AMB-LlP) meet these requirements. Results 
observed with PEG-AMB-LlP in two models of difficult to treat fungal infections are 
very encouraging. The development of pegylated AMB-liposomes opens new ways 
to improve the treatment of invasive fungal infections in the immunocompromised 
host. Further development of AMB-liposome-technology, thus, remains highly 
relevant. 
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Summary 
As the overall prognosis for patients with invasive fungal infections remains POOf, 
there is a critical need to improve the treatment of these infections. Parenteral 
administration of amphotericin B (AMB) remains the therapy of choice for most invasive 
fungal infections. AMB is administered as AMB·desoxycholate (AMB·DOC or 
Fungizone®), but its use is significantly limited by its toxic side effects. New antifungal 
agents, such as the triazole fluconazole (FLU) and liposomal AMB have been developed 
for the management of invasive fungal infections. The role of these new agents in the 
treatment of invasive fungal infections in the leukopenic host is not clearly defined nor 
well understood. 
The primary aim of the work presented in this thesis was to gain further insight into 
the therapeutic value of existing and newly developed liposomal formulations of AMB 
in the treatment of invasive fungal infections. 
First of all, the question of the impact of a fungistatic agent, FLU, versus that of the 
fungicidal agent, AMBMDOC, on treatment of invasive candidiasis was addressed 
(chapters 2 and 3). Although the in vitro activity of AMB·DOC against C.albicans was 
high, the antifungal activity was influenced by factors relevant to its efficacy in the 
treatment of infection: activity of AMB·DOC was substantially reduced by the presence 
of serum. AMB·DOC activity was only slightly hindered by an intracellular localization 
of the yeast (in peritoneal macrophages), For FLU, even at high concentrations, 
antifungal activity against extracellular C.albicans was restricted to inhibition of fungal 
growth. Furthermore, FLU was not effective against intracellular C.albicans. Therefore, 
it was questioned whether FLU could effectively eradicate C.albicans in vivo, in 
particular when host defense mechanisms are severely impaired. In immunocompetent 
mice FLU was effective as long as treatment was given, whereas in leukopenic mice 
efficacy was only obtained if treatment was started in the early phase of the disease. In 
well established C.albicans infection in leukopenic mice FLU was definitely not 
efficacious when treatment was delayed. In contrast with the potent antifungal activity 
of AMB·DOC in vitro, the in vivo therapeutic efficacy of AMB·DOC in invasive 
candidiasis was very limited, especially in leukopenic animals, due to the low 
maximum tolerated dosage (MTD). 
The rationale for the use of AmBisome", one of the industrially prepared AMB·lipid 
formulations, was to make use of the potent fungicidal effect of AMB while, at the same 
time, reducing its toxicity by liposomal encapsulation. The antifungal efficacy of AMB 
was far improved with AmBisome®, being highly effective in multidose treatment 
regimens. High dosages reduced C.albicans in the kidney and other organs as well as 
prevented relapse of infection, even in severe infection (chapter 3), It should be noted, 
however, that at equivalent dosages AmBisome@was less effective than AMB·DOC. On 
the other hand, much higher dosages were tolerated for AmBisome® in these mice, 
resulting in improved therapeutic efficacy. 
With respect to the biodistribution of AMB after administration of AMB·DOC or 
AmBisome" (chapter 4), it was shown for both formulations that the condition of the 
animals (immunocompetent uninfected mice versus leukopenic mice infected with 
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Ca/bicans) did not influence the biodistribution patterns. Comparing the biodistribution 
of AMB-DOC and AmBisome® at equivalent dosages revealed that encapsulation of 
AMB resulted in increased AMB levels in blood. In addition increased AMB 
concentrations were present in the mononuclear phagocyte system (MPS), particularly 
the liver and spleen/ whereas concentrations in kidney and lung were lower. Uptake 
of AmBisome® by MPS-tissues was highly dosage dependent and saturable. As a result, 
at high lipid dosages a prolonged circulation of AmBisome® in blood could be 
obtained. After administration of AmBisome® at the MTD, blood and tissues retained 
high AMB concentrations. It should be emphasized that these high concentrations of 
AMB did not lead to toxicity. By using radioactively labeled AmBisome® it was found 
that the high AMB concentrations in blood represented liposome entrapped AMB. 
During circulation slow release of AMB occurred (chapter 4). Even today it remains 
unclear whether release of AMB is of importance for antifungal activity. In vitro AMB 
remains tightly associated to the liposomes in AmBisome® in the presence of serum/ 
and AMB has not necessarily to be released from AmBisome® in order to express 
antifungal activity against Ca/bicans (chapter 5). 
The antifungal activity of AmBisome® against intracellularly growing Ca/bicans (in 
peritoneal macrophages) is described in chapter 5. In parallel with the antifungal 
activities against extracellular Ca/bicans (chapter 3), the intracellular antifungal activity 
of AMB-DOC was much higher than that of AmBisome®. localization experiments with 
fluorescens-Iabeled AmBisome® clearly showed that AmBisome® is taken up by 
macrophages, both by uninfected macrophages and macrophages infected with 
C.afbicans. The presence of AmBisome® inside un infected macrophages did not 
influence uptake of C.albicans by the same macrophages. Furthermore/ previous 
exposure of uninfected macrophages to AmBisome® was advantageous for antifungal 
activity of AmBisome® against intracellular Ca/bicans. 
Prolonged residence of liposomes in blood probably allows the localization of intact 
liposomes at sites of infection outside MPS~tissues. For liposome types such as 
AmBisome® blood residence time is primarily dependent on the lipid dose 
administered: only at high lipid dosages blood circulation times are prolonged (chapter 
4). Advances in liposome technology, especially the incorporation of hydrophilic 
phosphatidylethanolamine derivatives of monomethoxy polyethyleneglycols (PEG-PE) 
into Ii po somes/ have resulted in the ability to achieve longer blood residence time of 
liposomes without the constraints of high lipid dose/ small particle size, or rigid nature 
of the bilayer. Such pegylated long-circulating liposomes have been named sterically 
stabilized liposomes or MPS avoiding liposomes. 
It was investigated whether pegylated long-circulating AMB-liposomes could be 
prepared (chapter 6). Successfulliposomal encapsulation of AMB requires that AMB is 
complexed, e.g. to the negatively charged phospholipid distearoylphosphatidylglycerol 
(DSPG), as in AmBisome®. We reasoned that the net negative charge of PEG-DSPE 
could also be used for complexation of AMB. Two different formulations of PEG-DSPE 
containing liposomes with AMB were prepared (chapter 6). PEG-AMB-LlP type 1, in 
which AMB was complexed to DSPG, as well as PEG-AMB-LIP type 2, in which AMB 
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was complexed to PEG-DSPE and DSPG was omitted from the preparation. PEG-AMB-
LIP type 1 was as toxic as AMB-DOC, and was omitted from further studies on 
biodistribution. With PEG-AMB-LlP type 2 a relatively non-toxic preparation with a 
prolonged blood residence time was obtained. The efficacy of this PEG-AMB-LlP type 
2 (further referred to as PEG-AMB-LlP) in the treatment of invasive candidiasis in 
leukopenic mice was investigated (chapter 7). PEG-AMB-LlP was compared with 
industrially prepared AmBisome® and with AMB-liposomes (AMB-LlP), that had the lipid 
composition as in AmBisome®, but were prepared in our laboratory. PEG~AMB~UP and 
AMB·LlP were almost equal in in vivo toxicity and in vitro antifungal activity, however 
they differed in blood residence time. Blood residence time of PEG-AMB-LlP was more 
prolonged, even at a low lipid dosage. Industrially prepared AmBisome® and laboratory 
prepared AMB·LlP differed in in vivo toxicity and in vitro antifungal activity. 
AmBisome® was less toxic than AMB·LlP, however antifungal activity in vitro was 
substantially reduced as compared to AMB·LlP. In our model of invasive candidiasis in 
leukopenic mice PEG-AMB-LlP was completely effective at its MTD, whereas at this 
AMB dosage AMB-LlP was partially effective and AmBisome® was not effective. At its 
own MTD, which was almost six-fold higher than the MTD of PEG-AMB-LlP, 
AmBisome® was also completely effective. 
Evaluating the data from these three different AMB-liposome formulations on in vivo 
toxicity, in vitro antifungal activity, blood residence time and efficacy of treatment in 
vivo allow two important conclusions to be drawn: First, from a comparison between 
laboratory prepared AMB-LlP and industrially prepared AmBisome®, it became clear that 
the method of preparation of an AMB-liposome formulation greatly influences the 
toxicity, in vitro antifungal activity, and thereby the antifungal efficacy in vivo. A 
substantial reduction of AMB toxicity is clearly associated with considerable loss of 
potent antifungal activity in vitro and efficacy in vivo. Ideally, for optimization of an 
AMB·liposome formulation it is important to focus on reduction in AMB toxicity, 
without reducing its antifungal activity. The second conclusion, derived by comparing 
PEG-AMB-LlP and AMB-LlP, was that therapeutic efficacy is favored by a prolonged 
residence time of AMB·liposomes in the blood compartment. Apart from the prolonged 
blood circulation time of PEG-AMB-LlP its high intrinsic antifungal activity may be of 
great clinical significance in the treatment of severe invasive fungal infection. Only 
treatment with PEGHAMB-LlP, and not with AmBisome®, even if administered 
repeatedly, resulted in decreasing numbers of C.albicans in the kidney within short 
period of time after C.albicans inoculation (chapter 8). 
The final challenge was to investigate whether the improved antifungal efficacy of 
PEG-AMB-LlP, as observed in our candidiasis model, could be extrapolated to another 
very difficult to treat fungal infection: pulmonary invasive aspergillosis in the leukopenic 
host (chapter 9). Our first data from a model of invasive pulmonary aspergillosis in 
persistently leukopenic rats showed that survival was significantly prolonged after only 
a single dose of PEG·AMB·lIP. These data are very encouraging and warrant further 
exploration of the therapeutic advantages of PEG-AMB-LlP in this model of pulmonary 
aspergillosis in rats. 
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Coming back to the aim of the present study, stated on the first page of this 
summary, a number of clear answers were obtained. For treatment of established 
invasive fungal infections in the leukopenic host, it is absolutely necessary to use a 
fungicidal agent, such as AMB-DOC, even though it is highly toxic. With AmBisome'" 
it is possible to virtually eliminate the toxicity of AMB. However, the reduction of 
intrinsic antifungal activity associated with the reduction of AMB's toxicity is not well 
recognized. It should be emphasized that high dosages of AmBisome'" are needed for 
treatment to be effective. However, the present study shows that it is now possible to 
abolish the toxicity of AMB by liposomal encapsulation without reducing its intrinsic 
antifungal activity. Pegylated 10ng-circulatingAMB-liposomes (PEG-AMB-L1P) meet these 
requirements. Results observed with PEG-AMB-L1P in two models of difficult to treat 
fungal infections are very encouraging. The development of pegylated AMB-liposomes 
opens new ways to improve the treatment of invasive fungal infections in the 
immunocompromised host. Further development of AMB-liposome-technology, thus, 
remains highly relevant. 
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De prognose van patienten met invasieve mycosen (gistw en schimmel-infecties) is 
nog ahijd heel slecht. Er bestaat er grote behoefte aan verbetering van de behandeling 
van deze infecties. Het meest gebruikte middel voor de behandeling van invasieve 
mycosen is amphotericine B (AMB), parenteraal toegediend in de vorm van 
amphotericine B-desoxycholate (AMB-DOC of fungizone@). Het gebruik hiervan is 
echter beperkt vanwege de ernstige bijwerkingen. Ter verbetering van de behandeling 
van invasieve mycosen zijn nieuwe antifungale middelen, zoals het triazole fluconazole 
(fLU) en nieuwe formuleringen van AMB, zoals liposomaal AMB, ontwikkeld. De 
waarde van deze middelen / formuleringen yoor de behandelingvan invasieve mycosen 
in de leukopenische gastheer is echter nog onvoldoende duidelijk. 
Het belangrijkste doel van de studies zoals beschreven in dit proefschrift was het 
verwerven van meer inzicht in de therapeulische waarde van zowel bestaande als ook 
nieuw-ontwikkelde liposomale formuleringen van AMB in de behandeling van 
invasieve mycosen. 
In de eerste studies (hoofstukken 2 en 3) werd de bruikbaarheid van een 
fungistatisch middel, fLU, in de behandeling van invasieve candidiasis vergeleken met 
die van het fungicide middel AMB-DOC. In vitro wordt Candida a/bicans snel gedood 
bij lage concentraties AMB-DOC. factoren die belangrijk zijn voor de antifungale 
effectiviteit in vivo bleken van invloed op de actviteit van AMB-DOC. In aanwezigheid 
van serum was de activiteit van AMB-DOC aanzienlijk verminderd. Ten opzichte van 
intracellulair gelocaliseerde c.a/bicans (in peritoneaal macrofagen) bleek de antifungale 
activiteit slechts lets verminderd in vergelijking tot de activiteit t.o.v. extracellulair 
groeiende Ca/bicans. In aanwezigheid van fLU werd C.a/bicans ook bij hoge 
concentraties niet gedood, maar slechts geremd in de groei. FLU vertoonde geen 
antifungale activiteit Lo.v. intracellulair groeiende C.albicans. Op grond van deze 
resuhaten werd de vraag gesteld of behandeling met fLU effectief zou zijn in geval van 
Invasieve C.albicans infecties in vivo, met name in de situatie waarin de 
afweermechanismen van de gastheer ernstig zijn aangetast. In ons proediermodel van 
invasieve candidiasis in immuuncompetente muizen bleek FLU slechts effectief 
gedurende de behandelingsperiode. In het model van invasieve candidiasis in 
leukopenische muizen bleek fLU slechts effectief te zijn indien heel vroeg (empirisch) 
gestart werd met behandeling; bij een late start van behandeling, op een moment dat 
de ernst van de C.albicans infectie aanzienlijk was toegenomen, was FLU niet effectief 
meer. In tegenstelling tot de krachtige antifungale activiteit van AMB-DOC in vitro, 
bleek in vivo de therapeutische efiectiviteit in genoemde modellen beperkt, in verband 
met de lage maximaal toelaatbare dosis (MTD) van AMB-DOC. 
De gedachte om de krachtige fungicide activiteit van AMB te benutten, en 
tegelijkertijd de toxiciteit van AMB te verminderen door liposomale inkapseling, 
vormde de basis voor het gebruik van AmBisome®, een van de industrieel bereide 
AMB-lipid preparaten. De antifungale effectiviteit van AMB in vivo was sterk verbeterd 
als gevolg van inkapseling in de vorm van AmBisome®. Bij invasieve candidiasis in 
zowel immuuncompetente als leukopenische muizen bleek AmBisome® zeer effectief 
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(hoofdstuk 3). Herhaalde toediening van hoge doses AmBisome'" deed, zelfs in geval 
van ernstige Calbicans infectie, het aantal Calbicans in de nier en andere organen 
sterk afnemen, zodanig dat terugkeer van de infectie kon worden voork6men. 
Weliswaar bleek AmBisome® minder effeelief te zijn dan AMB-DOC bij een gelijke 
dosering. Vanwege de lage toxiciteit van AmBisome® kon echter hoog gedoseerd 
worden, hetgeen alsnog resulteerde in een sterk verbeterde effectiviteit van AMB. 
De verspreiding van AMB via het bloed naar versehillende organen (biodistributie) 
na toediening van AMB~DOC of AmBisome® in mulzen werd bestudeerd en beschreven 
in hoofdstuk 4. Allereerst bleek de eonditie van de dieren (immuuneompetente niet-
gernfecteerde mulzen versus leukopenische mulzen gernfecteerd met Calbicans) niet 
van invloed op de biodistributie van beide preparaten. Vergelijking van de biodistibutie 
van AMB-DOC met AmBisome'" bij een gelijke dosering laat zien dat bij liposomale 
Inkapseling hogere AMB concentraties in het bloed worden verkregeni ook zijn hogere 
AMB concentraties aanwezig in het mononucleaire fagocyten systeem (MPS), met name 
in de lever en milt, terwijl AMB concentraties in de nier en long lager zijn. De opname 
van AmBisome'" in de MPS-organen (lever en milt) is sterk dosis afhankelijk en 
verzadigbaar. Na toediening van de MTD van AmBisome®, worden gedurende 
aanzienlijke tljd hoge con centra ties AMB In bloed en organen verkregen, welke niet 
lelden tot toxiciteiL Door gebruik te maken van radioactief gemerkt AmBisome® kon 
worden vastgesteld dat de hoge AMB coneentraties in het bloed voornamelijk liposoom-
geassocieerd AMB representeren. Gedurende de circulatie van AmBisome®komt slechts 
een gering dee I van AMB vrij. Tot voor kort bestond onduidelijkheid over het belang 
van vrijkomen van AMB voor de antifungale aetiviteit van AmBisome"'. In hoofdstuk 5 
wordt getoond dat in vitro AMB sterk geassocieerd blijft aan de liposomen in 
AmBisome®, en dat voor antifungale activiteit van AmBisome® Lo.v. C.albicans AMB 
niet hoeft vrij te komen. 
De antifungale activiteit van AmBisome® Lo.v. intracellulair gelocaliseerde 
Ca/hieans (in peritoneaal maerofagen) werd in hoofdstuk 5 besehreven. Naar analogie 
met de antifungale aetivlteit van AMB-DOC en AmBisome® t.o.v. extraeellulair 
groeiende Ca/hieans (hoofdstuk 3), was de intraeellulaire aetiviteit van AMB-DOC vele 
malen groter dan die van AmBisome®, Lokalisatie experimenten met fluorescerne~ 
gemerkt AmBisome® (hoofdstuk 5) lieten een goede opname van AmBisome'" in 
macrofagen zien, zowel in niet~ge'infecteerde macrofagen als in macrofagen die al 
C.albicans hadden opgenomen. De aanwezigheid van AmBisome® In macrofagen 
beYnvloedde de opname van Ca/hieans door diezelfde maerofagen niet. Bovendien 
bleek voorafgaande blootstelling van niet~ge't'nfecteerde macrofagen aan AmBisome® 
een positief effect te hebben op de intracellulaire effectiviteit van AmBisome® indien 
de macrofagen vervolgens werden ge'lnfecteerd met C.albicans. 
Een lange circulatietijd van liposomen in het bloed maakt de lokalisatie van intacte 
liposomen op plaatsen van infeetie bulten het MPS mogelijk. Voor liposoomtypen zoals 
AmBisome'" is de cireulatietijd in bloed sterk afhankelijk van de lipid-dosis: een hoge 
lipid-dosis is nodig voor een lange cireulatietijd (hoofdstuk 4). Liposoom-teehnologisehe 
ontwikkelingen van de laatste jaren, met name de inbouw van hydrofiele fosfatidyl-
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ethanolamine derivaten van monomethoxy polyethyleenglycol (PEG-PE) in liposomen, 
hebben het mogelijk gemaakt de circulatietijd van liposomen aanzienlijk te verlengen 
zander dat hiervoor een hoge lipid dosis, een kleine deeltjesgrootte van het liposoom, 
of een rigide karakter van de fosfolipide-bilaag nodig zijn. Deze gepegyleerde lang-
circulerende liposomen worden sterisch gestabiliseerde of MPS ontwijkende liposomen 
genoemd. Onderzocht werd of er gepegyleerde lang-circulerende AMB-liposomen 
kunnen worden bereid (hoofdstuk 6). Voor een goede liposomale inkapseling van AMB 
is het nodig dat AMB wordt gecomplexeerd b.v. aan het negatief geladen fosfolipid 
distearoylfosfatidylglycerol (DSPG) dat voorkomt in AmBisome"'. De netto negatieve 
lading van PEG-DSPE zou mogelijk ook gebruikt kunnen worden voor complexering 
van AMB. Twee verschillende PEG-DSPE bevattende liposoom-preparaten met AMB 
werden bereid (hoofdstuk 6): PEG-AMB-LlP type 1, waarin AMB werd gecomplexeerd 
aan DSPG, en PEG-AMB-LlP type 2 waarin AMB werd gecomplexeerd aan PEG-DSPE 
en het DSPG was weggelaten uit de formulering. PEG-AMB-LlP type 1 bleek even 
toxisch als AMB~DOC, zodat verdere studies hiermee m.b.t. biodistributie achterwege 
werden gelaten. Het PEG-AMB-LlP type 2 preparaat was relatief weinig toxisch, en 
vertoonde een lange cirulatietijd in bloed. Onderzoek naar de antifungale activiteit van 
PEG-AMB-LlP type 2 (verder PEG-AMB-LlP genoemd) werd verricht in het model van 
invasieve candidiasis in leukopenische muizen. PEG-AMB-LlP werd vergeleken met 
industrieel bereid AmBisome'" en met AMB-liposomen (AMB-LlP), die de lipid-
samenstelling hadden als in AmBisome®, echter in het laboratorium waren bereid 
(hoofdstuk 7). PEG-AMB-LlP en AMB-LlP vertoonden een grote overeenkomst in 
toxiciteit (geringe toxiciteit in vivo), en in antifungale activiteit t.o.v. c.albicans in vitro 
(vrijwel gelijk aan die van AMB-DOC), maar verschilden van elkaar in circulatietijd in 
de bloedbaan. De circulatietijd van PEG-AMB-LlP was langer dan die van AMB-LlP, en 
dit bleef gehandhaafd als de dosis werd verlaagd. Industrieel bereid AmBisome® en in 
het laboratorium bereid AMB~lIP verschilden van elkaar in in vivo toxiciteit en in vitro 
antifungale activiteit. AmBisome® was nag minder toxisch dan AMB~LlP, maar liet 
tevens een sterk gereduceerde antjfungale activiteit in vitro zien. [n het model van 
invasieve candidiasis in leukopenischemuizen bleek PEG-AMB-LlP zeer effectief na een 
enkelvoudige toediening van de MTD, terwijl bij een gelijke dosis AMB-LlP slechts 
partieel effectief was, en AmBisome® niet effectief was. Blj de MTD van AmBisome®, 
bijna zes maal hoger dan de MTD van PEG-AMB-LlP, was AmBisome'" ook zeer 
effectief. 
Evalueren van de gegevens van deze drie verschillende AMB~liposoom preparaten 
m.b.t de in vivo toxiciteit, in vitro antifungale activitelt, circulatietijd in bloed, en 
therapeutische effectiviteit in vivo leidt tot twee belangrijke conclusies. Ten eerste, de 
vergelijking van in het laboratorium bereid AMB-LlP en industrieel be reid AmBisome® 
laat duidelijk zien dat de bereidingswijze van het liposoom de in vivo toxicitelt, de in 
vitro antifungale activitelt, en daarmee de therapeutische effectiviteit in vivo in grate 
mate kan be·(nvloeden. Een substantieleverminderingvan toxicitelt gaat blijkbaar samen 
met een aanzienlijk verlies aan in vitro antifungale activiteit, en daarmee aan de in vivo 
effectiviteit. Idealiter zou bij een optimaal AMB~liposoom preparaat de toxiciteit van 
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AMB verminderd moeten worden, zander dat de krachtige antifungale activiteit van 
AMB verloren gaat. Ten tweede, uit de vergelijking tussen PEG-AMB-LlP en AMB-LlP 
kan worden geconcludeerd dat een lange circulatietijd van AMB-liposomen in bloed 
gunstig is voor de therapeutische effectiviteit. Naast de lange circulatietijd van PEG-
AMB-LlP in bloed zou ook de krachtige 'intrinsieke' antifungale activiteit van PEG-AMB-
LIP van grote klinische betekenis kunnen zijn bij de behandeling van ernstige invasieve 
mycosen. In het model van invasieve candidiasis in leukopenische muizen deed 
behandeling met PEG-AMB-LlP het aantal c.albicans in de nier sterk afnemen kort na 
start van de behandeling, zelfs indien de ernst van de c.albicans infectie aanzienJijk 
was toegenomen. AmBisome<!J, zelfs herhaald toegediend, bleek niet meer effectief te 
zijn bij deze zeer ernstige vorm van C.albicans infectie (hoofdstuk 8). 
De laatste vraag was of de goede antifungale effectiviteit van PEG-AMB-LlP, zoals 
waargenomen in het candidiasis model, ook gevonden zou worden in een ander model 
van een bijzonder moeilijk te behandelen schimmelinfectie: pulmonale invasieve 
aspergillosis in de leukopenische gastheer (hoofdstuk 9). De eerste gegevens van 
behandeling met een enkelvoudige dosis PEG-AMB-LlP in een model van invasieve 
pulmonale aspergillosis in leukopenische ratten laten zien dat de overlevingsduur van 
de behandelde dieren significant langer is dan die van onbehandelde dieren. Deze 
resultaten zijn zeer bemoedigend en rechtvaardigen verder onderzoek naar de 
therapeutische mogelijkheden van PEG-AMB-LlP in dit model van pulmonale 
aspergillosis. 
T erugkomend op het doel van deze studie, zoals vermeld op de eerste pagina van deze 
samenvatting, zijn een aantal duidelijke antwoorden verkregen. Voar de behandeling 
van bewezen ernstige invasieve mycosen in de leukopenische gastheer, is het absoluut 
noodzakelijk om een fungicide middel te gebruiken, zoals AMB-DOC, of schoon dit 
middel erg toxisch is. In AmBisome® is de toxiciteit van AMB zeer sterk verminderd. 
De daarmee samenhangende vermindering van 'intrinsieke' antifungale activileit van 
AMB is echter een direct gevolg. Dit wordt als zodanig te weinig onderkend. Immers 
slechts bij hoge doseringen van AmBisome® wordt een effectieve behandeling bereikt. 
Het in dit proefschrift beschreven onderzoek laat zien dat het wei mogelijk is de 
toxiciteit van AMB door liposomale inkapseling aanzienlijk te verminderen, zonder dat 
er verlies van 'intrinsieke' antifungale activiteit optreedt. Gepegyleerde lang-drculerende 
AMB liposomen voldoen aan bovengenoemde vereisten. De resultaten die werden 
verkregen met PEG-AMB-LlP in twee modellen van moeilijk te behandelen mycosen in 
muizen en ratten zijn zeer bemoedigend. De ontwikkeling van gepegyleerde AMB-
liposomen opent een nieuwe richting in de verbetering van de behandeling van 
invasieve mycosen in de immuun-gecompromitteerde gastheer. Aldus blijft de verdere 
ontwikkeling van liposoom-technologie uiterst relevant voor de behandeling van 
Invasieve mycosen bij de mens. 
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